

# CITATION REPORT

List of articles citing

**Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study**

**DOI: 10.1093/jnci/90.18.1371**

**Journal of the National Cancer Institute, 1998, 90, 1371-88.**

**Source:** <https://exaly.com/paper-pdf/29403546/citation-report.pdf>

**Version:** 2024-04-05

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2341	Effect of early American results on patients in a tamoxifen prevention trial (IBIS). International Breast Cancer Intervention Study. <b>1998</b> , 352, 1222		8
2340	Tamoxifen in the treatment of breast cancer. <b>1998</b> , 339, 1609-18		981
2339	Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. <i>Journal of the National Cancer Institute</i> , <b>1998</b> , 90, 1601-8	9.7	383
2338	The 1998 St. Gallen's Consensus Conference: an assessment. <i>Journal of the National Cancer Institute</i> , <b>1998</b> , 90, 1587-9	9.7	36
2337	Cancer chemoprevention: progress and promise. <i>Journal of the National Cancer Institute</i> , <b>1998</b> , 90, 1514-38	9.7	124
2336	SERMs: the benefits of estrogen without the risks?. <b>1998</b> , 7, 1187-9		2
2335	National Surgical Adjuvant Breast and Bowel Project breast cancer prevention trial: a reflective commentary. <b>1999</b> , 17, 1632-9		36
2334	Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. <b>1999</b> , 17, 2659-69		386
2333	Tamoxifen: too much of a good thing?. <b>1999</b> , 17, 2629-30		12
2332	Breast cancer in carriers of BRCA1 and BRCA2 mutations: tackling a molecular and clinical conundrum. <b>1999</b> , 17, 3367-70		11
2331	Tamoxifen and sexuality: Let's listen to the data speak. <b>1999</b> , 17, 3689-90		
2330	American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. <b>1999</b> , 17, 1939-55		139
2329	Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women. <b>1999</b> , 159, 1458-66		43
2328	Hormonal ReplacementâEffect on Bone Density. <b>1999</b> , 84, 1802-1803		
2327	Breast cancer screening and management. <b>1999</b> , 171, 479-84		3
2326	Breast cancer. <b>1999</b> , 105, 43-44		2
2325	Potential tissue selectivity of dietary phytoestrogens and estrogens. <b>1999</b> , 10, 47-52		48

2324	Endocrine cancer risks for women during the perimenopause and beyond. <b>1999</b> , 17, 359-70		2
2323	Testing for hereditary cancer risk: Pandora or Prometheus?. <b>1999</b> , 84, 1882-5		3
2322	Alternatives to the use of estrogen in postmenopausal women. <b>1999</b> , 20, 308-20		22
2321	Selective estrogen receptor modulators: clinical spectrum. <b>1999</b> , 20, 418-34		153
2320	Relative versus attributable risk of breast cancer from estrogen replacement therapy. <b>1999</b> , 84, 1875-81		16
2319	The thrombophilic state induced by therapeutic agents in the cancer patient. <b>1999</b> , 25, 137-45		164
2318	Thrombophilic state in breast cancer. <b>1999</b> , 25, 157-66		14
2317	Therapeutic controversy: Hormone replacement therapy--where are we going?. <b>1999</b> , 84, 1798-812		20
2316	Tamoxifen, raloxifene, and the prevention of breast cancer. <b>1999</b> , 20, 253-78		173
2315	Risk/benefit assessment of tamoxifen to prevent breast cancer--still a work in progress?. <i>Journal of the National Cancer Institute</i> , <b>1999</b> , 91, 1792-3	9.7	30
2314	Tamoxifen prevention of breast cancer: an instance of the fingerpost. <i>Journal of the National Cancer Institute</i> , <b>1999</b> , 91, 1809-19	9.7	56
2313	Re: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. <i>Journal of the National Cancer Institute</i> , <b>1999</b> , 91, 730	9.7	17
2312	The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. <b>1999</b> , 281, 2189-97		1375
2311	RESPONSE: re: tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. <i>Journal of the National Cancer Institute</i> , <b>1999</b> , 91, 1891A-1892	9.7	8
2310	Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. <i>Journal of the National Cancer Institute</i> , <b>1999</b> , 91, 1891-2	9.7	8
2309	Re: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. <i>Journal of the National Cancer Institute</i> , <b>1999</b> , 91, 474-5	9.7	1
2308	Delayed adjuvant tamoxifen in postmenopausal women with axillary node-negative breast cancer: mortality over 10 years. <i>Journal of the National Cancer Institute</i> , <b>1999</b> , 91, 1167-8	9.7	7
2307	Activation of transcription by estrogen receptor alpha and beta is cell type- and promoter-dependent. <b>1999</b> , 274, 32008-14		79

2306	High mammographic breast density and its implications for the early detection of breast cancer. <b>1999</b> , 6, 200-4		26
2305	Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. <b>1999</b> , 282, 637-45		2346
2304	A 40-year-old woman with a strong family history of breast cancer. <b>1999</b> , 282, 1953-60		10
2303	N-demethylation accompanies alpha-hydroxylation in the metabolic activation of tamoxifen in rat liver cells. <b>1999</b> , 20, 2003-9		26
2302	Re: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. <i>Journal of the National Cancer Institute</i> , <b>1999</b> , 91, 188	9.7	5
2301	Bad news/good news: information about breast cancer risk following prophylactic oophorectomy. <i>Journal of the National Cancer Institute</i> , <b>1999</b> , 91, 1442-3	9.7	5
2300	A mechanism for tamoxifen-mediated inhibition of acidification. <b>1999</b> , 274, 18364-73		59
2299	Refining breast cancer risk assessment with molecular markers: the next step?. <i>Journal of the National Cancer Institute</i> , <b>1999</b> , 91, 2067-8	9.7	6
2298	Tamoxifen treatment of progressive precocious puberty in a patient with McCune-Albright syndrome. <b>1999</b> , 12, 681-6		29
2297	Encouraging news from the SERM frontier. Selective estrogen receptor modulator. <b>1999</b> , 281, 2243-4		8
2296	Hereditary breast cancer. <b>1999</b> , 38 Suppl 13, 29-32		4
2295	Further characterization of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N, N-didesmethyltamoxifen. <b>1999</b> , 20, 2011-6		31
2294	Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. <i>Journal of the National Cancer Institute</i> , <b>1999</b> , 91, 1847-56	9.7	347
2293	Hormones and breast cancer: evidence and implications for consideration of risks and benefits of hormone replacement therapy. <b>1999</b> , 8, 347-57		35
2292	Selective estrogen receptor modulators: a controversial approach for managing postmenopausal health. <b>1999</b> , 8, 321-33		6
2291	Women's Health LiteratureWatch. <b>1999</b> , 8, 129-38		
2290	Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. <i>Journal of the National Cancer Institute</i> , <b>1999</b> , 91, 1829-46	9.7	573
2289	Validation studies for models projecting the risk of invasive and total breast cancer incidence. <i>Journal of the National Cancer Institute</i> , <b>1999</b> , 91, 1541-8	9.7	576

2288	Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. <i>Journal of the National Cancer Institute</i> , <b>1999</b> , 91, 453-9	9.7	161
2287	Estimating the population impact of an intervention: a decision-analytic approach. <b>1999</b> , 8, 311-30		13
2286	Tamoxifen inhibits acidification in cells independent of the estrogen receptor. <b>1999</b> , 96, 4432-7		95
2285	Tamoxifen therapy for breast cancer and endometrial cancer risk. <i>Journal of the National Cancer Institute</i> , <b>1999</b> , 91, 1654-62	9.7	286
2284	TGF-beta and cancer. <b>1999</b> , 1, 1327-47		112
2283	Pilot study of an information aid for women with a family history of breast cancer. <b>1999</b> , 2, 118-128		11
2282	Lobular Carcinoma In Situ of the Breast. <b>1999</b> , 5, 296-303		72
2281	The Relationship Between Tamoxifen, Estrogen, and Depressive Symptoms. <b>1999</b> , 5, 375-382		39
2280	Laboratory identification of hereditary risk of breast and ovarian cancer. <b>1999</b> , 10, 289-94		4
2279	Progress in cancer chemoprevention. <b>1999</b> , 889, 1-13		101
2278	Breast cancer prevention by antiestrogens. <b>1999</b> , 889, 146-51		17
2277	Diagnostic work-up of breast cancer in females. <b>1999</b> , 11, 71-9; quiz 80-2		
2276	Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse. <b>1999</b> , 158, 24-32		25
2275	The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogens. <b>1999</b> , 4, 401-13		7
2274	Tamoxifen and risk of large bowel cancer in women with breast cancer. <b>1999</b> , 53, 271-7		49
2273	Antiestrogens--tamoxifen, SERMs and beyond. <b>1999</b> , 17, 285-311		91
2272	Cancer mortality rates in Menofeia, Egypt: comparison with US mortality rates. <b>1999</b> , 10, 345-7		3
2271	(Chemo-) Prävention des Mammakarzinoms. <b>1999</b> , 32, 150-157		2

2270	President's Address: Clinical Research on Breast Cancer at the Aichi Cancer Center: Past, Present, and Future of Hormone Therapy. <b>1999</b> , 6, 264-269	
2269	[Efficacy of bilateral mastectomy in women with familial breast cancer]. <b>1999</b> , 175, 295-6	
2268	The 1999 James Ewing Lecture: in pursuit of molecules of oncogenesis and neoplastic therapy. <b>1999</b> , 6, 528-41	2
2267	Ductal carcinoma in situ of the breast: a surgeon's disease. <b>1999</b> , 6, 802-10	12
2266	Highlights from recent National Surgical Adjuvant Breast and Bowel Project studies in the treatment and prevention of breast cancer. <b>1999</b> , 49, 159-77	36
2265	What can randomized controlled trials tell us about nutrition and cancer prevention?. <b>1999</b> , 49, 353-61	39
2264	Estrogen receptor as a target for the prevention of breast cancer. <b>1999</b> , 133, 408-14	14
2263	BRCA-associated cancer risk: molecular biology and clinical practice. <b>1999</b> , 134, 11-8	4
2262	Prophylactic mastectomy: can this approach be defended?. <b>1999</b> , 56, 218-221	
2261	Management of recurrent desmoid tumor after surgery and radiation: role of cytotoxic and non-cytotoxic therapies. <b>1999</b> , 8, 191-6	9
2260	The evaluation of high risk and pre-invasive breast lesions and the decision process for follow up and surgical intervention. <b>1999</b> , 8, 55-65	15
2259	Adjuvant systemic management of early stage carcinoma of the breast. <b>1999</b> , 8, 93-101	1
2258	The evolving role of specific estrogen receptor modulators (SERMs). <b>1999</b> , 8, 103-23	19
2257	Surgical oncology. <b>1999</b> , 188, 178-83	
2256	Tamoxifen and contralateral breast cancer. <b>1999</b> , 188, 678-83	6
2255	Drug update: emerging therapies for breast cancer. <b>1999</b> , 7, 100-3	2
2254	The American Cancer Society challenge goals. <b>1999</b> , 86, 715-727	82
2253	Genetic cancer risk assessment. <b>1999</b> , 86, 2483-2492	44

2252	Special considerations in breast cancer risk and survival. <b>1999</b> , 71, 250-60	4
2251	Another view of the tamoxifen trial. <b>1999</b> , 72, 1-6; discussion 6-8	1
2250	Current status of tamoxifen use: An update for the surgical oncologist. <b>1999</b> , 72, 42-9	12
2249	Commentary. <b>1999</b> , 72, 6-8	
2248	Breast cancer prevention. <b>2000</b> , 2, 10-2	
2247	Clinical pharmacology of selective estrogen receptor modulators. <b>1999</b> , 14, 323-36	23
2246	Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. <b>1999</b> , 340, 77-84	1134
2245	Genetic testing for breast cancer predisposition. <b>1999</b> , 79, 1171-87, xxi	5
2244	Interspecies differences in cancer susceptibility and toxicity. <b>1999</b> , 31, 917-70	102
2243	Selective estrogen receptor modulators: tissue selectivity and differential uterine effects. <b>1999</b> , 2, 268-83	29
2242	Tamoxifen treatment for breast cancer was associated with an increased risk of endometrial cancer. <b>1999</b> , 1, 117	
2241	Clinical use of selective estrogen receptor modulators. <b>1999</b> , 25, 115-8	10
2240	Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women. <b>1999</b> , 35, 596-600	26
2239	Comments on: Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics, Vasen et al., Eur J Cancer 1998, 34, 1922-1926. <b>1999</b> , 35, 859-60	1
2238	Cancer prevention: epidemiology and perspectives. <b>1999</b> , 35, 1046-58	32
2237	Cancer chemoprevention: progress and promise. <b>1999</b> , 35, 1755-62	33
2236	Selective oestrogen receptor modulation: molecular pharmacology for the millennium. <b>1999</b> , 35, 1628-39	109
2235	From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century. <b>1999</b> , 35, 1963-73	110

2234	Screening for hereditary cancer and genetic testing, epitomized by breast cancer. <b>1999</b> , 35, 1954-62	14
2233	Cancer prevention: epidemiology and perspectives. <b>1999</b> , 35, 1912-24	39
2232	Selective oestrogen receptor modulation: molecular pharmacology for the millennium. <b>1999</b> , 35, 1974-85	46
2231	Cancer chemoprevention: progress and promise. <b>1999</b> , 35, 2031-8	55
2230	EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. <b>1999</b> , 69, 51-84	149
2229	Targeted Antiestrogens to Prevent Breast Cancer. <b>1999</b> , 10, 312-317	25
2228	[Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial]. <b>1999</b> , 3, 524-5	
2227	Sonohysterography: technique, endometrial findings, and clinical applications. <b>1999</b> , 20, 250-8	18
2226	Penn Health for Women: the evolution of a women's health program in an academic setting. <b>1999</b> , 9, 162-75	
2225	Tamoxifen for intraductal cancer. <b>1999</b> , 354, 1211-2	2
2224	Drop-outs in tamoxifen prevention trials. <b>1999</b> , 353, 244	13
2223	Tamoxifen hits the target in situ. <b>1999</b> , 353, 1986-7	7
2222	Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. <b>1999</b> , 353, 1993-2000	799
2221	Perspectives on cancer chemoprevention research and drug development. <b>2000</b> , 78, 199-334	196
2220	Selected hormonal agents in gynecology. <b>1999</b> , 28, 545-53	
2219	New vs old fashioned oestradiol antagonists in mammary carcinoma: 'in vitro' and 'in vivo' pharmacological approaches. <b>1999</b> , 39, 335-44	6
2218	Breast cancer screening, diagnosis, and treatment. <b>1999</b> , 45, 333-405	3
2217	Effect of a half dose of tamoxifen on proliferative activity in normal breast tissue. <b>1999</b> , 67, 33-8	23



2216	Clinical options for women at high risk for breast cancer. <b>1999</b> , 79, 1189-206	17
2215	Hormonal therapy for breast cancer. An update. <b>1999</b> , 13, 435-55, vii	11
2214	Principles of screening. <b>1999</b> , 83, 1323-37, v	40
2213	Management of ductal carcinoma in situ. <b>1999</b> , 79, 1007-30, viii	15
2212	Chemoprevention of breast cancer. <b>1999</b> , 79, 1207-21	26
2211	Adjuvant therapy for resectable breast cancer. <b>1999</b> , 13, 391-413, vi	6
2210	Recent advances in cancer chemotherapy. <b>1999</b> , 6, 696-705	
2209	Selective estrogen receptor modulators: a look ahead. <b>1999</b> , 57, 653-63	95
2208	Tamoxifen-DNA adducts formed by alpha-acetoxytamoxifen N-oxide. <b>1999</b> , 12, 1083-9	17
2207	The effects of SERMs on the skeleton. <b>1999</b> , 22, 604-8	7
2206	Postmenopausal hormone therapy, SERMs, and coronary heart disease in women. <b>1999</b> , 22, 616-24	11
2205	Effect of SERMs on the uterus and menopausal symptoms. <b>1999</b> , 22, 625-35	5
2204	Effect of SERMs on breast tissue. <b>1999</b> , 22, 636-40	7
2203	Tolerability profile of SERMs. <b>1999</b> , 22, 641-5	4
2202	Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. <b>1999</b> , 12, 646-53	83
2201	The Epidemiology of Cardiovascular Disease in Postmenopausal Women. <b>1999</b> , 84, 1803-1806	15
2200	Genetic Testing in Familial Breast Cancer—Pandora's Box?. <b>1999</b> , 21, 787-794	
2199	Endocrine Therapies in Breast Cancer. Present Status and Future Directions. <b>1999</b> , 21, 796-807	

2198 Breast Cancer: A New Challenge for the Gynaecologist. **1999**, 21, 767-768

2197 Le cancer du sein: un nouveau défi pour le gynécologue. **1999**, 21, 769-770

2196 Raloxifene as a multifunctional medicine? Current trials will show whether it is effective in both osteoporosis and breast cancer. **1999**, 319, 331-2 25

2195 Cancer chemoprevention: present status, future expectations. **1999**, 34, 101-5; discussion 105-6; quiz 164 2

2194 Has surgical subspecialization gone too far?. **1999**, 60, 206-9 9

2193 Auf dem Weg zur koordinierten klinischen Prävention in der Onkologie. Das neue Zentrum für Tumordiagnostik und Prävention in St. Gallen. **1999**, 22, 327-332 1

2192 Preventing heart disease and cancer. What randomized, primary-prevention studies show. **1999**, 106, 143-8 1

2191 Individually randomized intervention trials for disease prevention and control. **1999**, 8, 287-309 12

2190 New Hormonal Therapies for Breast Cancer. **1999**, 6, 247-255 4

2189 Risk communication in clinical practice: putting cancer in context. **1999**, 124-33 94

2188 Assessing risk of breast cancer. **1999**, 105, 49-58 5

2187 When should tamoxifen be offered for breast cancer prevention?. **1999**, 105, 61-78

2186 After breast cancer. **1999**, 105, 103-112 3

2185 Hormone replacement therapy and cardiovascular disease. **1999**, 10, 429-34 28

2184 BRCA1/2 carriers and endocrine risk modifiers. **1999**, 6, 521-8 8

2183 Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. **1999**, 17, 2633-8 72

2182 Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. **1999**, 281, 2091-7 164

2181 Prescribing hormone replacement therapy for menopausal symptoms. **1999**, 131, 605-16 47

2180	Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. <b>1999</b> , 130, 270-7	278
2179	Survival in hereditary breast cancer associated with germline mutations of BRCA2. <b>1999</b> , 17, 3396-402	153
2178	Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. <b>1999</b> , 17, 2050-4	123
2177	Surveillance for endometrial cancer in women receiving tamoxifen. <b>1999</b> , 131, 127-35	47
2176	Selective estrogen receptor modulators: structure, function, and clinical use. <b>2000</b> , 18, 3172-86	284
2175	Tamoxifen-induced hyperplasia of the endometrium. <b>2000</b> , 20, 60-8	4
2174	Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. <b>2000</b> , 18, 3748-57	737
2173	Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. <b>2000</b> , 132, 689-96	459
2172	Selective Estrogen Receptor Modulators (SERMs) in Clinical Practice. <b>2000</b> , 7, S38-S46	4
2171	Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. <b>2000</b> , 18, 3459-63	88
2170	Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. <b>2000</b> , 18, 3464-70	157
2169	Significance of endovaginal ultrasonography in assessing tamoxifen-associated changes of the endometrium: A prospective study. <b>2000</b> , 79, 697-701	6
2168	Benefits and Costs of Genetic Screening for Breast Cancer. <b>2000</b> , 3, 190-192	
2167	Selective oestrogen receptor modulators. <b>2000</b> , 53 Suppl 3, 25-9	26
2166	Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. <b>2000</b> , 130, 467S-471S	319
2165	Secondary Primary Cancer after Cancer and Immunosuppressive Chemotherapy and Radiotherapy. <b>2000</b> , 55, 165-202	
2164	Systematic review of epidemiological studies on meat, dairy products and egg consumption and risk of colorectal adenomas. <b>2000</b> , 9, 151-164	59
2163	Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan. <b>2000</b> , 11, 1537-43	49

2162 Systemic therapy. **2000**, 12, 532-40

2161 Breast Cancer. **2000**, 100, 9

2160 PREVENTIVE SERVICES FOR THE YOUNG ADULT (21-40 YEARS). **2000**, 2, 313-329

2159 Controversies in postmenopausal hormone replacement. **2000**, 7, 325-331

2158 Surveillance of the endometrium in tamoxifen treated women. **2000**, 12, 27-31

4

2157 Management of women at risk for malignancy. **2000**, 12, 508-13

2156 Evaluation and treatment of BRCA-positive patients. **2000**, 105, 714-9

6

2155 Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. **2000**, 21, 1461-1467

77

2154 High dose tamoxifen and radiotherapy in patients with glioblastoma multiforme: a phase IB study. **2000**, 27, 302-6

15

2153 Cancer, thrombosis, and anticoagulants. **2000**, 6, 301-8

12

2152 Trends in survival for patients diagnosed with cancer in Vaud, Switzerland, between 1974 and 1993. **2000**, 11, 957-63

33

2151 Breast Cancer. **2000**, &NA,, 9-12

2150 Impact of nodal status on indication for adjuvant treatment in clinically node negative breast cancer. Istituto Nazionale per lo Studio e la Cura dei Tumori. **2000**, 11, 1137-40

10

2149 Uterine Effects of 3-Year Raloxifene Therapy in Postmenopausal Women Younger Than Age 60. **2000**, 95, 104-110

2

2148 Kill and cure: dietary augmentation of immune defences against colon cancer. **2000**, 59, 215-20

9

2147 Cytologic features of proliferative breast disease: a study designed to minimize sampling error. **2000**, 90, 33-40

18

2146 The relation between the presence and extent of lobular carcinoma in situ and the risk of local recurrence for patients with infiltrating carcinoma of the breast treated with conservative surgery and radiation therapy. **2000**, 88, 1072-7

70

2145 Despite limited data, coexistent lobular carcinoma in situ should not be a contraindication to breast conservation for women with invasive breast carcinoma. **2000**, 88, 978-81; discussion 982-3

2

2144	Effects of high dose raloxifene in selected patients with advanced breast carcinoma. <b>2000</b> , 88, 2047-53	68
2143	Hormone-dependent nuclear localization of the tyrosine kinase <i>tyk</i> in the normal human breast epithelium and loss of expression during carcinogenesis. <b>2000</b> , 85, 889-94	10
2142	Clinical development of estrogen modulators for breast cancer chemoprevention in premenopausal vs. postmenopausal women. <b>2000</b> , 77, 103-114	41
2141	Criteria for implementation of large and multiagent clinical chemoprevention trials. <b>2000</b> , 34, 115-20	6
2140	BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials. <b>2000</b> , 77, 13-18	2
2139	Chemoprevention of breast cancer: the Italian experience. <b>2000</b> , 34, 84-96	16
2138	Clinical management of BRCA1- and BRCA2-associated breast cancer. <b>2000</b> , 18, 296-304	8
2137	Psychosocial aspects of cancer genetics: women at high risk for breast and ovarian cancer. <b>2000</b> , 18, 333-8	36
2136	The insulin-like growth factor-1 elevates urokinase-type plasminogen activator-1 in human breast cancer cells: a new avenue for breast cancer therapy. <b>2000</b> , 27, 10-7	32
2135	Bilateral breast carcinoma. <b>2000</b> , 88, 2739-2750	140
2134	Surveillance for uterine abnormalities in tamoxifen-treated breast carcinoma survivors: a community based study. <b>2000</b> , 89, 800-10	12
2133	ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. <b>2000</b> , 89, 817-25	320
2132	Randomized population trials and screening for lung cancer. <b>2000</b> , 89, 2399-2421	17
2131	Benign Breast Tissue Sampling for Prevention Studies. <b>2000</b> , 6, 215-219	7
2130	Quality of Life Across the Continuum of Breast Cancer Care. <b>2000</b> , 6, 324-330	42
2129	Hormonal Therapy and Chemoprevention. <b>2000</b> , 6, 317-323	4
2128	An Evaluation of Plasma Antioxidant Levels and the Risk of Breast Cancer: A Pilot Case Control Study. <b>2000</b> , 6, 388-395	16
2127	Epidemiology Versus Scare Mongering: The Case for the Humane Interpretation of Statistics and Breast Cancer. <b>2000</b> , 6, 331-334	5

2126	The Diagnosis and Treatment of Ductal Carcinoma In Situ of the Breast. <b>2000</b> , 6, 78-95	11
2125	Use of tamoxifen in hepatocellular carcinoma: a review and paradigm shift. <b>2000</b> , 15, 725-9	23
2124	Significance of endovaginal ultrasonography in assessing tamoxifen-associated changes of the endometrium. <b>2000</b> , 79, 697-701	2
2123	Cancer chemoprevention. <b>2000</b> , 33, 155-6	3
2122	Chemoprevention: general perspective. <b>2000</b> , 33, 157-67	46
2121	Prevention of breast cancer. <b>2000</b> , 33, 221-38	6
2120	R�sultats cliniques des modulateurs s�lectifs du r�cepteur des estrog�nes (SERM). <b>2000</b> , 67, 15-22	
2119	Triarylethylene bisphenols with a novel cycle are ligands for the estrogen receptor. <b>2000</b> , 8, 785-93	19
2118	Diphenyl quinolines and isoquinolines: synthesis and primary biological evaluation. <b>2000</b> , 8, 2629-41	95
2117	Part V. Adjuvant therapies for ductal carcinoma in situ. <b>2000</b> , 24, 163-74	
2116	High constant incidence in twins and other relatives of women with breast cancer. <b>2000</b> , 26, 411-4	233
2115	Adiposity as a risk determinant for postmenopausal breast cancer. <b>2000</b> , 24, 527-33	46
2114	Induction of p21WAF1 expression via Sp1-binding sites by tamoxifen in estrogen receptor-negative lung cancer cells. <b>2000</b> , 19, 3766-73	57
2113	Tomatoes, Pap smears, and tea? Adopting behaviors that may prevent reproductive cancers and improve health. <b>2000</b> , 29, 641-52	1
2112	Breast cancer genetics and the role of tamoxifen in prevention. <b>2000</b> , 12, 21-8; quiz 29-31	1
2111	The role of genetic screening and prophylactic surgery in surgical oncology. <b>2000</b> , 190, 619-28	6
2110	Prophylactic mastectomy. <b>2000</b> , 191, 322-30	29
2109	Obstetrics and gynecology. <b>2000</b> , 190, 173-8	1

2108	Surgical oncology. <b>2000</b> , 190, 215-26	1
2107	Not everyone with ductal carcinoma in situ of the breast treated with breast preservation needs post-excisional radiation therapy. <b>2000</b> , 9, 189-93	6
2106	Rationale for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer. <b>2000</b> , 9, 72-7	16
2105	Management of the contralateral breast in patients with hereditary breast cancer. <b>2000</b> , 9, 301-5	2
2104	Risk of breast cancer among BRCA2 mutation carriers lower than previously estimated. <b>2000</b> , 1, 6-7	
2103	In DCIS patients, the combination of lumpectomy and radiation therapy with tamoxifen improves the prevention of invasive breast cancer. <b>2000</b> , 1, 25-26	1
2102	Preventive treatment with tamoxifen is most beneficial for younger women with an elevated risk of breast cancer. <b>2000</b> , 1, 93-94	
2101	Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women. <b>2000</b> , 182, 568-74	43
2100	Drugs for the gynecologist to prescribe in the prevention of breast cancer: current status and future trends. <b>2000</b> , 182, 1121-6	8
2099	Exacerbation of endometriosis as a result of premenopausal tamoxifen exposure. <b>2000</b> , 183, 507-8	15
2098	Altering the estrogenic milieu of breast cancer with a focus on the new aromatase inhibitors. <b>2000</b> , 20, 280-91	2
2097	Breast cancer prevention: a review of current evidence. <b>2000</b> , 50, 156-70	41
2096	Update in internal medicine. <b>2000</b> , 31, 329-52	
2095	Association of tamoxifen biliary excretion rate with prior tamoxifen exposure and increased mdr1b expression. <b>2000</b> , 60, 233-9	13
2094	Eye problems in breast cancer patients treated with tamoxifen. <b>2000</b> , 60, 167-72	66
2093	Cyclin D1 overexpression in a model of human breast premalignancy: preferential stimulation of anchorage-independent but not anchorage-dependent growth is associated with increased cdk2 activity. <b>2000</b> , 59, 27-39	24
2092	Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. <b>2000</b> , 64, 165-76	199
2091	Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. <b>2000</b> , 63, 225-34	43

2090	Management of familial breast cancer risk. <b>2000</b> , 62, 19-33	10
2089	Chemoprevention of breast cancer. <b>2000</b> , 62, 1-17	60
2088	Biological features of premalignant disease in the human breast. <b>2000</b> , 5, 351-64	37
2087	Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients. <b>2000</b> , 78, 148-51	33
2086	Selective oestrogen receptor modulators (SERMs). <b>2000</b> , 2, 6-10	1
2085	Hormone replacement therapy for menopausal women. <b>2000</b> , 26, 197-202	1
2084	Reproductive and hormonal factors associated with mammographic breast density by age (United States). <b>2000</b> , 11, 955-63	84
2083	Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects. <b>2000</b> , 5, 388-92	96
2082	Mechanisms of cancer prevention by tea polyphenols based on inhibition of TNF-alpha expression. <b>2000</b> , 13, 67-72	57
2081	Early operable breast cancer. <b>2000</b> , 1, 210-20	5
2080	Chemoprevention of breast and colon cancer. <b>2000</b> , 2, 223-4	1
2079	Biomarkers as surrogates for cancer development. <b>2000</b> , 2, 242-50	16
2078	Breast cancer prevention trials. <b>2000</b> , 2, 558-65	12
2077	Integration of breast imaging into cancer management. <b>2000</b> , 2, 572-81	1
2076	Hormonale Substitution und extragenitale Neoplasien. <b>2000</b> , 33, 416-422	0
2075	Uterine Blutungen bei internistischen Grunderkrankungen. <b>2000</b> , 33, 645-651	0
2074	Coagulation and cancer: implications for diagnosis and management. <b>2000</b> , 6, 301-12	32
2073	Symposium overview: estrogens and antiestrogens in managing the patient with breast cancer. <b>2000</b> , 7, 568-74	2



2072	Tamoxifen for the prevention of breast cancer in the high-risk woman. <b>2000</b> , 7, 67-71	6
2071	Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery. <b>2000</b> , 7, 325-32	24
2070	Ductal carcinoma-in-situ: long-term results of breast-conserving therapy. <b>2000</b> , 7, 656-64	32
2069	BRCA1 and BRCA2--breast cancer susceptibility genes. <b>2000</b> , 126, 487-96	29
2068	Identification of tamoxifenâDNA adducts in the endometrium of women treated with tamoxifen. <b>2000</b> , 21, 1461-1467	98
2067	Practical issues in counseling healthy women about their breast cancer risk and use of tamoxifen citrate. <b>2000</b> , 160, 3034-42	12
2066	Molecular Pharmacology of Estrogen and Progesterone Receptors. <b>2000</b> , 3-11	1
2065	2nd European Breast Cancer Conference: A colloquio con Antony Howell. <b>2000</b> , 86, A1-A4	
2064	Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. <b>2000</b> , 7, 1299-304	52
2063	Cancer chemoprevention: a clinical reality. <b>2000</b> , 93, 518-20	5
2062	Second malignancies after treatment of early-stage breast cancer: lumpectomy and radiation therapy versus mastectomy. <b>2000</b> , 18, 2406-12	123
2061	What would you do? Specialists' perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination. <b>2000</b> , 18, 2484-92	94
2060	Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women. <b>2000</b> , 18, 284-6	34
2059	Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. <b>2000</b> , 18, 1980-95	110
2058	Safety and efficacy of antiestrogens for prevention of breast cancer. <b>2000</b> , 57, 1315-1322	11
2057	Declining cancer rates in the 1990s. <b>2000</b> , 18, 2258-68	74
2056	American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. <b>2000</b> , 18, 1378-91	296
2055	Gynecologic surveillance of women on tamoxifen: first do no harm. <b>2000</b> , 18, 3457-8	18

2054	Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer. <b>2000</b> , 18, 275-83	63
2053	Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. <b>2000</b> , 18, 3360-9	229
2052	Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. <b>2000</b> , 18, 3758-67	863
2051	Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. <b>2000</b> , 18, 3487-94	105
2050	The Role of Medical Oncology in an Interdisciplinary Comprehensive Breast Center. <b>2000</b> , 9, 339-345	3
2049	Genetics and the Multidisciplinary Breast Center. <b>2000</b> , 9, 367-396	1
2048	The Breast Health Center at Women & Infants Hospital: Origin, Philosophy, and Features. <b>2000</b> , 9, 199-216	
2047	Private Practice Interdisciplinary Breast Centers. <b>2000</b> , 9, 177-198	7
2046	INTRODUCTION TO CANCER. <b>2000</b> , 855-862	1
2045	Antiestrogens: Clinical Applications of Pharmacology. <b>2000</b> , 7, S47-S48	5
2044	Estrogen and depression in aging women. <b>2000</b> , 84-113	
2043	Selective estrogen receptor modulators. <b>2000</b> , 291-303	1
2042	Reducing the risk of breast cancer. <b>2000</b> , 343, 191-8	49
2041	Rat strain-specific actions of 17beta-estradiol in the mammary gland: correlation between estrogen-induced lobuloalveolar hyperplasia and susceptibility to estrogen-induced mammary cancers. <b>2000</b> , 97, 2779-84	87
2040	Ductal carcinoma in situ of the breast. <b>2000</b> , 51, 17-32	46
2039	Should women at increased risk for breast and ovarian cancer be randomized to prophylactic surgery? An ethical and empirical assessment. <b>2000</b> , 9, 223-33	7
2038	Tamoxifen induces endometrial and vaginal cancer in rats in the absence of endometrial hyperplasia. <b>2000</b> , 21, 793-7	58
2037	Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women. <b>2000</b> , 20, 1606-12	54

2036	Re: Tamoxifen Prevention of Breast Cancer: an Instance of the Fingerpost. <i>Journal of the National Cancer Institute</i> , <b>2000</b> , 92, 657a-657	9.7	5
2035	RESPONSE: re: tamoxifen prevention of breast cancer: an instance of the fingerpost. <i>Journal of the National Cancer Institute</i> , <b>2000</b> , 92, 658	9.7	2
2034	Mechanism of action of estrogens and selective estrogen receptor modulators. <b>2000</b> , 60, 123-47		39
2033	Re: Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors. <i>Journal of the National Cancer Institute</i> , <b>2000</b> , 92, 943-4	9.7	3
2032	Tamoxifen versus the newer SERMs: what is the evidence?. <b>2000</b> , 11 Suppl 3, 255-65		0
2031	Joint effects of nine polychlorinated biphenyl (PCB) congeners on breast cancer risk. <b>2000</b> , 29, 975-82		57
2030	Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. <b>2000</b> , 283, 617-24		156
2029	A 12-Month Comparative Study of Raloxifene, Estrogen, and Placebo on the Postmenopausal Endometrium. <b>2000</b> , 95, 95-103		1
2028	Evolution of cancer epidemiology. <b>2000</b> , 22, 35-56		13
2027	Individual risk prediction and population-wide disease prevention. <b>2000</b> , 22, 176-80		44
2026	In Pursuit of the Prevention of Breast Cancer. <b>2000</b> , 320, 263-272		
2025	A pilot study of the effects of short-term tamoxifen therapy on Ki-67 labelling index in women with primary breast cancer. <b>2000</b> , 16, 25-30		10
2024	A farewell. <b>2000</b> , 342, 1989		1
2023	Marcia Angell and the Journal. <b>2000</b> , 342, 1989-1990		
2022	Warfarin for cancer prevention. <b>2000</b> , 342, 1991-3		17
2021	Clinical targets for anti-metastasis therapy. <b>2000</b> , 79, 91-121		99
2020	Non-small cell lung cancer: staging at whole-body PET. <b>2000</b> , 217, 918-9		0
2019	Imaging of tamoxifen-induced uterine abnormalities. <b>2000</b> , 217, 917-8		0

2018	Tamoxifen-induced uterine abnormalities: the role of imaging. <b>2000</b> , 214, 29-38		82
2017	A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. <i>Journal of the National Cancer Institute</i> , <b>2000</b> , 92, 418-23	9.7	105
2016	The Etiology of Female Breast Cancer. <b>2000</b> , 9, 1-24		2
2015	Involving minority and underrepresented women in clinical trials: the National Centers of Excellence in Women's Health. <b>2000</b> , 9, 1061-70		97
2014	Impact of BRCA1 testing on women with cancer: a pilot study. <b>2000</b> , 4, 265-72		31
2013	Identification of hepatic tamoxifen-DNA adducts in mice: alpha-(N(2)-deoxyguanosinyl)tamoxifen and alpha-(N(2)-deoxyguanosinyl)tamoxifen N-oxide. <b>2000</b> , 21, 1737-44		24
2012	The retinoids and cancer prevention mechanisms. <b>2000</b> , 5, 361-8		91
2011	RESPONSE: re: estimation of Tamoxifen's efficacy for preventing the formation and growth of breast tumors. <i>Journal of the National Cancer Institute</i> , <b>2000</b> , 92, 943B-944	9.7	2
2010	Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients. <b>2000</b> , 21, 845-7		22
2009	Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. <i>Journal of the National Cancer Institute</i> , <b>2000</b> , 92, 1217-27	9.7	234
2008	Hormonal carcinogenesis. <b>2000</b> , 21, 427-33		662
2007	Primary care for survivors of breast cancer. <b>2000</b> , 343, 1086-94		192
2006	Expression of estrogen receptor coactivators in the rat uterus. <b>2000</b> , 63, 361-7		40
2005	Communicating genetic risk: pros, cons, and counsel. <b>2000</b> , 5, 152-61		3
2004	Re: tamoxifen prevention of breast cancer: an instance of the fingerpost. <i>Journal of the National Cancer Institute</i> , <b>2000</b> , 92, 659-60	9.7	4
2003	Predicting breast cancer: the search for a model. <i>Journal of the National Cancer Institute</i> , <b>2000</b> , 92, 1196-7	9.7	5
2002	Retinoids and demethylating agents- looking for partners. <i>Journal of the National Cancer Institute</i> , <b>2000</b> , 92, 780-1	9.7	15
2001	Re: Intra-alveolar haemorrhage in sudden infant death syndrome: a cause for concern?. <b>2000</b> , 53, 484		0

2000	Breast cancer: new aspects of adjuvant hormonal therapy. <b>2000</b> , 11 Suppl 3, 13-25		2
1999	Re: weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2000</b> , 92, 757-8	9.7	3
1998	Human tissue research in the genomic era of medicine: balancing individual and societal interests. <b>2000</b> , 160, 3377-84		34
1997	E. coli, antibiotics, and the hemolytic-uremic syndrome. <b>2000</b> , 342, 1990-1		49
1996	Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. <b>2000</b> , 160, 3444-50		151
1995	Oral contraceptives and breast cancer: A note of caution for high-risk women. <b>2000</b> , 284, 1837-8		6
1994	Tamoxifen inhibits lipoprotein activity: in vivo and in vitro studies. <b>2000</b> , 53, 36-9		12
1993	Re: Gynaecological effects of tamoxifen. <b>2000</b> , 53, 484		2
1992	Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors. <i>Journal of the National Cancer Institute</i> , <b>2000</b> , 92, 48-53	9.7	53
1991	Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. <i>Journal of the National Cancer Institute</i> , <b>2000</b> , 92, 1926-34	9.7	143
1990	RESPONSE: re: weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2000</b> , 92, 758	9.7	0
1989	Hormone replacement therapy (estrogen and progesterone): is it necessary for heart disease prevention?. <b>2000</b> , 3, 21-23		6
1988	Breast cancer chemoprevention. <b>2000</b> , 180, 249-51		18
1987	Breast surgery: past, present, and future. <b>2000</b> , 180, 246-8		2
1986	The breast surgeon's role in BRCA1 and BRCA2 testing. <b>2000</b> , 180, 294-8		11
1985	Occurrence of stroke with tamoxifen in NSABP B-24. <b>2000</b> , 355, 848-9		24
1984	Trends in breast cancer incidence, survival, and mortality. <b>2000</b> , 356, 591-2; author reply 593		3
1983	Hormone replacement therapy and breast cancer. <b>2000</b> , 34 Suppl 2, S11-24		7

1982 Gynaecology and breast cancer. **2000**, 92, 179-81

1981 Tamoxifen enhances myoepithelial cell suppression of human breast carcinoma progression in vitro by two different effector mechanisms. **2000**, 157, 133-44

32

1980 Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives. **2000**, 26, 103-25

44

1979 Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy. **2000**, 26, 205-27

15

1978 Breast cancer risk following irradiation for Hodgkin's disease. **2000**, 26, 291-302

94

1977 Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors. **2000**, 31, 593-600

38

1976 Breast cancer: risk factors, screening, and prevention. **2000**, 16, 176-84

17

1975 Estrogen, lipids, and coronary heart disease in women. **2000**, 4, 2-3

1974 Chemoprevention of cancer. **2000**, 21, 525-30

375

1973 Tamoxifen: a personal retrospective. **2000**, 1, 43-9

34

1972 Signal transduction pathways: targets for chemoprevention of skin cancer. **2000**, 1, 181-8

119

1971 Importance of field cancerisation in clinical oncology. **2000**, 1, 15-6

24

1970 Hereditary cancer – the evidence for current recommended management. **2000**, 1, 9-16

14

1969 Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist?. **2000**, 27, 765-8

7

1968 The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. **2000**, 36, 151-69

162

1967 Tamoxifen for the prevention of breast cancer. **2000**, 36, 142-50

31

1966 Tamoxifen for breast cancer prevention. **2000**, 36, 148-150

1

1965 Prophylactic mastectomy; evolving perspectives. **2000**, 36, 567-78

7

1964	Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring?. <b>2000</b> , 74, 255-9	45
1963	Progress in the prevention of breast cancer: concept to reality. <b>2000</b> , 74, 269-77	25
1962	Estrogens and women's health: interrelation of coronary heart disease, breast cancer and osteoporosis. <b>2000</b> , 74, 297-309	30
1961	Regulation of the estrogen-responsive pS2 gene in MCF-7 human breast cancer cells. <b>2000</b> , 74, 157-68	44
1960	Inherited coagulopathies in OB/GYN. <b>2000</b> , 7, 70-73	
1959	Familial predisposition to breast cancer in a British population: implications for prevention. <b>2000</b> , 36, 773-9	41
1958	Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer. <b>2000</b> , 36, 694-709	48
1957	Cancer population genetics and tumour prevention: an unfulfilled paradigm. <b>2000</b> , 36, 1189-92	7
1956	Use of risk determinants for different breast cancer prevention strategies. <b>2000</b> , 36, 1283-7	3
1955	Insulin-like growth factor physiology and cancer risk. <b>2000</b> , 36, 1224-8	248
1954	A brief review of the current breast cancer prevention trials and proposals for future trials. <b>2000</b> , 36, 1298-302	19
1953	Incidence of BRCA1/2 germ line alterations in a high risk cohort participating in a phase II chemoprevention trial. <b>2000</b> , 36, 1209-14	5
1952	The oestrogen receptor and its selective modulators in gynaecological and breast cancer. <b>2000</b> , 36 Suppl 4, S1-9	26
1951	Breast cancer prevention: results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) breast cancer prevention trial (NSABP P-1: BCPT). <b>2000</b> , 36 Suppl 4, S49-50	84
1950	A brief review of the breast cancer prevention trials. <b>2000</b> , 36 Suppl 4, S51-3	6
1949	Breast cancer prevention: the next steps. <b>2000</b> , 36 Suppl 4, S53-4	3
1948	Update on raloxifene to prevent endometrial-breast cancer. <b>2000</b> , 36 Suppl 4, S54-6	18
1947	Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. <b>2000</b> , 36 Suppl 4, S84-5	23

1946	The decline in cancer mortality in the European Union, 1988-1996. <b>2000</b> , 36, 1965-8	34
1945	Selection of cancer chemopreventive agents based on inhibition of topoisomerase II activity. <b>2000</b> , 36, 2146-56	38
1944	Protective action of 17beta-estradiol and tamoxifen on glutamate toxicity in glial cells. <b>2000</b> , 18, 289-97	39
1943	New opportunities for nurses as patient advocates. <b>2000</b> , 16, 57-64	125
1942	A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. <b>2000</b> , 95, 95-103	98
1941	Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60. <b>2000</b> , 95, 104-10	88
1940	Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer. <b>2000</b> , 65, 579-84	48
1939	Aromatase inhibitors and their application in breast cancer treatment*. <b>2000</b> , 65, 171-9	94
1938	Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. <b>2000</b> , 355, 2015-20	250
1937	One step forward or one step back with tamoxifen?. <b>2000</b> , 356, 868-9	10
1936	Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. <b>2000</b> , 356, 881-7	422
1935	Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. <b>2000</b> , 356, 1711-7	108
1934	Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. <b>2000</b> , 356, 1876-81	473
1933	Update on cancer control in women. <b>2000</b> , 70, 263-303	35
1932	Hormone replacement therapy and coronary heart disease. A new debate. <b>2000</b> , 84, 181-98, ix-x	7
1931	Indicaci3n de la Hormonoterapia en el C3ncer de Mama. <b>2000</b> , 97, 119-121	1
1930	Transforming growth factors-beta are not good biomarkers of chemopreventive efficacy in a preclinical breast cancer model system. <b>2001</b> , 3, 66-75	2
1929	Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. <b>2000</b> , 2, 335-44	206



1928	Future possibilities in the prevention of breast cancer: intervention strategies in BRCA1 and BRCA2 mutation carriers. <b>2000</b> , 2, 283-90	23
1927	Future possibilities in the prevention of breast cancer: role of genetic variation in breast cancer prevention. <b>2000</b> , 2, 277-82	18
1926	Future possibilities in the prevention of breast cancer: fat and fiber and breast cancer research. <b>2000</b> , 2, 268-76	30
1925	Future possibilities in the prevention of breast cancer: breast cancer prevention trials. <b>2000</b> , 2, 258-63	16
1924	Breast cancer research: where we are and where we should go. <b>2000</b> , 2, 73-6	1
1923	Breast Cancer Epidemiology, Prevention and Costs of Care. <b>2000</b> , 8, 197-210	1
1922	The Management of Women at High Risk of Experiencing Hereditary Breast and Ovarian Cancer. <b>2000</b> , 7, 201-215	3
1921	Preventing fractures in postmenopausal women with osteoporosis. A review of recent controlled trials of antiresorptive agents. <b>2000</b> , 17, 317-30	41
1920	Assessing the risk of breast cancer. <b>2000</b> , 342, 564-71	221
1919	Tamoxifen for treatment of premenopausal women with breast cancer. <b>2000</b> , 18, 681-4	
1918	Cancer in women: prevention and early detection. <b>2000</b> , 9, 483-8	9
1917	New generation aromatase inhibitors in breast cancer. Weighing out potential costs and benefits. <b>2000</b> , 17, 121-32	8
1916	The Prevention of Breast Cancer: An Overview. <b>2000</b> , 16, 252-257	1
1915	Pharmacology and clinical experience with exemestane. <b>2000</b> , 9, 1897-905	19
1914	Characterization of the major DNA adduct formed by alpha-hydroxy-N-desmethyltamoxifen in vitro and in vivo. <b>2000</b> , 13, 200-7	24
1913	Synthesis and reactivity of a potential carcinogenic metabolite of tamoxifen: 3,4-dihydroxytamoxifen-o-quinone. <b>2000</b> , 13, 53-62	78
1912	The relationship of tamoxifen with dementia, depression, and dependence in activities of daily living in elderly nursing home residents. <b>2000</b> , 31, 71-85	55
1911	Breast cancer chemoprevention. <b>2000</b> , 14, 727-38	1

1910	Prevention and treatment of osteoporosis in women with breast cancer. <b>2000</b> , 75, 821-9	32
1909	Breast cancer genetics. Implications of clinical practice. <b>2000</b> , 14, 705-25	5
1908	[The prevention of breast cancer in primary care]. <b>2000</b> , 26, 419-27	4
1907	Breast cancer and aging. Clinical interactions. <b>2000</b> , 14, 213-34	59
1906	[Molecular diagnosis of hereditary cancer]. <b>2000</b> , 115, 190-7	0
1905	Chemoprevention of breast cancer in the older patient. <b>2000</b> , 14, 113-30	8
1904	Primary cancer prevention trials. <b>2000</b> , 14, 809-30	5
1903	Multidisciplinary care for patients with breast cancer. <b>2000</b> , 80, 505-33	19
1902	Exemestane in breast cancer: current status and future directions. <b>2000</b> , 1 Suppl 1, S28-33	2
1901	Treating breast precancer. <b>2000</b> , 1 Suppl 1, S74-9	7
1900	Guidelines for monitoring patients taking tamoxifen treatment. <b>2000</b> , 22, 1-11	49
1899	Exemestane: a review of its use in postmenopausal women with advanced breast cancer. <b>2000</b> , 59, 1279-96	24
1898	Is there a growing role for endocrine therapy in the treatment of breast cancer?. <b>2000</b> , 60, 11-21	4
1897	Raloxifene: a review of its use in postmenopausal osteoporosis. <b>2000</b> , 60, 379-411	96
1896	Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible?. <b>2000</b> , 73, 292-9	57
1895	Chemoprevention of breast cancer by tamoxifen: risks and opportunities. <b>2000</b> , 30, 571-94	60
1894	Side effects of adjuvant treatment of breast cancer. <b>2001</b> , 344, 1997-2008	488
1893	Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. <b>2001</b> , 345, 159-64	768

1892	Commentary on "Low Proliferative Rate of Invasive Node-Negative Breast Cancer Predicts for a Favorable Outcome: A Prospective Evaluation of 669 Patients" <b>2001</b> , 1, 315-317	
1891	Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention. <b>2001</b> , 24, 1039-53	9
1890	Chemoprevention of breast cancer with fenretinide. <b>2001</b> , 61, 909-18	22
1889	Tamoxifen resistance in breast cancer: elucidating mechanisms. <b>2001</b> , 61, 1721-33	72
1888	Breast cancer prevention: present and future. <b>2001</b> , 27, 261-73	28
1887	Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer. <b>2001</b> , 85, 1838-41	32
1886	Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials. <b>2001</b> , 2, 33-6; discussion 37-40	5
1885	Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials: an alternative view. <b>2001</b> , 2, 41-6	9
1884	Resistance to endocrine therapy of breast cancer: recent advances and tomorrow's challenges. <b>2001</b> , 1, 297-308; discussion 309	17
1883	Anti-oestrogenic drugs and endometrial cancers. <b>2001</b> , 120, 21-9	15
1882	Estrogen and the risk of breast cancer. <b>2001</b> , 344, 276-85	789
1881	Breast cancer chemoprevention: beyond tamoxifen. <b>2001</b> , 3, 99-103	18
1880	Controversias en el tratamiento del carcinoma ductal in situ de mama: desenlace desafortunado en una paciente de 32 a�s. <b>2001</b> , 44, 443-448	
1879	Metabolismo lip�dico y aterog�nesis femenina: acci�n de hormonas, SERM y fitoestr�genos. <b>2001</b> , 44, 99-107	
1878	Epidemiology of breast cancer in older women: implications for future healthcare. <b>2001</b> , 18, 761-72	43
1877	Identifying and characterizing one-time and never users of mammography screening services among medicare eligible women. <b>2001</b> , 32, 529-33	15
1876	Design considerations for efficient prostate cancer chemoprevention trials. <b>2001</b> , 57, 205-12	15
1875	Tamoxifen use for 2 years or more doubled the risk of endometrial cancer in women with breast cancer. <b>2001</b> , 3, 156-157	1

1874	Tamoxifen after breast cancer reduces the risk of cancer in the second breast in BRCA1 and BRCA2 carriers. <b>2001</b> , 3, 154-155	
1873	Procedures of data and safety monitoring committees. <b>2001</b> , 141, 289-94	20
1872	Terms of reference for Data and Safety Monitoring Committees. <b>2001</b> , 141, 542-7	16
1871	Tamoxifen is not detrimental to endothelial function in postmenopausal women with breast cancer. <b>2001</b> , 142, E6	7
1870	Atypical hyperplasia, proliferative fibrocystic change, and exogenous hormone use. <b>2001</b> , 130, 732-7	4
1869	[What do we think about selective estrogen receptor modulators?]. <b>2001</b> , 22, 1173-6	
1868	[Hormone therapy and breast cancer: a review]. <b>2001</b> , 22, 1213-24	4
1867	Tamoxifen and risk of endometrial cancer. <b>2001</b> , 357, 65; author reply 67	0
1866	Tamoxifen and risk of endometrial cancer. <b>2001</b> , 357, 67	2
1865	Tamoxifen and risk of endometrial cancer. <b>2001</b> , 357, 67-8	2
1864	Tamoxifen and risk of endometrial cancer. <b>2001</b> , 357, 68	2
1863	Menopause, hormone replacement therapy and cancer. <b>2001</b> , 39, 97-115	47
1862	Endometrial and other primary cancers after tamoxifen treatment of breast cancer -- results of retrospective cohort study. <b>2001</b> , 95, 105-10	8
1861	Tamoxifen mutagenesis and carcinogenesis in livers of lambda/lacI transgenic rats: selective influence of phenobarbital promotion. <b>2001</b> , 162, 117-22	9
1860	Cyclin D1 in breast premalignancy and early breast cancer: implications for prevention and treatment. <b>2001</b> , 162, 3-17	30
1859	"Natural history" clinical trials: an enduring contribution to modern medical practice. <b>2001</b> , 56, 1-12	1
1858	Screening women at high risk of breast cancer on the basis of evidence. <b>2001</b> , 39, 50-9	15
1857	Breast cancer chemoprevention: current clinical practice and future direction. <b>2001</b> , 55, 559-64	6

1856	Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). <b>2001</b> , 7, 395-400	126
1855	Commentary on "Results and Implications of the Royal Marsden and Other Tamoxifen Chemoprevention Trials" <b>2001</b> , 2, 37-38	2
1854	Commentary on "Results and Implications of the Royal Marsden and Other Tamoxifen Chemoprevention Trials" <b>2001</b> , 2, 39-40	1
1853	Anti-genotoxicity of galangin as a cancer chemopreventive agent candidate. <b>2001</b> , 488, 135-50	148
1852	Colorectal cancer chemoprevention: biochemical targets and clinical development of promising agents. <b>2001</b> , 37, 12-22	41
1851	Germ line mutations associated with breast cancer susceptibility. <b>2001</b> , 37, 300-21	39
1850	Canada's Population Health Model (POHEM): a tool for performing economic evaluations of cancer control interventions. <b>2001</b> , 37, 1797-804	39
1849	The incidence of breast cancer from screening women according to predicted family history risk: Does annual clinical examination add to mammography?. <b>2001</b> , 37, 1668-73	32
1848	Perspectives in cancer chemotherapy. <b>2001</b> , 37 Suppl 8, S128-47	37
1847	Standard medical treatment for early breast cancer. <b>2001</b> , 37 Suppl 7, S45-58	3
1846	Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351. <b>2001</b> , 76, 61-70	35
1845	Recent advances in the clinical application of aromatase inhibitors. <b>2001</b> , 76, 179-86	23
1844	Molecular and pharmacological aspects of antiestrogen resistance. <b>2001</b> , 76, 71-84	113
1843	Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells. <b>2001</b> , 78, 41-50	14
1842	EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. <b>2001</b> , 79, 213-25	40
1841	Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?. <b>2001</b> , 79, 227-37	25
1840	Adjuvant trials of aromatase inhibitors: determining the future landscape of adjuvant endocrine therapy. <b>2001</b> , 79, 133-41	7
1839	Chemoprevention with aromatase inhibitors--trial strategies. <b>2001</b> , 79, 143-9	9

1838	Estrogens and cell-cycle regulation in breast cancer. <b>2001</b> , 12, 320-7		151
1837	Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. <b>2001</b> , 11, 95-102		39
1836	Selective estrogen receptor modulators: the ideal estrogen replacement?(2)(2). <b>2001</b> , 8, 25-30		6
1835	Tamoxifen treatment and gynecologic side effects: a review. <b>2001</b> , 97, 855-66		97
1834	Raloxifene effect on frequency of surgery for pelvic floor relaxation. <b>2001</b> , 98, 91-6		42
1833	Androgen antagonists: Potential role in prostate cancer prevention. <b>2001</b> , 57, 64-7		17
1832	Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development. <b>2001</b> , 58, 83-90		23
1831	Misconceptions about the use of genetic tests in populations. <b>2001</b> , 357, 709-12		115
1830	Common hereditary cancers and implications for primary care. <b>2001</b> , 358, 56-63		62
1829	Screening recommendation for women taking tamoxifen. <b>2001</b> , 358, 1018		1
1828	Cáncer de mama. Clasificación y concepto. <b>2001</b> , 8, 3041-3049		
1827	Identifying and managing hereditary risk of breast and ovarian cancer. <b>2001</b> , 28, 395-406		6
1826	HORMONE REPLACEMENT THERAPY AND CORONARY HEART DISEASE. <b>2001</b> , 19, 327-341		1
1825	[Clinical and pathological characteristics and clinical course of patients with breast cancer and BRCA1/BRCA2 mutations]. <b>2001</b> , 117, 161-6		0
1824	The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis. <b>2001</b> , 27, 163-85, vii		19
1823	National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 979-89	9:7	578
1822	Prostaglandin inhibitors and the chemoprevention of noncolonic malignancy. <b>2001</b> , 30, 981-1000		10
1821	Tumor Biology: Implications for Management. <b>2001</b> , 12, P212-P217		

1820 Hormonoterapia con tamoxifeno y el mđico de familia. **2001**, 27, 269-270

1819 Prevention and treatment of breast cancer. **2001**, 28, 711-26

0

1818 A practical approach to the older patient with cancer. **2001**, 25, 7-76

8

1817 Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. **2001**, 142, 838-46

70

1816 Identification and quantification of tamoxifen-DNA adducts in the liver of rats and mice. **2001**, 14, 1006-13

37

1815 Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. *Journal of the National Cancer Institute*, **2001**, 93, 358-66

9.7 463

1814 Rischio oncogeno da terapia sostitutiva in menopausa. **2001**, 2, 140-147

1813 Chemoprevention of Breast Cancer. **2001**, 94, 7-15

2

1812 Breast cancer screening. **2001**, 383-398

1811 Sex steroids and bone. **2001**, 81, 419-447

382

1810 Women's interest in chemoprevention for breast cancer. **2001**, 161, 1639-44

40

1809 Prophylactic Breast Surgery for Women with Brca1 and BRCA2 Germline Mutations. **2001**, 87, 13-15

3

1808 The surgeon's role in breast cancer chemoprevention. **2001**, 12, 103-12

1

1807 Diet-gene interactions in estrogen-induced mammary carcinogenesis in the ACI rat. **2001**, 131, 3087S-91S

10

1806 Changed trends of cancer mortality in the elderly. **2001**, 12, 1467-77

48

1805 Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations. **2001**, 19, 2754-63

41

1804 Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. **2001**, 19, 322-8

227

1803 Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. **2001**, 19, 3817-27

532

1802	Selective estrogen receptor modulators: from bench to bedside and back. <b>2001</b> , 7, 113-9	3
1801	Hormone Therapy and Risk for Venous Thromboembolism: Comments and Correction. <b>2001</b> , 134, 81	
1800	Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. <b>2001</b> , 19, 2357-63	106
1799	Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. <b>2001</b> , 19, 1885-92	203
1798	A longitudinal study of physical activity and breast cancer prediction. <b>2001</b> , 24, 371-7	6
1797	Hereditary cancers in obstetrics and gynecology. <b>2001</b> , 44, 450-63	7
1796	Breast cancer chemoprevention âQuo vadis?. <b>2001</b> , 10, 58-61	1
1795	Optimal endocrine therapy. <b>2001</b> , 10, 114-122	
1794	Clinical use of selective estrogen receptor modulators. <b>2001</b> , 13, 333-9	5
1793	Breast cancer prevention. <b>2001</b> , 44, 478-84	2
1792	Expanding role of breast cytopathology as a risk predictor. <b>2001</b> , 8, 255-63	3
1791	The impact of cancer therapy on reproductive function. <b>2001</b> , 56, 251-3	
1790	TAMOXIFEN TREATMENT AND GYNECOLOGIC SIDE EFFECTS. <b>2001</b> , 97, 855-866	57
1789	Breast cancer: risk, prevention, & tamoxifen. <b>2001</b> , 101, 26-35; quiz 36	4
1788	Breast cancer epidemiology, prevention, and early detection. <b>2001</b> , 13, 420-5	31
1787	Selenium in cancer prevention: clinical issues and implications. <b>2001</b> , 19, 540-53	36
1786	The complexities of predictive genetic testing. <b>2001</b> , 322, 1052-6	139
1785	Prevention of venous thromboembolism. <b>2001</b> , 119, 132S-175S	1321



1784	Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast. <b>2001</b> , 12, 819-24	85
1783	Aromatase inhibitors in the treatment and prevention of breast cancer. <b>2001</b> , 19, 881-94	243
1782	Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. <b>2001</b> , 19, 3524-31	377
1781	Molecular and pharmacokinetic evaluation of rat hepatic and gastrointestinal cytochrome p450 induction by tamoxifen. <b>2001</b> , 63, 210-9	14
1780	Ductal carcinoma in situ. <b>2001</b> , 12, 23-33	
1779	Overconfident Physician Opinion on the Effectiveness of BRCA1 Risk Reduction Measures. <b>2001</b> , 3, 1	
1778	Raloxifene Effect on Frequency of Surgery for Pelvic Floor Relaxation. <b>2001</b> , 98, 91-96	25
1777	Oestrogen receptors, growth factors and the control of breast cancer. <b>2001</b> , 10, 27-35	3
1776	Antioestrogens and breast cancer. <b>2001</b> , 7, 21-26	1
1775	Cancer prevention in postmenopausal women. <b>2001</b> , 7, 151-160	
1774	Systemic treatments for ductal carcinoma in situ. <b>2001</b> , 10, 54-57	
1773	The privatization of risk. <b>2001</b> , 91, 365-8	60
1772	White button mushroom phytochemicals inhibit aromatase activity and breast cancer cell proliferation. <b>2001</b> , 131, 3288-93	91
1771	Cancer genetics in oncology practice. <b>2001</b> , 12, 895-908	24
1770	Hormone und Mammakarzinom. <b>2001</b> , 17, 194-205	
1769	Operable breast cancer. <b>2001</b> , 2, 157-67	1
1768	Mammographic densities as a marker of human breast cancer risk and their use in chemoprevention. <b>2001</b> , 3, 314-21	109
1767	Educational review: role of the surgeon in hereditary breast cancer. <b>2001</b> , 8, 368-78	5

1766	Patient reluctance toward tamoxifen use for breast cancer primary prevention. <b>2001</b> , 8, 580-5	165
1765	New strategies for the treatment of breast cancer. <b>2001</b> , 8, 265-74	
1764	From adjuvant therapy to breast cancer prevention: BCPT and STAR. <b>2001</b> , 7, 144-57	47
1763	Biomarker assays in nipple aspirate fluid. <b>2001</b> , 7, 378-87	33
1762	SiteSelect: minimally invasive excision of breast lesions. <b>2001</b> , 7, 427-9	2
1761	Understanding mathematical models for breast cancer risk assessment and counseling. <b>2001</b> , 7, 224-32	93
1760	Chemoprevention for high-risk women: tamoxifen and beyond. <b>2001</b> , 7, 311-20	21
1759	Hereditary prostate cancer. <b>2000</b> , 85, 588-98	26
1758	Breast conservation in BRCA1 or BRCA2 mutation carriers with early stage breast cancer. <b>2001</b> , 45, 200-4	
1757	Prevention of disease with pharmaceuticals. <b>2001</b> , 88, 111-8	3
1756	Chemoprevention of breast cancer with selective estrogen receptor modulators: views from broadly diverse focus groups of women with elevated risk for breast cancer. <b>2001</b> , 10, 521-33	21
1755	MRI: a role in clinical trials. <b>2001</b> , 13, 837-41	4
1754	The role of hormones in breast carcinogenesis: issues of relevance to female childhood cancer survivors. <b>2001</b> , 36, 514-8	4
1753	Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast. <b>2001</b> , 77, 139-47	10
1752	A continuing medical education lecture and workshop, physician behavior, and barriers to change. <b>2001</b> , 21, 110-6	19
1751	Small cells in cervical-vaginal smears of patients treated with tamoxifen. <b>2001</b> , 93, 23-28	10
1750	Risk reduction endpoints should be part of the design of adjuvant therapy clinical trials for patients with melanoma. <b>2001</b> , 91, 881-888	1
1749	Impact of breast carcinoma on African-American women: the Detroit experience. <b>2001</b> , 91, 1834-43	15

1748	A case-control study of unilateral and bilateral breast carcinoma patients. <b>2001</b> , 91, 1845-53	60
1747	Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation. <b>2001</b> , 91, 1862-9	61
1746	Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. <b>2001</b> , 92, 959-68	83
1745	Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. <b>2001</b> , 92, 2247-58	516
1744	Biomonitoring of urinary tamoxifen and its metabolites from breast cancer patients using nonaqueous capillary electrophoresis with electrospray mass spectrometry. <b>2001</b> , 22, 2730-6	33
1743	Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. <b>2001</b> , 80, 176-80	161
1742	Tamoxifen as systemic treatment of advanced breast cancer during pregnancy--case report and literature review. <b>2001</b> , 80, 405-8	104
1741	Breast cancer risk assessment in indigent women at a public hospital. <b>2001</b> , 81, 287-90	25
1740	Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma. <b>2001</b> , 83, 501-3	33
1739	Comparison of physicians' and cancer prone women's attitudes about breast/ovarian prophylactic surgery. Results from two national surveys. <b>2001</b> , 1, 157-62	9
1738	Risk models used to counsel women for breast and ovarian cancer: a guide for clinicians. <b>2001</b> , 1, 197-206	27
1737	Cancer prone persons. A randomized screening trial based on colonoscopy: background, design and recruitment. <b>2001</b> , 1, 175-9	6
1736	Breast cancer in the clinic: treatments past, treatments future. <b>2001</b> , 6, 487-95	8
1735	Treatment of postmenopausal osteoporosis: an evidence-based approach. <b>2001</b> , 2, 35-43	7
1734	Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulation. <b>2001</b> , 2, 129-38	38
1733	Divergent effects of raloxifene HCl on the pharmacokinetics and pharmacodynamics of warfarin. <b>2001</b> , 18, 1024-8	14
1732	Clinical management of women with genomic BRCA1 and BRCA2 mutations. <b>2001</b> , 69, 101-13	22
1731	Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women. <b>2001</b> , 69, 21-7	32

1730	Familial breast cancer: an investigation into the outcome of treatment for early stage disease. <b>2001</b> , 1, 65-72	39
1729	Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. <b>2001</b> , 65, 125-34	539
1728	Tamoxifen suppresses histologic progression to atypia and DCIS in MCFIOAT xenografts, a model of early human breast cancer. <b>2001</b> , 65, 41-7	10
1727	Acute abdomen during adjuvant chemotherapy: superior mesenteric artery thrombosis associated with CMF chemotherapy. <b>2001</b> , 13, 441-3	3
1726	A practical approach to the older patient with cancer. <b>2001</b> , 25, 7-76	23
1725	First do no harm: extending the debate on the provision of preventive tamoxifen. <b>2001</b> , 85, 1280-8	13
1724	Acquired thrombophilic syndromes. <b>2001</b> , 15, 31-48	11
1723	Cyclin proteolysis as a retinoid cancer prevention mechanism. <b>2001</b> , 952, 13-22	27
1722	Hormonal prevention of hereditary breast cancer. <b>2001</b> , 952, 36-43	44
1721	Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention. <b>2001</b> , 952, 44-59	25
1720	Chemoprevention with antiestrogens: the beginning of the end for breast cancer. Daniel G. Miller Lecture. <b>2001</b> , 952, 60-72	6
1719	Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. <b>2001</b> , 943, 296-315	190
1718	Second cancers after conservative surgery and radiation for stages I-II breast cancer: identifying a subset of women at increased risk. <b>2001</b> , 51, 679-90	106
1717	Molecular targets for breast cancer therapy and prevention. <b>2001</b> , 7, 548-52	235
1716	Will the experience with tamoxifen in breast cancer help define the role of antiandrogens in prostate cancer?. <b>2001</b> , 4, 72-80	11
1715	Seaweed prevents breast cancer?. <b>2001</b> , 92, 483-7	109
1714	Hereditary breast cancer. <b>2001</b> , 38, 387-480	111
1713	Cancer prevention with green tea and monitoring by a new biomarker, hnRNP B1. <b>2001</b> , 480-481, 299-304	55

1712	Ovarian steroids and control of proliferation in the normal human breast. <b>2001</b> , 10, 273-8		10
1711	Screening for the major malignancies affecting women: current guidelines. <b>2001</b> , 184, 1021-30		34
1710	Estrogens, progestins, selective estrogen receptor modulators, and the arterial tree. <b>2001</b> , 184, 1031-9		7
1709	Ductal carcinoma in situ (DCIS) of the breast: diagnostic and therapeutic controversies. <b>2001</b> , 192, 196-214		25
1708	The Lynn Sage Memorial Lecture: new developments in breast cancer management. <b>2001</b> , 192, 761-7		3
1707	Tamoxifen, screening and new oestrogen receptor modulators. <b>2001</b> , 15, 365-80		21
1706	Oestrogen and selective oestrogen receptor modulators (SERMs): current roles in the prevention and treatment of osteoporosis. <b>2001</b> , 15, 451-68		5
1705	Results of a community pharmacy-based breast cancer risk-assessment and education program. <b>2001</b> , 21, 243-53		41
1704	American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001--testing for early lung cancer detection. <b>2001</b> , 51, 38-75; quiz 77-80		554
1703	Tamoxifen but not 4-hydroxytamoxifen initiates apoptosis in p53(-) normal human mammary epithelial cells by inducing mitochondrial depolarization. <b>2001</b> , 276, 5384-94		55
1702	The proto-oncoprotein Brx activates estrogen receptor beta by a p38 mitogen-activated protein kinase pathway. <b>2001</b> , 276, 46792-7		44
1701	Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer. <b>2001</b> , 19, 649-59		32
1700	Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 2-4	9.7	18
1699	Gynecologic Problems in Patients with Breast Cancer. <b>2001</b> , 382-405		
1698	Comparisons of the effects of tamoxifen, toremifene and raloxifene on enzyme induction and gene expression in the ovariectomised rat uterus. <b>2001</b> , 170, 555-64		12
1697	Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 824-42	9.7	589
1696	Validating and improving models for projecting the absolute risk of breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 334-5	9.7	95
1695	Is hormone replacement therapy safe for breast cancer patients?. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 733-4	9.7	16

1694	Studies of epidermal growth factor receptor inhibition in breast cancer. <b>2001</b> , 8, 183-9		25
1693	Chemoprevention for Healthy Women: Harbinger of Things to Come?. <b>2001</b> , 5, 311-333		11
1692	The management of ductal carcinoma in situ of the breast. <b>2001</b> , 8, 33-45		35
1691	Re: Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 1420; author reply 1421-2	9.7	
1690	Risk-reduction mastectomy: clinical issues and research needs. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 1297-306	9.7	53
1689	Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect. <b>2001</b> , 21, 255-61		77
1688	Management of thrombosis in women with antiphospholipid syndrome. <b>2001</b> , 44, 36-47		16
1687	Efficacy of systemic adjuvant therapy for breast cancer in African-American and Caucasian women. <b>2001</b> , 36-43		61
1686	Duration of adjuvant tamoxifen therapy. <b>2001</b> , 56-61		52
1685	Lung epithelial proliferation: a biomarker for chemoprevention trials?. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 1042-3	9.7	12
1684	Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life. <b>2001</b> , 130-4		60
1683	National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000. <b>2001</b> , 2001, 5-15		115
1682	Pathologic features of breast cancers in women with previous benign breast disease. <b>2001</b> , 115, 362-9		19
1681	Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. <b>2001</b> , 135-42		205
1680	Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. <b>2001</b> , 86, 4216-22		68
1679	Tamoxifen and breast cancer risk in women harboring a BRCA1 germline mutation: computed efficacy, effectiveness and impact.. <b>2001</b> , 18, 5		1
1678	Chapter 15. Targeting the estrogen receptor with SERMs. <b>2001</b> , 36, 149-158		7
1677	Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women. <b>2001</b> , 84, 897-902		34

1676	Sonohysterography for evaluation of the endometrium in women treated with tamoxifen. <b>2001</b> , 177, 337-42		30
1675	Proliferative lesions of ovarian granulosa cells and reversible hormonal changes induced in rats by a selective estrogen receptor modulator. <b>2001</b> , 29, 403-10		28
1674	Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 605-18	9.7	267
1673	RESPONSE: Re: Prognosis and Treatment of Patients With Breast Tumors of One Centimeter or Less and Negative Axillary Lymph Nodes. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 1421-1422	9.7	0
1672	New drugs in breast cancer. <b>2001</b> , 2, 975-85		1
1671	Short-term dosing of alpha-hydroxytamoxifen results in DNA damage but does not lead to liver tumours in female Wistar/Han rats. <b>2001</b> , 22, 553-7		11
1670	Hormone replacement therapy (HRT)--risks and benefits. <b>2001</b> , 30, 423-6		76
1669	Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities. <b>2001</b> , 56, 293-368		13
1668	Methodologic challenges in chronic disease population research. <b>2001</b> , 2, 365-81		9
1667	Familiar drugs may prevent cancer. <b>2001</b> , 77, 492-7		3
1666	A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. <b>2001</b> , 98, 3232-6		158
1665	Epidemiology of thrombosis in cancer. <b>2001</b> , 106, 6-12		163
1664	Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrozole, paclitaxel, bexarotene. <b>2001</b> , 6, 4-11		72
1663	Hormonal Carcinogenesis III. <b>2001</b> ,		1
1662	Bone mass and breast cancer risk in older women: differences by stage at diagnosis. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 930-6	9.7	72
1661	Breast cancer. <b>2001</b> , 6, 338-46		7
1660	Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 1624-32	9.7	227
1659	Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 1615-23	9.7	85

1658	Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. <b>2001</b> , 286, 2251-6		564
1657	Proliferative lesions of ovarian granulosa cells and reversible hormonal changes induced in rats by a selective estrogen receptor modulator. <b>2001</b> , 29, 719-26		14
1656	Tamoxifen and contralateral breast cancer: the other side. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 963-5	9.7	12
1655	Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells. <b>2001</b> , 276, 40888-95		100
1654	Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 16-21	9.7	123
1653	Estrogen receptors and proliferation markers in primary and recurrent breast cancer. <b>2001</b> , 98, 15197-202		179
1652	Re: Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 1420-1; author reply 1421-2	9.7	1
1651	Hormones and hormone antagonists: mechanisms of action in carcinogenesis of endometrial and breast cancer. <b>2001</b> , 33, 451-7		65
1650	Epidemiology of pulmonary embolism. <b>2001</b> , 1, 139-46		14
1649	Tumour angiogenesis: a novel therapeutic target in patients with malignant disease. <b>2001</b> , 6, 155-74		4
1648	Endometrial evaluation with transvaginal US and hysterosonography in asymptomatic postmenopausal women with breast cancer receiving tamoxifen. <b>2001</b> , 220, 765-73		36
1647	Susceptibility to estrogen-induced mammary cancer segregates as an incompletely dominant phenotype in reciprocal crosses between the ACI and Copenhagen rat strains. <b>2001</b> , 142, 5124-30		25
1646	Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. <b>2001</b> , 86, 16-23		78
1645	Management of breast cancer: is there a role for somatostatin and its analogs?. <b>2001</b> , 47 Suppl 2, 62-77		8
1644	Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 1008-13	9.7	65
1643	Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. <b>2001</b> , 344, 305-6; author reply 306-7		12
1642	Shortened zidovudine regimens to prevent mother-to-child transmission of HIV-1. <b>2001</b> , 344, 307		3
1641	Treatment of systemic mast-cell disease with cladribine. <b>2001</b> , 344, 307-9		130



1640	Survivors of breast cancer. <b>2001</b> , 344, 309; author reply 309-10		5
1639	Transmission of histoplasmosis by organ transplantation. <b>2001</b> , 344, 310		4
1638	Aspergillus fungus balls on the mitral valve. <b>2001</b> , 344, 310-1		5
1637	Prophylactic mastectomy for women with BRCA1 and BRCA2 mutations--facts and controversy. <b>2001</b> , 345, 207-8		18
1636	The major infectious diseases in the world--to treat or not to treat?. <b>2001</b> , 345, 208-10		34
1635	Epidemiology of venous thromboembolism. <b>2001</b> , 1, 7-26		63
1634	Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 51-6	9.7	110
1633	Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen. <b>2002</b> , 1, 253-67		56
1632	Medical management of breast cancer: today and tomorrow. <b>2002</b> , 17, 137-49		9
1631	Chromatin remodeling and tissue-selective responses of nuclear hormone receptors. <b>2002</b> , 80, 343-51		30
1630	American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. <b>2002</b> , 20, 3328-43		166
1629	Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. <b>2002</b> , 20, 4141-9		482
1628	A peptide derived from alpha-fetoprotein prevents the growth of estrogen-dependent human breast cancers sensitive and resistant to tamoxifen. <b>2002</b> , 99, 2211-5		39
1627	The effects of tamoxifen and estrogen on brain metabolism in elderly women. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 592-7	9.7	76
1626	Raloxifene is associated with less side effects than tamoxifen in women with early breast cancer: a questionnaire study from one physician's practice. <b>2002</b> , 11, 291-301		9
1625	Adherence to therapy with oral antineoplastic agents. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 652-61	9.7	413
1624	Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers. <b>2002</b> , 225, 519-26		100
1623	Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. <b>2002</b> , 301, 945-52		64

1622	Tamoxifen induction of angiogenic factor expression in endometrium. <b>2002</b> , 86, 761-7		17
1621	Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations. <b>2002</b> , 86, 218-21		26
1620	Hobson's choice and the need for combinations of new agents for the prevention and treatment of breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 242-3	9.7	15
1619	Outcomes of Tamoxifen Chemoprevention for Breast Cancer in Very High-Risk Women: A Cost-Effectiveness Analysis. <b>2002</b> , 20, 9-16		23
1618	American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. <b>2002</b> , 20, 3317-27		196
1617	Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. <b>2002</b> , 30, 869-74		208
1616	Screening trials are even more difficult than we thought they were. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 156-7	9.7	21
1615	Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. <b>2002</b> , 23, 1897-901		72
1614	Change in the gene expression of hepatic tamoxifen-metabolizing enzymes during the process of tamoxifen-induced hepatocarcinogenesis in female rats. <b>2002</b> , 23, 491-8		23
1613	An estrogen receptor repressor induces cataract formation in transgenic mice. <b>2002</b> , 99, 9427-32		25
1612	Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells. <b>2002</b> , 277, 9189-98		60
1611	Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). <b>2002</b> , 288, 58-66		490
1610	Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells. <b>2002</b> , 62, 911-20		31
1609	Breast cancer prevention. <b>2002</b> , 7, 60-4		20
1608	Informing clinical trial participants about study results. <b>2002</b> , 288, 363-5		119
1607	Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. <b>2002</b> , 346, 1660-2		67
1606	Inhibition of lung metastasis of B16 melanoma cells exposed to blue light in mice. <b>2002</b> , 10, 701		
1605	Lung cancer prevention with (-)-epigallocatechin gallate using monitoring by heterogeneous nuclear ribonucleoprotein B1. <b>2002</b> , 20, 1233		2

1604	Serum estradiol level and risk of breast cancer during treatment with raloxifene. <b>2002</b> , 287, 216-20		154
1603	Analysis of anticancer drugs and their metabolites by mass spectrometry. <b>2002</b> , 3, 463-80		12
1602	Raloxifene and cardiovascular disease. <b>2002</b> , 5, 109-111		1
1601	Ovarian hyperstimulation by LH leads to mammary gland hyperplasia and cancer predisposition in transgenic mice. <b>2002</b> , 143, 3671-80		27
1600	Antiestrogens: the past and the future. <b>2002</b> , 124, 551-8		1
1599	The agonist activity of tamoxifen is inhibited by the short heterodimer partner orphan nuclear receptor in human endometrial cancer cells. <b>2002</b> , 143, 853-67		18
1598	Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 1564-9	9.7	58
1597	Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. <b>2002</b> , 287, 847-57		415
1596	How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. <b>2002</b> , 20, 2109-17		394
1595	Cancer risks in BRCA1 carriers: time for the next generation of studies. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 1344-5	9.7	17
1594	Risk assessment and management of high risk familial breast cancer. <b>2002</b> , 39, 865-71		43
1593	Breast Cancer. <b>2002</b> , 287-299		
1592	Chemoprevention, Pharmacology of. <b>2002</b> , 449-455		6
1591	Chemoprevention Trials. <b>2002</b> , 457-472		
1590	Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 1504	9.7	41
1589	Survival impact of tamoxifen use for breast cancer risk reduction: projections from a patient-specific Markov model. <b>2002</b> , 22, 386-93		8
1588	The influence of menstrual cycle phase on surgical treatment of primary breast cancer: have we made any progress over the past 13 years?. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 641-3	9.7	13
1587	Biomedicine. Defining the "S" in SERMs. <b>2002</b> , 295, 2380-1		174

1586	Prevention in the balance. <b>2002</b> , 7, 103-5		1
1585	Retrospective assessment of hypercoagulability in breast cancer prevention trial. <b>2002</b> , 20, 4133-4		9
1584	Breast cancer prevention. <b>2002</b> , 7, 100-2		2
1583	Selective Estrogen Receptor Modulators. <b>2002</b> , 677-XXXI		
1582	Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 274-83	9.7	60
1581	Failure of estrogen plus progestin therapy for prevention. <b>2002</b> , 288, 366-8		134
1580	Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. <b>2002</b> , 20, 3396-403		557
1579	Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. <b>2002</b> , 20, 3386-95		532
1578	Progress in breast cancer chemoprevention. <b>2002</b> , 9, 15-32		13
1577	Breast health and disease over a lifetime. <b>2002</b> , 45, 1140-61		6
1576	In situ breast carcinoma: diagnosis and treatment. <b>2002</b> , 45, 774-7		1
1575	Multiple-dose, safety, pharmacokinetics, and pharmacodynamics of a new selective estrogen receptor modulator, ERA-923, in healthy postmenopausal women. <b>2002</b> , 42, 157-65		15
1574	Association of tamoxifen and uterine sarcoma. <b>2002</b> , 20, 2758-60		168
1573	Role of antiestrogens and aromatase inhibitors in breast cancer treatment. <b>2002</b> , 14, 5-12		10
1572	Breast cancer: introduction. <b>2002</b> , 45, 738-45		5
1571	Molecular and biologic markers of premalignant lesions of human breast. <b>2002</b> , 9, 185-97		42
1570	Strain differences in tamoxifen sensitivity of Sprague-Dawley and Fischer 344 rats. <b>2002</b> , 13, 939-47		11
1569	Venous thromboembolism guidebook. <b>2002</b> , 1, 26-43		6

1568	What Outcomes Matter to Patients. <b>2002</b> , 40, III-11-III-19	18
1567	Applications of advances in molecular biology and genomics to clinical cancer care. <b>2002</b> , 25, 110-22; quiz 123-4	5
1566	Controversy about uterine effects and safety of SERMs: the saga continues. <b>2002</b> , 9, 381-4	20
1565	BRCA gene mutations and cancer. <b>2002</b> , 102, 28-36	1
1564	Trait anxiety and tamoxifen effects on bone mineral density and sex hormone- binding globulin. <b>2002</b> , 64, 612-20	8
1563	Inherited risk of women's cancers: what's changed for the practicing physician?. <b>2002</b> , 45, 671-83; discussion 730-2	5
1562	Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. <b>2002</b> , 100, 1989-96	347
1561	Making good decisions about breast cancer chemoprevention. <b>2002</b> , 137, 52-4	11
1560	Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. <b>2002</b> , 136, 680-90	127
1559	Breast cancer. <b>2002</b> , 324, 410-4	13
1558	Who's liable for breast cancer prevention? Your patient can sue--and win--if preventive options aren't made clear. <b>2002</b> , 111, 83-4, 87-8, 91-2	2
1557	Hormone replacement therapy and coronary heart disease in women: a review of the evidence. <b>2002</b> , 324, 180-4	18
1556	Aromatase inhibitors in breast cancer: an update. <b>2002</b> , 9, 490-8	29
1555	Chemoprevention. <b>2002</b> , 374-388	1
1554	. <b>2002</b> , 4, 173-192	3
1553	Breast cancer prevention and surveillance. <b>2002</b> , 45, 778-83	2
1552	The genetics of breast cancer. <b>2002</b> , 8, 24-29	
1551	New challenges in the treatment of early breast cancer or surgery for early breast cancer ... can less be more?. <b>2002</b> , 102, 97-109	5

1550	DNA adducts formed from 4-hydroxytamoxifen are more mutagenic than those formed by alpha-acetoxymoxifen in a shuttle vector target gene replicated in human Ad293 cells. <b>2002</b> , 41, 8899-906	21
1549	Hereditary premenopausal breast cancer. <b>2002</b> , 25, 24-7	2
1548	Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy. <b>2002</b> , 20, 2092-100	75
1547	Bioactivation of tamoxifen by recombinant human cytochrome p450 enzymes. <b>2002</b> , 15, 614-22	47
1546	Preparation of oligodeoxynucleotides containing a diastereoisomer of alpha-(N(2)-2'-deoxyguanosinyl)tamoxifen by phosphoramidite chemical synthesis. <b>2002</b> , 15, 218-25	12
1545	Genes involved in breast cancer progression: analysis of global changes in gene expression or retroviral tagging?. <b>2002</b> , 161, 1973-7	2
1544	Breast cancer-treatment for the future based on lessons from the past. <b>2002</b> , 184, 477-83	5
1543	Interest in BRCA1/2 testing in a primary care population. <b>2002</b> , 34, 590-5	54
1542	Reduction of a 7,12-dimethylbenz[a]anthracene DNA adduct in rat mammary tissue in vivo when pretreated with tamoxifen. <b>2002</b> , 132, 71-9	3
1541	New opportunities in chemoprevention research. <b>2002</b> , 20, 237-45	11
1540	Estrogens and Antiestrogens. <b>2002</b> , 179-188	
1539	Molecular determinants for the tissue specificity of SERMs. <b>2002</b> , 295, 2465-8	987
1538	Premenopausal breast cancer: chemotherapy and endocrine therapy. <b>2002</b> , 62, 2025-38	5
1537	Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade. <b>2002</b> , 2, 272-81	31
1536	A rationale for the reinitiation of adjuvant tamoxifen therapy in women receiving fewer than 5 years of therapy. <b>2002</b> , 2, 282-6	15
1535	Antiaromatase agents: evolving role in adjuvant therapy. <b>2002</b> , 3, 33-42	
1534	Breast cancer chemoprevention: current challenges and a look toward the future. <b>2002</b> , 3, 113-24	17
1533	The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. <b>2002</b> , 3, 153-9	72

1532	Overview: gemcitabine as single-agent therapy for advanced breast cancer. <b>2002</b> , 3 Suppl 1, 8-11	18
1531	Concepts in Breast Surgery. <b>2002</b> , 819-827	
1530	The role of the IGF system in cancer: from basic to clinical studies and clinical applications. <b>2002</b> , 63, 317-32	272
1529	A new day dawns: women without oestrogen or is a balance best?. <b>2002</b> , 4, 218-21	2
1528	Has tamoxifen had its day?. <b>2002</b> , 4, 213-7	16
1527	The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. <b>2002</b> , 4, 197-201	166
1526	Hormonal control of p53 and chemoprevention. <b>2002</b> , 4, 91-4	3
1525	The utility of ductal lavage in breast cancer detection and risk assessment. <b>2002</b> , 4, 51-3	8
1524	Adjuvant Tamoxifen. <b>2002</b> , 1, 375-386	1
1523	Breast Cancer Prevention. <b>2002</b> , 1, 173-178	
1522	Efficacy and economics of hormonal therapies for advanced breast cancer. <b>2002</b> , 19, 453-63	17
1521	Chemoprevention of breast cancer: implications for postmenopausal women. <b>2002</b> , 19, 43-78	6
1520	Estado actual en el tratamiento del c�ncer. <b>2002</b> , 9, 546-551	
1519	Adjuvant therapy in breast cancer. <b>2002</b> , 29, 201-8, ix	4
1518	Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. <b>2002</b> , 20, 2520-9	127
1517	Breast cancer risk reduction: strategies for women at increased risk. <b>2002</b> , 53, 519-40	28
1516	The search for the ideal SERM. <b>2002</b> , 3, 681-91	27
1515	Female hormones and thrombosis. <b>2002</b> , 22, 201-10	197

1514	The role of cyclooxygenase inhibitors in cancer prevention. <b>2002</b> , 8, 1035-62	69
1513	Claims and disclaimers: whose expertise counts?. <b>2002</b> , 21, 275-306	22
1512	Risk, prevention and the breast cancer continuum: The NCI, the FDA, health activism and the pharmaceutical industry. <b>2002</b> , 18, 309-353	28
1511	Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety. <b>2002</b> , 1, 93-107	26
1510	Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. <b>2002</b> , 32, 863-78	66
1509	Breast cancer chemoprevention--an update. <b>2002</b> , 18, 329-31	3
1508	Cancer chemoprevention. <b>2002</b> , 324, 714-8	86
1507	Dietary fat reduction to reduce prostate cancer risk: controlled enthusiasm, learning a lesson from breast or other cancers, and the big picture. <b>2002</b> , 59, 51-62	23
1506	Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women. <b>2002</b> , 59, 20-33	111
1505	Tamoxifen for breast cancer among hysterectomised women. <b>2002</b> , 359, 1122-4	119
1504	Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer. <b>2002</b> , 359, 2126-7	10
1503	First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. <b>2002</b> , 360, 817-24	611
1502	Chemoprevention of breast cancer: a promising idea with an uncertain future. <b>2002</b> , 360, 813-4	7
1501	BRCA1: mechanisms of inactivation and implications for management of patients. <b>2002</b> , 360, 1007-14	99
1500	Tamoxifen for breast cancer in hysterectomised women. <b>2002</b> , 360, 1784-5; author reply 1785	1
1499	Hot flushes. <b>2002</b> , 360, 1851-61	313
1498	The effect of tamoxifen on the proliferative activity of fibroadenomas. <b>2002</b> , 77, 155-6	
1497	Chemoprevention of precursors to colon cancer by dehydroepiandrosterone (DHEA). <b>2002</b> , 70, 2623-30	15



1496	Insulin-like growth factors and cancer. <b>2002</b> , 3, 298-302	440
1495	Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. <b>2002</b> , 346, 1609-15	1198
1494	Combined E-cadherin and high molecular weight cytokeratin immunoprofile differentiates lobular, ductal, and hybrid mammary intraepithelial neoplasias. <b>2002</b> , 33, 620-7	107
1493	Resveratrol--a prostate cancer chemopreventive agent?. <b>2002</b> , 7, 223-7	42
1492	Steroid receptors in human breast tumorigenesis and breast cancer progression. <b>2002</b> , 56, 65-77	44
1491	The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. <b>2002</b> , 3, 207-14	97
1490	A case for geriatric oncology. <b>2002</b> , 3, 289-97	110
1489	Hormone-replacement therapy and breast cancer. <b>2002</b> , 3, 303-11	35
1488	Population screening for cancer-related germline gene mutations. <b>2002</b> , 3, 341-8	14
1487	Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. <b>2002</b> , 3, 461-9	361
1486	Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies. <b>2002</b> , 3, 611-9	32
1485	Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. <b>2002</b> , 8, 82-8	98
1484	Focus on cancer prevention. <b>2002</b> , 8, 315-7	
1483	Osteoporosis: non-HRT treatments. <b>2002</b> , 2, 48-53	2
1482	Erratum. <b>2002</b> , 3, 159	
1481	Focus on breast cancer. <b>2002</b> , 1, 319-22	76
1480	Steroid hormone mimics: molecular mechanisms of cell growth and apoptosis in normal and malignant mammary epithelial cells. <b>2002</b> , 80, 191-201	27
1479	Effect of 4-hydroxytamoxifen isomers on growth and ultrastructural aspects of normal human breast epithelial (HBE) cells in culture. <b>2002</b> , 82, 289-96	9

1478	A mechanism of drug resistance to tamoxifen in breast cancer. <b>2002</b> , 83, 75-83	28
1477	The menopause, hormone replacement therapy and breast cancer. <b>2002</b> , 83, 123-32	23
1476	Aromatase inhibitors in breast cancer. <b>2002</b> , 13, 61-5	43
1475	[Approach of menopause in women at risk for breast cancer]. <b>2002</b> , 30, 101-13	1
1474	Guidelines on endocrine therapy of breast cancer EUSOMA. <b>2002</b> , 38, 615-34	49
1473	Lung cancer risks in women with previous breast cancer. <b>2002</b> , 38, 1520-5	51
1472	Endocrine treatment and prevention of breast and gynaecological cancers. <b>2002</b> , 38 Suppl 6, S1-11	4
1471	Tamoxifen for primary breast cancer prevention in BRCA heterozygotes. <b>2002</b> , 38 Suppl 6, S18-9	32
1470	Tamoxifen versus raloxifene in the prevention of breast cancer. <b>2002</b> , 38 Suppl 6, S20-1	5
1469	Rationale for a study adding tamoxifen to HRT. <b>2002</b> , 38 Suppl 6, S22-3	3
1468	Adjuvant hormone therapy following primary therapy for endometrial cancer. <b>2002</b> , 38 Suppl 6, S41-3	3
1467	How do endogenous oestrogens affect breast cancer?. <b>2002</b> , 38 Suppl 6, S59-60	2
1466	Evolving uses of hormonal agents for breast cancer therapy. <b>2002</b> , 24 Suppl C, C3-25	17
1465	Tamoxifen ("Nolvadex"): a review. <b>2002</b> , 28, 165-80	171
1464	Management of the menopause in cancer survivors. <b>2002</b> , 28, 321-33	7
1463	Cancer in the family and implications for hormone replacement therapy. <b>2002</b> , 1229, 157-161	1
1462	Growth-stimulatory and transcriptional activation properties of raloxifene in human endometrial Ishikawa cells. <b>2002</b> , 190, 65-73	9
1461	Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells. <b>2002</b> , 192, 93-104	44

- 1460 Induction of lacI mutations in Big Blue rats treated with tamoxifen and alpha-hydroxytamoxifen. **2002**, 176, 37-45 16
- 1459 Inhibition of progesterone-induced VEGF production in human breast cancer cells by the pure antiestrogen ICI 182,780. **2002**, 181, 47-53 12
- 1458 A 60-year-old woman trying to discontinue hormone replacement therapy. **2002**, 287, 2130-7 29
- 1457 Prevention in the year 2002: some news, some issues. **2002**, 29, 727-49, xi 4
- 1456 Quimioprevenci3 del c3ncer de mama. **2002**, 28, 80-83
- 1455 Diagn3stico precoz de carcinoma de endometrio en una paciente tratada con tamoxifeno. **2002**, 45, 448-452
- 1454 Counseling the at risk patient in the BRCA1 and BRCA2 Era. **2002**, 29, 341-66, vii 7
- 1453 The role of nutrition and nutrients in the prevention of chronic diseases. **2002**, 29, 615-27, x 5
- 1452 Risk factors for breast cancer. **2002**, 29, 159-72 8
- 1451 Identifying and counseling women at increased risk for breast cancer. **2002**, 77, 355-60; quiz 360-1 11
- 1450 Preventive care for the menopausal woman. **2002**, 29, 583-97 6
- 1449 Prevention of cancer in the older person. **2002**, 18, 505-28 14
- 1448 An Acknowledgment. **2002**, 20, 2761-2761
- 1447 The natural history of hereditary breast cancer. **2002**, 81-107
- 1446 Management of BRCA1/2 mutation carriers. **2002**, 237-274 1
- 1445 Altera33s Endometriais em Pacientes com C3ncer de Mama Tratadas com Tamoxifeno. **2002**, 24, 233 1
- 1444 Glycolysis as a metabolic marker in orthotopic breast cancer, monitored by in vivo (13)C MRS. **2002**, 283, E623-30 43
- 1443 Therapeutic potentials of androgens, estrogen and SERMs in glucocorticoid-induced osteoporosis. **2002**, 30, 136-44

1442	Statistical explanations for a community-based study of once-weekly epoetin alfa therapy in patients receiving chemotherapy. <b>2002</b> , 20, 2757-8	2
1441	A trial of two questions. <b>2002</b> , 20, 4135-8	2
1440	Hypersensitivity reaction (HSR) to docetaxel after a previous HSR to paclitaxel. <b>2002</b> , 20, 2760-1	22
1439	Why do we still use hormone replacement therapy? Why don't we use it more?. <b>2002</b> , 20, 616-9	2
1438	A rose is no longer a rose. <b>2002</b> , 20, 3365-8	6
1437	Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. <b>2002</b> , 20, 9-16	48
1436	Weight loss in breast cancer patient management. <b>2002</b> , 20, 1128-43	457
1435	Chemoprevention of breast cancer: a model for change. <b>2002</b> , 20, 1-3	315
1434	Critical factors in optimizing graft-versus-leukemia effect for relapsed leukemias. <b>2002</b> , 20, 2756; author reply 2756-7	3
1433	Targeting the estrogen receptor in clinical breast cancer. <b>2002</b> , 15, 3-11	7
1432	Hereditary breast cancer and handling of patients at risk. <b>2002</b> , 91, 280-7	6
1431	Ductal lavage for breast cancer risk assessment. <b>2002</b> , 9, 473-9	4
1430	Acupuncture in the Treatment of Menopause-related Symptoms in Women Taking Tamoxifen. <b>2002</b> , 88, 128-130	45
1429	Prevention of venous thromboembolism in acute medical illness. <b>2002</b> , 22, 1564-78	21
1428	Breast cancer 2002: where do we stand?. <b>2002</b> , 52, 253-5	3
1427	Radiotherapy for breast cancer in BRCA1/BRCA2 carriers: clinical issues and management dilemmas. <b>2002</b> , 12, 352-61	14
1426	Considerations in genetic counseling for inherited breast cancer predisposition. <b>2002</b> , 12, 362-70	
1425	Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. <b>2002</b> , 187, 521-7	97

1424	Tamoxifen and toremifene cause impairment of learning and memory function in mice. <b>2002</b> , 71, 269-76	48
1423	A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer. <b>2002</b> , 29, 129-133	1
1422	Effects of hormone replacement therapy and estrogen receptor modulators on markers of inflammation and coagulation. <b>2002</b> , 90, 7F-10F	36
1421	Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. <b>2002</b> , 90, 1204-10	69
1420	A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) Study. <b>2002</b> , 23, 728-56	225
1419	17Beta-estradiol epoxidation as the molecular basis for breast cancer initiation and prevention. <b>2002</b> , 11 Suppl 7, S460-6	8
1418	Soy foods and soybean isoflavones and menopausal health. <b>2002</b> , 5, 272-82	39
1417	Cancer risk in menopausal women. <b>2002</b> , 16, 293-307	7
1416	Hereditary risk of women's cancers. <b>2002</b> , 16, 703-13	11
1415	A working model for the time sequence of genetic changes in breast tumorigenesis. <b>2002</b> , 194, 202-16	16
1414	Evaluation and management of the woman with an abnormal ductal lavage. <b>2002</b> , 194, 648-56	32
1413	Effects of oral estrogen, raloxifene and arzoxifene on gene expression in serotonin neurons of macaques. <b>2002</b> , 27, 431-45	81
1412	Mammography screening and breast cancer biology in African American women--a review. <b>2002</b> , 26, 180-91	8
1411	A proposed mechanism of tamoxifen in breast cancer prevention. <b>2002</b> , 26, 370-5	16
1410	Risk estimation for breast cancer development; a clinical perspective. <b>2002</b> , 10, 183-92	38
1409	Effect of all-trans-retinoic acid on the hypercoagulable state of patients with breast cancer. <b>2002</b> , 70, 9-15	13
1408	Ploidy differences between hormone- and chemical carcinogen-induced rat mammary neoplasms: comparison to invasive human ductal breast cancer. <b>2002</b> , 33, 56-65	51
1407	Molecular markers and therapeutic targets in ductal carcinoma in situ. <b>2002</b> , 59, 3-11	9

1406	Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. <b>2002</b> , 99, 273-8	33
1405	Is the telomerase assay useful for screening of endometrial lesions?. <b>2002</b> , 100, 714-8	10
1404	Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center. <b>2002</b> , 94, 305-13	25
1403	Ductal lavage and the clinical management of women at high risk for breast carcinoma: a commentary. <b>2002</b> , 94, 292-8	40
1402	Utilization of BRCA1/2 genetic testing in the clinical setting: report from a single institution. <b>2002</b> , 94, 1876-85	48
1401	Selection and description of cancer clinical trials participants--science or happenstance?. <b>2002</b> , 95, 950-9	64
1400	Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. <b>2002</b> , 95, 2059-67	214
1399	Advanced age and adjuvant tamoxifen prescription in early-stage breast carcinoma patients. <b>2002</b> , 95, 2465-72	22
1398	Selective estrogen receptor modulators (SERM) for the brain: Recent advances and remaining challenges for developing a NeuroSERM. <b>2002</b> , 56, 380-392	10
1397	4-Hydroxytamoxifen sulfation metabolism. <b>2002</b> , 16, 279-85	34
1396	Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention. <b>2002</b> , 39, 264-70	11
1395	Breast cancer prevention through the eyes of a survivor. <b>2002</b> , 39, 108-11	
1394	Current role of endocrine therapy in the management of breast cancer. <b>2002</b> , 9, 276-81	2
1393	Lasofoxifene (CP-336,156), a novel selective estrogen receptor modulator, in preclinical studies. <b>2002</b> , 25, 87-99	6
1392	Postmenopausal hormone replacement therapy as antiatherosclerotic therapy. <b>2002</b> , 4, 52-8	9
1391	New approaches to lung cancer prevention. <b>2002</b> , 4, 487-94	15
1390	[Breast carcinoma. Biological principles, classification and prognostic factors]. <b>2002</b> , 43, 329-30, 333-9	1
1389	Genetische Risikofaktoren des Mammakarzinoms. <b>2002</b> , 35, 527-536	4

1388	Chromosome 3p and breast cancer. <b>2002</b> , 47, 453-9	34
1387	Prävention und Brustkrebsfrüherkennung. <b>2002</b> , 8, 797-807	1
1386	SERMs: current status and future trends. <b>2002</b> , 43, 63-76	64
1385	Symposium 21: (Risk) indicator lesions and carcinoma in situ of the breast. <b>2002</b> , 41, 346-363	
1384	Prospects for chemoprevention of cancer. <b>2002</b> , 251, 286-300	58
1383	Toxicity of antiestrogens. <b>2002</b> , 8, 92-6	35
1382	Breast cancer risk assessment in patients seen in a gynecologic oncology clinic. <b>2002</b> , 12, 389-93	4
1381	Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature. <b>2002</b> , 12, 496-500	49
1380	The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. <b>2002</b> , 54, 157-67	107
1379	Genetic predisposition to breast cancer: a surgical perspective. <b>2000</b> , 87, 149-62	19
1378	Prevention of radiation-induced mammary tumors. <b>2002</b> , 52, 212-23	30
1377	Clinical trials in the new millennium. <b>2002</b> , 21, 2779-87	13
1376	Combined effects on tumor growth and metastasis by anti-estrogenic and antiangiogenic therapies in MMTV-neu mice. <b>2002</b> , 9, 1338-41	20
1375	Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression). <b>2002</b> , 21, 836-43	95
1374	DNA methylation and breast carcinogenesis. <b>2002</b> , 21, 5462-82	386
1373	Breast cancer: aromatase inhibitors take on tamoxifen. <b>2002</b> , 8, 1341-4	28
1372	Endocrine-responsive breast cancer and strategies for combating resistance. <b>2002</b> , 2, 101-12	665
1371	Modifiers of risk of hereditary breast and ovarian cancer. <b>2002</b> , 2, 113-23	139

1370	Breast cancer activism: past lessons, future directions. <b>2002</b> , 2, 225-30	15
1369	Chemoprevention: an essential approach to controlling cancer. <b>2002</b> , 2, 537-43	299
1368	Anti-oestrogenic prevention of breast cancer--the make or break point. <b>2002</b> , 2, 787-94	44
1367	Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy. <b>2002</b> , 86, 1546-50	71
1366	A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. <b>2002</b> , 87, 1354-9	68
1365	Surgery "ain't" going to cut it. Are we ready?. <b>2002</b> , 84, 357-9	0
1364	Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. <b>2002</b> , 84, 201-9	82
1363	The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women. <b>2002</b> , 85, 388-90	27
1362	Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells. <b>2002</b> , 85, 498-506	44
1361	[Breast calcifications with percutaneous vacuum-assisted biopsy diagnosis of malignancy or atypical hyperplasia: correlations with surgical findings]. <b>2002</b> , 94, 299-305	7
1360	Functional mutations of estrogen receptor protein: assay for detection. <b>2002</b> , 72, 61-8	2
1359	Hysteroscopic assessment of menopausal breast-cancer patients taking tamoxifen; there is a bias from the mode of endometrial sampling in estimating endometrial morbidity?. <b>2002</b> , 72, 245-53	9
1358	Effect of selective ablation of proliferating mammary epithelial cells on MNU induced rat mammary tumorigenesis. <b>2002</b> , 73, 75-83	12
1357	Mitogenic properties of insulin-like growth factors I and II, insulin-like growth factor binding protein-3 and epidermal growth factor on human breast epithelial cells in primary culture. <b>2002</b> , 75, 203-12	26
1356	Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. <b>2002</b> , 76, 27-36	408
1355	Effects of anastrozole on lipid metabolism compared with tamoxifen in rats. <b>2002</b> , 76, 131-6	13
1354	Retinoid, retinoic acid receptor beta and breast cancer. <b>2002</b> , 76, 167-73	48
1353	Chemoprevention of breast cancer: current and future prospects. <b>2002</b> , 21, 311-21	16



1352	Chemoprevention of prostate cancer: current status and future directions. <b>2002</b> , 21, 297-309	35
1351	Cancer chemoprevention. <b>2002</b> , 21, 189-97	13
1350	Chemoprevention for pancreatic cancer. <b>2003</b> , 33, 27-41	10
1349	A novel approach of targeted ablation of mammary carcinoma cells through luteinizing hormone receptors using Hecate-CGbeta conjugate. <b>2003</b> , 79, 1-10	24
1348	Inositol hexaphosphate (IP6) enhances the anti-proliferative effects of adriamycin and tamoxifen in breast cancer. <b>2003</b> , 79, 301-12	32
1347	Prevention of breast cancer using SERMs and aromatase inhibitors. <b>2003</b> , 8, 5-18	10
1346	Novel agents for chemoprevention, screening methods, and sampling issues. <b>2003</b> , 8, 75-89	6
1345	Prevention of mammary cancer with conjugated linoleic acid: role of the stroma and the epithelium. <b>2003</b> , 8, 103-18	80
1344	Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways. <b>2003</b> , 8, 45-73	51
1343	Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients. <b>2003</b> , 82, 103-11	46
1342	Breast and gastric cancer: comparing what we learn. <b>2003</b> , 10, 92-4	4
1341	Hereditary breast and ovarian cancer. <b>2003</b> , 27, 24-8	1
1340	General keynote: the impact of cancer chemoprevention. <b>2003</b> , 88, S56-8	21
1339	Androgen receptor gene alterations in Finnish male breast cancer. <b>2003</b> , 77, 167-70	27
1338	Phytoestrogens and breast cancer risk. Review of the epidemiological evidence. <b>2003</b> , 77, 171-83	180
1337	Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors. <b>2003</b> , 77, 253-64	29
1336	Third International Congress on MR-mammography, 25-27 September 2003, Jena, Germany - Abstracts. <b>2003</b> , 13, D1-D86	1
1335	Estimation of individualized probabilities of developing breast cancer for Japanese women. <b>2003</b> , 10, 54-62	18

1334	Current status of endocrine therapy for breast cancer. <b>2003</b> , 10, 105-11	5
1333	Hormone Replacement Therapy for Primary and Secondary Prevention of Heart Disease. <b>2003</b> , 5, 25-33	9
1332	The role of aromatase inhibitors in early breast cancer. <b>2003</b> , 4, 133-40	12
1331	What is the cardioprotective role of hormone replacement therapy?. <b>2003</b> , 5, 56-66	13
1330	Tamoxifen and gallstone formation in postmenopausal breast cancer patients: retrospective cohort study. <b>2003</b> , 27, 395-9	14
1329	New approaches to the endocrine prevention and treatment of breast cancer. <b>2003</b> , 52 Suppl 1, S39-44	26
1328	Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen. <b>2003</b> , 368, 41-8	37
1327	Chemoprävention des Mammakarzinoms durch Tamoxifen und Raloxifen. <b>2003</b> , 36, 97-102	1
1326	Osteoporoserisiko nach adjuvanter Therapie des Mammakarzinoms. <b>2003</b> , 36, 671-681	
1325	Current management of ductal carcinoma in situ of the breast. <b>2003</b> , 8, 18-22	15
1324	Optimal management of ductal carcinoma in situ of the breast. <b>2003</b> , 12, 221-40	42
1323	Pharmacological prevention of breast cancer: quo vadis?. <b>2003</b> , 12, 379-86	1
1322	Changing role of the oestrogen receptor in the life and death of breast cancer cells. <b>2003</b> , 12, 432-41	20
1321	The best use of adjuvant endocrine treatments. <b>2003</b> , 12, 497-508	12
1320	Challenges in the endocrine management of breast cancer. <b>2003</b> , 12 Suppl 2, S2-19	41
1319	Thrombophilias and gynaecology. <b>2003</b> , 17, 509-28	15
1318	Second cancers after breast cancer treatment. <b>2003</b> , 30, 740-8	71
1317	Follow-up care of breast cancer survivors. <b>2003</b> , 30, 817-25	16

1316	Osteopenia and osteoporosis in women with breast cancer. <b>2003</b> , 30, 763-75	108
1315	Does stage at diagnosis influence the observed relationship between socioeconomic status and breast cancer incidence, case-fatality, and mortality?. <b>2003</b> , 57, 2265-79	45
1314	Prevention and early detection clinical trials: opportunities for primary care providers and their patients. <b>2003</b> , 53, 82-101	25
1313	Ongoing care of patients after primary treatment for their cancer. <b>2003</b> , 53, 172-96	74
1312	Diagnosis and treatment of breast cancer in the elderly. <b>2003</b> , 53, 227-44	79
1311	Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial. <b>2003</b> , 4 Suppl 1, S42-8	17
1310	Validity of the general practice research database. <b>2003</b> , 23, 686-9	437
1309	Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer. <b>2003</b> , 12, 569-82	30
1308	Available models for breast cancer risk assessment: how accurate are they?. <b>2003</b> , 197, 1029-35	4
1307	Arzoxifene as therapy for endometrial cancer. <b>2003</b> , 90, S40-6	26
1306	The follow-up of breast cancer. <b>2003</b> , 30, 338-48	48
1305	Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer. <b>2003</b> , 30, 58-69	43
1304	New TNF-alpha releasing inhibitors as cancer preventive agents from traditional herbal medicine and combination cancer prevention study with EGCG and sulindac or tamoxifen. <b>2003</b> , 523-524, 119-25	59
1303	Breast cancer risk assessment models: applicability to African-American women. <b>2003</b> , 97, 230-5	46
1302	Increasing the pool of academically oriented African-American medical and surgical oncologists. <b>2003</b> , 97, 329-34	25
1301	Sentinel lymph node versus axillary lymph node dissection for early-stage breast carcinoma: a comparison using a utility-adjusted number needed to treat analysis. <b>2003</b> , 97, 359-66	23
1300	A simple model of breast carcinoma growth may provide explanations for observations of apparently complex phenomena. <b>2003</b> , 97, 2951-9	33
1299	Coagulopathic complications in breast cancer. <b>2003</b> , 98, 1578-86	59

1298	Effect of treatment sequence with radiotherapy and the antiestrogen EM 800 on the growth of ZR 75 1 human mammary carcinoma in nude mice. <b>2003</b> , 103, 268-76	5
1297	Plasma sex steroid hormones and breast cancer risk in Chinese women. <b>2003</b> , 105, 92-7	59
1296	Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. <b>2003</b> , 105, 384-9	27
1295	Antiestrogens are pro-apoptotic in normal human breast epithelial cells. <b>2003</b> , 105, 607-12	35
1294	Breast cancer-have we been chasing the wrong target?. <b>2003</b> , 83, 57-60	
1293	Parents' and children's attitudes toward the enrollment of minors in genetic susceptibility research: implications for informed consent. <b>2003</b> , 116A, 315-23	53
1292	Life insurance and breast cancer risk assessment: adverse selection, genetic testing decisions, and discrimination. <b>2003</b> , 120A, 359-64	70
1291	The prevention of breast cancer. <b>2003</b> , 90, 772-83	9
1290	4-(4-alkylpiperazin-1-yl)phenyl group: a novel class of basic side chains for selective estrogen receptor modulators. <b>2003</b> , 13, 4317-20	26
1289	Hormonal therapy of breast cancer. <b>2003</b> , 27, 279-331	2
1288	Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. <b>2003</b> , 56, 1038-45	338
1287	Geriatric oncology. <b>2003</b> , 46, 211-20	73
1286	Venous thromboembolism and cancer: new issues for an old topic. <b>2003</b> , 48, 65-80	29
1285	Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy. <b>2003</b> , 64, 111-21	16
1284	Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study. <b>2003</b> , 81, 495-9	27
1283	Separation and detection methods for covalent drug-protein adducts. <b>2003</b> , 797, 63-90	44
1282	Development and evaluation of a breast cancer prevention decision aid for higher-risk women. <b>2003</b> , 6, 3-18	59
1281	Oxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: an appraisal of in vitro studies. <b>2003</b> , 30, 845-8	17

1280	Prevalence of family history of breast and ovarian cancer in a single primary care practice using a self-administered questionnaire. <b>2003</b> , 9, 19-25	45
1279	The effect of tamoxifen on PCNA expression in fibroadenomas. <b>2003</b> , 9, 302-6	13
1278	Physicians-in-training recommendations for prophylactic bilateral mastectomies. <b>2003</b> , 9, 397-402	1
1277	Hormonal Therapy: Current and New Directions. <b>2003</b> , 9, S17-S21	1
1276	Meta-analysis of vascular and neoplastic events associated with tamoxifen. <b>2003</b> , 18, 937-47	286
1275	A randomized trial of three videos that differ in the framing of information about mammography in women 40 to 49 years old. <b>2003</b> , 18, 875-83	25
1274	From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. <b>2003</b> , 1, 1456-63	68
1273	Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healthy women. <b>2003</b> , 1, 2149-52	22
1272	Training and skills for breast surgeons in the new millennium. <b>2003</b> , 73, 511-6	29
1271	A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate. <b>2003</b> , 110, 157-167	21
1270	Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity. <b>2004</b> , 57, 105-11	17
1269	Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. <b>2003</b> , 120, 109-16	54
1268	A competing-risks nomogram for sarcoma-specific death following local recurrence. <b>2003</b> , 22, 3515-25	101
1267	The gene expression of hepatic proteins responsible for DNA repair and cell proliferation in tamoxifen-induced hepatocarcinogenesis. <b>2003</b> , 94, 582-8	13
1266	The influence of tamoxifen treatment on the oestrogen receptor in metachronous contralateral breast cancer. <b>2003</b> , 88, 707-10	9
1265	Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast. <b>2003</b> , 89, 277-83	14
1264	Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. <b>2003</b> , 22, 7316-39	370
1263	Lobular carcinoma in situ diagnosed by core needle biopsy: when should it be excised?. <b>2003</b> , 16, 120-9	112

1262	Tamoxifen: a most unlikely pioneering medicine. <b>2003</b> , 2, 205-13	538
1261	Border-cell migration: the race is on. <b>2003</b> , 4, 13-24	251
1260	Inference in spline-based models for multiple time-to-event data, with applications to a breast cancer prevention trial. <b>2003</b> , 59, 859-68	12
1259	The benefits and costs of tamoxifen for breast cancer prevention. <b>2003</b> , 27, 34-40	19
1258	Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. <b>2003</b> , 21, 3357-65	573
1257	Hereditary and acquired defects in the fibrinolytic system associated with thrombosis. <b>2003</b> , 17, 103-14	14
1256	Risk of breast cancer and breast cancer characteristics in women treated with supradiaphragmatic radiation for Hodgkin lymphoma: Mayo Clinic experience. <b>2003</b> , 78, 708-15	49
1255	Advances in breast cancer detection and management. <b>2003</b> , 87, 997-1028	19
1254	Clinical and laboratory evaluation of thrombophilia. <b>2003</b> , 24, 153-70	21
1253	Management of the high-risk patient. <b>2003</b> , 83, 733-51	12
1252	Neoplasias primarias múltiples de mama y endometrio secundarias a un tratamiento con tamoxifeno. Nuestra casuística. <b>2003</b> , 46, 333-339	
1251	Cáncer de mama y ovario heredofamiliar. Reflexiones basadas en la evidencia. <b>2003</b> , 46, 552-560	
1250	Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis. <b>2003</b> , 32, 219-32	14
1249	Selective estrogen-receptor modulators. <b>2003</b> , 19, 371-9	22
1248	Ductal lavage: clinical utility and future promise. <b>2003</b> , 83, 753-69, vii	5
1247	Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. <b>2003</b> , 46, 1484-91	20
1246	Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. <b>2003</b> , 46, 1081-111	353
1245	Pharmacokinetics of selective estrogen receptor modulators. <b>2003</b> , 42, 361-72	134

1244	Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience. <b>2003</b> , 4, 273-9	45
1243	Primary and secondary prevention of non-small-cell lung cancer: the SPORE Trials of Lung Cancer Prevention. <b>2003</b> , 5 Suppl 1, S36-40	12
1242	Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. <b>2003</b> , 124, 361-7	161
1241	Hormonal and genetic risk factors for breast cancer. <b>2003</b> , 1, 23-31	6
1240	Hormone therapy and venous thromboembolism. <b>2003</b> , 17, 149-64	42
1239	Cancer Prevention and Treatment by Ganoderma, a Mushroom with Medicinal Properties. <b>2003</b> , 19, 275-325	43
1238	Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. <b>2003</b> , 46, 883-908	357
1237	Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites. <b>2003</b> , 16, 832-7	27
1236	Alpha-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. <b>2003</b> , 16, 1138-44	48
1235	The effect of high dehydroepiandrosterone sulfate levels on tamoxifen blockade and breast cancer progression. <b>2003</b> , 185, 411-5	12
1234	European Code Against Cancer and scientific justification: third version (2003). <b>2003</b> , 14, 973-1005	197
1233	Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. <b>2003</b> , 348, 618-29	755
1232	[Tamoxifen, endometrial cancer and levonorgestrel intra-uterine device]. <b>2003</b> , 31, 867-71	1
1231	Polymorphisms of estrogen synthesizing and metabolizing genes and breast cancer risk in Japanese women. <b>2003</b> , 57, 471-81	50
1230	Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk. <b>2003</b> , 39, 2531-7	39
1229	Molecular targets as therapeutic strategies in the management of breast cancer. <b>2003</b> , 7, 543-57	5
1228	Oestrogens, Oestrogen Receptors and Breast Cancer. <b>2003</b> , 1, 1-12	6
1227	The curability of breast cancer. <b>2003</b> , 1, 24-34	9

1226	Gene screening and prevention of hereditary breast cancer. <b>2003</b> , 1, 13-23	3
1225	Cancer control in women. Update 2003. <b>2003</b> , 83 Suppl 1, 179-202	41
1224	Tamoxifen for breast-cancer prevention. <b>2003</b> , 361, 177; author reply 178	3
1223	Tamoxifen for breast-cancer prevention. <b>2003</b> , 361, 178	3
1222	Overview of the main outcomes in breast-cancer prevention trials. <b>2003</b> , 361, 296-300	815
1221	Breast-cancer prevention: is the risk-benefit ratio in favour of tamoxifen?. <b>2003</b> , 362, 183-4	9
1220	Dam medicine. <b>2003</b> , 362, 184	3
1219	Risk of breast cancer with progestins: critical assessment of current data. <b>2003</b> , 68, 953-64	45
1218	Antioxidant inhibits tamoxifen-DNA adducts in endometrial explant culture. <b>2003</b> , 307, 157-64	20
1217	Acute abdomen due to endometriosis in a premenopausal woman taking tamoxifen. <b>2003</b> , 109, 234-5	3
1216	In vitro effects of estradiol, dydrogesterone, tamoxifen and cyclophosphamide on proliferation vs. death in human breast cancer cells. <b>2003</b> , 190, 113-8	10
1215	Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ. <b>2003</b> , 362, 1154; author reply 1155-6	2
1214	Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. <b>2003</b> , 44 Suppl 1, S59-65	89
1213	The management of women at high risk for the development of breast cancer: risk estimation and preventative strategies. <b>2003</b> , 29, 79-89	14
1212	The risks and benefits of hormonal replacement therapy in healthy women and in breast cancer survivors. <b>2003</b> , 29, 355-61	8
1211	Towards optimal management of ductal carcinoma in situ of the breast. <b>2003</b> , 29, 191-7	38
1210	Effects of low dose tamoxifen on normal breast tissue from premenopausal women. <b>2003</b> , 39, 891-8	64
1209	Anti-oestrogenic chemoprevention of breast cancer-the need to progress. <b>2003</b> , 39, 572-9	15



1208	Phenoxodiol, a novel isoflavone derivative, inhibits dimethylbenz[a]anthracene (DMBA)-induced mammary carcinogenesis in female Sprague-Dawley rats. <b>2003</b> , 39, 1012-8	34
1207	Neuropsychological functioning following systemic treatment in women treated for breast cancer: a review. <b>2003</b> , 39, 2288-97	35
1206	Low risk of hip fracture among elderly breast cancer survivors. <b>2003</b> , 13, 698-703	31
1205	Clinical evaluation of women previously treated for breast cancer: an algorithm for the primary care physician. <b>2003</b> , 10, 1-8	
1204	Psychoneuroendocrinology and psychoneuroimmunology of cancer: Plausible mechanisms worth pursuing?. <b>2003</b> , 17 Suppl 1, S84-91	30
1203	[Can breast cancer be chemoprevented in 2003?]. <b>2003</b> , 31, 327-36	1
1202	[Problems raised by the gynaecologic management of women with BRCA 1 & 2 mutations]. <b>2003</b> , 31, 370-7	3
1201	[Endometrial surveillance of women on tamoxifen]. <b>2003</b> , 31, 647-56	8
1200	Tamoxifen reduced the incidence of breast cancer in women at increased risk, but had more adverse events. <b>2003</b> , 5, 141-142	
1199	Breast cancer in women after treatment for Hodgkin's disease. <b>2003</b> , 4, 207-14	37
1198	17 beta-estradiol- and 4-hydroxytamoxifen-induced transactivation in breast, endometrial and liver cancer cells is dependent on ER-subtype, cell and promoter context. <b>2003</b> , 84, 23-31	14
1197	Estrogen and growth factor signaling pathway: basic approaches for clinical application. <b>2003</b> , 86, 433-42	12
1196	Structure activity relationship studies on C2 side chain substituted 1,1-bis(4-methoxyphenyl)-2-phenylalkenes and 1,1,2-tris(4-methoxyphenyl)alkenes. <b>2003</b> , 87, 75-83	2
1195	Neurologic complications of cancer therapy. <b>2003</b> , 21, 279-318, x	68
1194	Aromatase inhibitors in breast cancer. <b>2003</b> , 348, 2431-42	704
1193	Ductal carcinoma in situ. <b>2003</b> , 83, 821-39	20
1192	Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. <b>2004</b> , 6, 39-52	141
1191	Prevention of breast cancer by recapitulation of pregnancy hormone levels. <b>2004</b> , 6, E8	17

1190	The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions. <b>2003</b> , 5, 320-8	18
1189	The diagnosis and management of pre-invasive breast disease: problems associated with management of pre-invasive lesions. <b>2003</b> , 5, 309-12	8
1188	Effect of reproductive hormones and selective estrogen receptor modulators on mood during menopause. <b>2003</b> , 20, 85-100	58
1187	A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. <b>2003</b> , 349, 1793-802	1500
1186	Adjuvant Therapy for Early Breast Cancer in Pre-/Perimenopausal Women. <b>2003</b> , 2, 227-235	
1185	Postmenopausal Metastatic Breast Cancer. <b>2003</b> , 2, 95-109	1
1184	Health Outcomes Assessment in Cancer. <b>2003</b> , 11, 709-721	2
1183	Plausible interaction of an alpha-fetoprotein cyclopeptide with the G-protein-coupled receptor model GPR30: docking study by molecular dynamics simulated annealing. <b>2003</b> , 20, 751-8	11
1182	Safety issues surrounding the use of aromatase inhibitors in breast cancer. <b>2003</b> , 2, 73-86	4
1181	Evidence-based management options for women at increased breast/ovarian cancer risk. <b>2003</b> , 14, 9-19	37
1180	The impact of a family history of breast cancer on screening practices and attitudes in low-income, rural, African American women. <b>2003</b> , 12, 779-87	18
1179	The therapeutic potential of aromatase inhibitors. <b>2003</b> , 12, 337-51	28
1178	Breast cancer management: quality-of-life and cost considerations. <b>2003</b> , 21, 383-96	74
1177	Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. <b>2003</b> , 21, 1431-9	1245
1176	Biosynthesis of MUC1 mucin in human endometrial adenocarcinoma is modulated by estradiol and tamoxifen. <b>2003</b> , 17, 37-44	12
1175	MRI of occult breast carcinoma in a high-risk population. <b>2003</b> , 181, 619-26	285
1174	Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. <b>2003</b> , 21, 602-6	509
1173	Nonsteroidal anti-inflammatory drugs protect against Parkinson neurodegeneration: can an NSAID a day keep Parkinson disease away?. <b>2003</b> , 60, 1043-4	31

1172 Major conceptual change required to improve lung cancer: see a respiratory physician. **2003**, 22, 866

1171 CORRESPONDENCE. **2003**, 21, 2446-2447

1170 Genetics and the management of women at high risk for breast cancer. **2003**, 8, 466-73

26

1169 American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. **2003**, 21, 4042-57

812

1168 Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. *Journal of the National Cancer Institute*, **2003**, 95, 1597-608

9.7 100

1167 Variations in lung cancer risk among smokers. *Journal of the National Cancer Institute*, **2003**, 95, 470-8

9.7 443

1166 Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. *Journal of the National Cancer Institute*, **2003**, 95, 302-7

9.7 61

1165 The use of gene tests to detect hereditary predisposition to chronic disease: is cost-effectiveness analysis relevant?. **2003**, 23, 441-8

11

1164 New approaches to cancer therapy. **2003**, 14, 813-6

5

1163 The ups and downs of the estrogen receptor. **2003**, 21, 3-4

8

1162 Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. *Journal of the National Cancer Institute*, **2003**, 95, 526-32

9.7 219

1161 Behavioral risk factors in breast cancer: can risk be modified?. **2003**, 8, 326-34

112

1160 CORRESPONDENCE. **2003**, 21, 2445-2446

1159 From the Authors. **2003**, 22, 865.2-865

1158 Tamoxifen for Prevention of Breast Cancer. **2003**, 37, 268-273

4

1157 NSABP breast cancer clinical trials: recent results and future directions. **2003**, 1, 309-26

35

1156 Communicating the value of adjuvant chemotherapy. **2003**, 21, 948-9

7

1155 Correction to "Congestive heart failure after treatment for Wilms' tumor". **2003**, 21, 2447-8

26

1154	Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12. <b>2003</b> , 278, 7630-8		46
1153	Biological significance of interventions that change breast density. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 4-5	9.7	26
1152	Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 1586-97	9.7	120
1151	Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 1825-33	9.7	79
1150	Mortality from major cancer sites in the European Union, 1955-1998. <b>2003</b> , 14, 490-5		44
1149	Integrative tumor board: recurrent breast cancer or new primary? <i>Medical oncology</i> . <b>2003</b> , 2, 270-2		
1148	Cancer genetics or cancer genomics in the era of genomic medicine?. <b>2003</b> , 14 Suppl 3, iii19-25		3
1147	Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer. <b>2003</b> , 14, 233-41		21
1146	Is low-dose tamoxifen useful for the treatment and prevention of breast cancer?. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 766-7	9.7	7
1145	Breast cancer detection and treatment: a personal and historical perspective. <b>2003</b> , 138, 397-408		3
1144	Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. <b>2003</b> , 21, 1007-14		63
1143	Radiation therapy plus tamoxifen versus tamoxifen alone after breast-conserving surgery in postmenopausal women with stage I breast cancer: a decision analysis. <b>2003</b> , 21, 2260-7		19
1142	Chemoprevention of cancer--focusing on clinical trials. <b>2003</b> , 33, 421-42		51
1141	Attitudes to prophylactic surgery and chemoprevention in Australian women at increased risk for breast cancer. <b>2003</b> , 12, 769-78		36
1140	Effects of raloxifene therapy on the anticoagulant system in postmenopausal women. <b>2003</b> , 6, 140-145		15
1139	Raloxifene inhibits estrogen-induced up-regulation of telomerase activity in a human breast cancer cell line. <b>2003</b> , 278, 43363-72		51
1138	Combined endocrine blockade in premenopausal breast cancer: a superior therapeutic option for adjuvant management?. <b>2003</b> , 21, 2445		
1137	Tamoxifen induction of aryl sulfotransferase and hydroxysteroid sulfotransferase in male and female rat liver and intestine. <b>2003</b> , 31, 637-44		36

1136	Full activation of estrogen receptor alpha activation function-1 induces proliferation of breast cancer cells. <b>2003</b> , 278, 26704-14			69
1135	Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. <b>2003</b> , 21, 3588-93			74
1134	Combining trastuzumab (Herceptin) with hormonal therapy in breast cancer: what can be expected and why?. <b>2003</b> , 14, 1697-704			29
1133	Application of breast cancer risk prediction models in clinical practice. <b>2003</b> , 21, 593-601			150
1132	Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 1758-64	9.7		627
1131	Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention?. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 1813-5	9.7		7
1130	Chemoprevention of melanoma: an unexplored strategy. <b>2003</b> , 21, 158-65			57
1129	Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. <b>2003</b> , 21, 1825-35			47
1128	Can endocrine treatment for hormone-positive premenopausal women with early breast cancer replace adjuvant chemotherapy?. <b>2003</b> , 21, 2444-5; author reply 2446-7			
1127	A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 779-90	9.7		168
1126	Hormone replacement therapy and risk of cardiovascular disease: implications of the results of the Women's Health Initiative. <b>2003</b> , 23, 11-6			91
1125	The impact of the Women's Health Initiative on the search for improved treatments for the conditions associated with long-term oestrogen deprivation. <b>2003</b> , 9, 4-10			
1124	The importance of paternal family history in hereditary breast cancer is underappreciated by health care professionals. <b>2003</b> , 64, 220-6			23
1123	Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. <b>2003</b> , 289, 2827-34			366
1122	Paradigm shift in adjuvant treatment of receptor positive premenopausal breast cancer patients? Not yet!. <b>2003</b> , 21, 2444; author reply 2445-7			
1121	Effects of tamoxifen therapy on the expression of p27 protein in the endometrium of women with primary breast cancer. <b>2003</b> , 23, 1545			
1120	Chemoprevention of prostate cancer by diet-derived antioxidant agents and hormonal manipulation (Review). <b>2003</b> , 22, 5			5
1119	Differences in physician referral practices and attitudes regarding hereditary breast cancer by clinical practice location. <b>2003</b> , 5, 364-9			36

1118	New insights into estrogen receptor function in human breast cancer. <b>2003</b> , 35, 614-31	41
1117	Transvaginal US and hysterosonography in postmenopausal women with breast cancer receiving tamoxifen: correlation with hysteroscopy and pathologic study. <b>2003</b> , 23, 137-50; discussion 151-5	24
1116	Genes, hormones, and pathways to breast cancer. <b>2003</b> , 348, 2352-4	7
1115	Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians. <b>2003</b> , 21, 4322-8	22
1114	The combination of a novel selective estrogen receptor modulator with an estrogen protects the mammary gland and uterus in a rodent model: the future of postmenopausal women's health?. <b>2003</b> , 144, 4700-6	29
1113	Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage. <b>2003</b> , 17, 1344-55	42
1112	Ductal Lavage for Breast Cancer Risk Assessment. <b>2003</b> , 8, 233-239	
1111	Soy protein isolate with isoflavones does not prevent estradiol-induced endometrial hyperplasia in postmenopausal women: a pilot trial. <b>2003</b> , 10, 456-64	54
1110	Update on clinical role of tamoxifen. <b>2003</b> , 15, 13-23	15
1109	Molecular and clinical evidence for the unique nature of individual selective estrogen receptor modulators. <b>2003</b> , 46, 265-97	6
1108	Invasive mammary carcinoma after immediate and short-term follow-up for lobular neoplasia on core biopsy. <b>2003</b> , 27, 325-33	84
1107	Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy. <b>2003</b> , 26, S17-26	12
1106	. <b>2003</b> , 237, 474-482	16
1105	The early response of the postmenopausal endometrium to tamoxifen: expression of estrogen receptors, progesterone receptors, and Ki-67 antigen. <b>2003</b> , 10, 154-9	6
1104	Current status of selective estrogen receptor modulators (SERMs). <b>2003</b> , 9, 4-14	9
1103	Emerging role of aromatase inhibitors in the adjuvant setting. <b>2003</b> , 26, S27-33	33
1102	Ductal Lavage for Breast Cancer Risk Assessment. <b>2003</b> , 8, 233-239	
1101	Preventing hormone-dependent breast cancer in high-risk women. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 91-3	9.7 12

1100 Psychosocial implications of prophylactic surgical intervention for ovarian cancer. **2003**, 16, 207-213

1099 Venous Thromboembolism Guidebook, fourth edition. **2003**, 2, 247-65

2

1098 Rating the risk factors for breast cancer. **2003**, 237, 474-82

155

1097 Hormone therapy revisited: data from the population, treatment for the patient. **2003**, 10, 269-70

1096 Breast cancer risk assessment: a guide for clinicians using the NCCN Breast Cancer Risk Reduction Guidelines. **2003**, 1, 297-301

2

1095 Tamoxifen for prevention of breast cancer. **2003**, 37, 268-73

5

1094 The advanced practice nursing role in a high-risk breast cancer clinic. **2003**, 30, 115-22

19

1093 The role of DNA testing in breast, ovarian, and colon cancers. **2003**, 325, 120-4

2

1092 Lung cancer prevention: the guidelines. **2003**, 123, 60S-71S

29

1091 Breast Cancer Prevention Trials. 48-52

1090 Dehydroepiandrosterone sulfate causes proliferation of estrogen receptor-positive breast cancer cells despite treatment with fulvestrant. **2003**, 138, 879-83

16

1089 Medical Management of High-Risk Lesions. **2003**, 20, 92-98

3

1088 Surgical Management of High Risk Breast Lesions. **2003**, 20, 99-112

1087 Selective estrogen receptor modulators. **2003**, 96, 469-76

16

1086 History of the Baylor Charles A. Sammons Cancer Center. **2003**, 16, 30-58

9

1085 Comprehensive breast cancer screening. Programs now include individual risk assessment. **2003**, 113, 34-6, 39-40, 43-6

2

1084 Sonohysterography compared with endometrial biopsy for evaluation of the endometrium in tamoxifen-treated women. **2003**, 22, 1173-9

15

1083 Chemoprevention of breast cancer. **2003**, 37-60

1082 Familial breast cancer. **2003**, 61-71

1081 Hormone replacement therapy and breast cancer. **2003**, 72-102

1080 Hormonal therapy in postmenopausal women with breast cancer. **2003**, 64, 289-99 19

1079 Breast Cancer. **2003**, 393-416 0

1078 Invited Commentary. **2003**, 23, 151-155 4

1077 Diseases of the Breast. **2003**, 655-670

1076 A Study of the Clinical Features and the Treatment of Breast Cancer in 374 Patients in Iran. **2003**, 89, 132-135 3

1075 Breast Cancer. 429-464

1074 Progress in lung cancer chemoprevention. **2003**, 10, 315-24 14

1073 Development of the breast cancer education and risk assessment program. **2003**, 30, 803-8 13

1072 Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans. **2003**, 4, 223-39 44

1071 Carcinoma In Situ. **2003**, 196-203

1070 Cancer chemoprevention drug targets. **2003**, 4, 45-54 31

1069 Ductal carcinoma in situ of the breast: diagnosis and management. **2003**, 26, 588-95 1

1068 Treatment of Desmoids and Mesenteric Fibromatosis in Familial Adenomatous Polyposis with Raloxifene. **2003**, 89, 391-396 47

1067 Bisphosphonates in Oncology: Physiopathologic Bases and Clinical Activity. **2003**, 89, 223-236 9

1066 Breast Cancer. 85-99

1065 Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial. **2004**, 11, 217-21 25



1064	The consequences of exhaustive antiestrogen therapy in breast cancer: estrogen-induced tumor cell death. <b>2004</b> , 229, 722-31	23
1063	Meeting Report: Breast Cancer in the Older Woman. <b>2004</b> , 90, 437-445	0
1062	SERMS (Selective Estrogen Receptor Modulators). <b>2004</b> , 221-228	
1061	Epidemiology of Uterine Corpus Cancers. <b>2004</b> , 188-207	1
1060	The Role of Cancer Cooperative Groups within the Spectrum of Cancer Care. <b>2004</b> , 11, 55-63	6
1059	Quality of life in breast cancer: what have we learned and where do we go from here?. <b>2004</b> , 93-125	3
1058	Short-term outcomes of chemoprevention, genetic susceptibility testing, and screening interventions: What are they? How are they measured? When should they be measured?. <b>2004</b> , 216-240	1
1057	Breast cancer risk in primary care: implications for chemoprevention. <b>2004</b> , 164, 1897-903	12
1056	Breast cancer: screening and prevention. <b>2004</b> , 275-286	
1055	Long-term complications of adjuvant chemotherapy for early stage breast cancer. <b>2004</b> , 21, 55-64	26
1054	The Cancer Genetics Program at the Cancer Institute at Alexian Brothers Hospital Network. <b>2004</b> , 19, 28-31	
1053	Benefits and harms associated with hormone replacement therapy: clinical decision analysis. <b>2004</b> , 328, 371	43
1052	Neoplasms of the reproductive tract: the role of hormone exposure. <b>2004</b> , 45, 179-88	15
1051	Cancer Risk Assessment. <b>2004</b> , 127-134	
1050	Breast cancer risk associated with ovulation-stimulating drugs. <b>2004</b> , 19, 2005-13	75
1049	Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells. <b>2004</b> , 18, 1643-57	42
1048	Hereditäres Mamma- und Ovarialkarzinom - ein Update Teil II - Früherkennung, Prävention und Therapie. <b>2004</b> , 64, 1037-1051	2
1047	Lobular carcinoma in situ or atypical lobular hyperplasia at core-needle biopsy: is excisional biopsy necessary?. <b>2004</b> , 231, 813-9	131

1046	[Chemoprevention of lung cancer. A review about previous studies, results and future developments]. <b>2004</b> , 58, 408-15		
1045	Breast Cancer Genetics. <b>2004</b> , 91-133		2
1044	Thrombosis and cancer. <b>2004</b> , 5 Suppl 3, S20-3		10
1043	Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. <b>2004</b> , 5, 415-42		138
1042	HOXA10 regulates p53 expression and matrigel invasion in human breast cancer cells. <b>2004</b> , 3, 568-72		93
1041	Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. <b>2004</b> , 64, 423-8		484
1040	Principles of Molecular Oncology. <b>2004</b> ,		6
1039	A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. <b>2004</b> , 350, 1081-92		1500
1038	Nutrition and physical activity and chronic disease prevention: research strategies and recommendations. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 1276-87	9.7	75
1037	Clinical infrastructures to support proteomic studies of tissue and fluids in breast cancer. <b>2004</b> , 3, 302-10		3
1036	Genetic determination of susceptibility to estrogen-induced mammary cancer in the ACI rat: mapping of Emca1 and Emca2 to chromosomes 5 and 18. <b>2004</b> , 168, 2113-25		44
1035	Hereditary cancer: guidelines in clinical practice--general overview. <b>2004</b> , 15 Suppl 4, iv121-5		6
1034	Regulating the tumor suppressor gene maspin in breast cancer cells: a potential mechanism for the anticancer properties of tamoxifen. <b>2004</b> , 10, 449-54		35
1033	Hormones and breast cancer. <b>2004</b> , 10, 281-93		74
1032	Management of risk of breast carcinoma in postmenopausal women. <b>2004</b> , 11, 69-83		12
1031	Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer. <b>2004</b> , 10, 5375-80		15
1030	Ductal lavage and risk assessment of breast cancer. <b>2004</b> , 9, 599-605		4
1029	Curcumin impairs tumor suppressor p53 function in colon cancer cells. <b>2004</b> , 25, 1611-7		96

1028	Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. <b>2004</b> , 10, 2029-34		234
1027	Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 1856-65	9.7	407
1026	HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. <b>2004</b> , 10, 5670-6		196
1025	Defining the role of raloxifene for the prevention of breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 1731-3	9.7	10
1024	Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 1762-9	9.7	28
1023	Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?. <b>2004</b> , 11, 191-205		30
1022	Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. <b>2004</b> , 10, 2336-43		146
1021	Tamoxifen--what next?. <b>2004</b> , 9, 378-84		60
1020	Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. <b>2004</b> , 22, 2046-52		124
1019	Arzoxifene: a promising new selective estrogen receptor modulator for clinical chemoprevention of breast cancer. <b>2004</b> , 10, 5313-5		17
1018	A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia. <b>2004</b> , 10, 7583-91		18
1017	RESPONSE: Re: Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor-Negative Mammary Tumors. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 715-716	9.7	1
1016	Constructing "High-Risk Women" The Development and Standardization of a Breast Cancer Risk Assessment Tool. <b>2004</b> , 29, 291-313		43
1015	Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 70-4	9.7	94
1014	A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer. <b>2004</b> , 10, 5425-31		18
1013	Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. <b>2004</b> , 22, 1605-13		343
1012	Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. <b>2004</b> , 10, 5717-23		100
1011	Breast cancer highlights: key findings from the San Antonio Breast Cancer Symposium: a U.S. perspective. <b>2004</b> , 9, 471-8		6

1010	Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. <b>2004</b> , 15, 79-87		55
1009	Interactions of the stereoisomers of alpha-hydroxytamoxifen with human hydroxysteroid sulfotransferase SULT2A1 and rat hydroxysteroid sulfotransferase STa. <b>2004</b> , 32, 1501-8		20
1008	Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 516-23	9.7	81
1007	Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 883; author reply 884-5	9.7	11
1006	Lower-category benign breast disease and the risk of invasive breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 616-20	9.7	76
1005	NF-kappaB activation by the chemopreventive dithiolethione oltipraz is exerted through stimulation of MEKK3 signaling. <b>2004</b> , 279, 26019-27		22
1004	The WHI estrogen-alone trial--do things look any better?. <b>2004</b> , 291, 1769-71		109
1003	The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials. <b>2004</b> , 9, 116-25		32
1002	Estrogen plus progestin and risk of venous thrombosis. <b>2004</b> , 292, 1573-80		432
1001	Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 1751-61	9.7	589
1000	A single mathematical model predicts physicians' recommendations and postmenopausal women's decisions to participate in a clinical trial to prevent breast cancer or coronary heart disease. <b>2004</b> , 24, 330-50		3
999	Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?. <b>2004</b> , 15, 1622-6		23
998	Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. <b>2004</b> , 292, 1480-9		250
997	Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <b>2004</b> , 126, 338S-400S		2244
996	Targeting steroid hormone receptor pathways in the treatment of hormone dependent cancers. <b>2004</b> , 5, 459-70		33
995	Prophylactic mastectomy for the prevention of breast cancer. <b>2004</b> , CD002748		87
994	Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. <b>2004</b> , 22, 3694-9		109
993	Chemopreventive drug treatment in subjects with genetic predisposition to cancer: prescriber liability and healthcare disparities. <b>2004</b> , 5, 319-29		3

992	Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. <b>2004</b> , 15, 1749-59		73
991	Expression of Somatostatin Receptors in Human Tissues in Health and Disease. <b>2004</b> , 107-121		1
990	Biological relevance of adduct detection to the chemoprevention of cancer. <b>2004</b> , 10, 4901-12		73
989	interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant). <b>2004</b> , 64, 4030-9		56
988	Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. <b>2004</b> , 22, 4951-7		119
987	Stroke risk and tamoxifen therapy for breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 1528-36	9.7	42
986	Interaction of the aryl hydrocarbon receptor ligand 6-methyl-1,3,8-trichlorodibenzofuran with estrogen receptor alpha. <b>2004</b> , 64, 2889-97		33
985	Stepped-care, community clinic interventions to promote mammography use among low-income rural African American women. <b>2004</b> , 31, 29S-44S		30
984	Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. <b>2004</b> , 64, 1522-33		279
983	Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy. <b>2004</b> , 10, 2570-7		57
982	Advances in chemoprevention of head and neck cancer. <b>2004</b> , 9, 302-11		28
981	Targeting oestrogen to kill the cancer but not the patient. <b>2004</b> , 90, 944-9		23
980	Recognition and management of hereditary breast cancer syndromes. <b>2004</b> , 9, 13-24		85
979	Profiling Breast Cancer Using Real-Time Quantitative PCR. <b>2004</b> , 95-106		1
978	Chemoprevention of breast cancer. <b>2004</b> , 8, 421-3		1
977	Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life. <b>2004</b> , 8, 629-37		17
976	Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer. <b>2004</b> , 22, 3309-15		221
975	Phospho-serine-118 estrogen receptor-alpha detection in human breast tumors in vivo. <b>2004</b> , 10, 1354-9		46

974	Effects of estrogen deprivation due to breast cancer treatment. <b>2004</b> , 11, 523-35		21
973	Electrospray ionization-tandem mass spectrometry and 32P-postlabeling analyses of tamoxifen-DNA adducts in humans. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 1099-104	9-7	35
972	Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. <b>2004</b> , 26, 955-69		298
971	Unspeakable women's problems and the hidden epidemic of female pelvic floor dysfunction. <b>2004</b> , 10 Suppl 2, 4-6		1
970	Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. <b>2004</b> , 63, 1230-3		85
969	A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity. <b>2004</b> , 10, 8332-40		10
968	Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama. <b>2004</b> , 15 Suppl 1, I27-I34		13
967	Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention. <b>2004</b> , 15, 1738-47		17
966	Re: Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 715; author reply 715-6	9-7	6
965	Ethical Issues in Genetic Testing for Cancer Susceptibility. <b>2004</b> , 61-82		
964	Hormones and pregnancy: thromboembolic risks for women. <b>2004</b> , 126, 443-54		56
963	Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease. <b>2004</b> , 256, 361-74		43
962	Effect of tamoxifen on breast tissue density in premenopausal breast cancer. <b>2004</b> , 10, 27-32		6
961	Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations. <b>2004</b> , 10 Suppl 1, S5-9		53
960	Predictors of pessimistic breast cancer risk perceptions in a primary care population. <b>2004</b> , 19, 310-5		71
959	Do physicians tailor their recommendations for breast cancer risk reduction based on patient's risk?. <b>2004</b> , 19, 302-9		24
958	Leading the way in breast cancer screening and prevention. <b>2004</b> , 19, 390-1		3
957	The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women. <b>2004</b> , 10, 211-7		34

956	Contralateral breast cancer: factors associated with stage and size at presentation. <b>2004</b> , 10, 304-12	14
955	Breast cancer from a public health perspective. <b>2004</b> , 10, 136-40	8
954	Increase in mammographic breast density associated with the use of domperidone. <b>2004</b> , 10, 256-8	3
953	Design and analysis of group sequential clinical trials with multiple primary endpoints. <b>2004</b> , 60, 134-45	30
952	Polyamines and cancer: old molecules, new understanding. <b>2004</b> , 4, 781-92	847
951	Tamoxifen and tamoxifen ethyl bromide induce apoptosis in acutely damaged mammary epithelial cells through modulation of AKT activity. <b>2004</b> , 23, 3851-62	15
950	Interferon-regulatory factor-1 is critical for tamoxifen-mediated apoptosis in human mammary epithelial cells. <b>2004</b> , 23, 8743-55	39
949	Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids. <b>2004</b> , 91, 476-81	16
948	Targeting signal transduction pathways by chemopreventive agents. <b>2004</b> , 555, 33-51	97
947	Selective estrogen receptor modulation: concept and consequences in cancer. <b>2004</b> , 5, 207-13	268
946	Therapeutic targeting in the estrogen receptor hormonal pathway. <b>2004</b> , 31, 28-38	81
945	Anti-insulin-like growth factor strategies in breast cancer. <b>2004</b> , 31, 54-63	11
944	Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma. <b>2004</b> , 92, 719-25	39
943	Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis. <b>2004</b> , 92, 519-20	20
942	The endometrium in asymptomatic breast cancer patients on tamoxifen: value of transvaginal ultrasonography with saline infusion and Doppler flow. <b>2004</b> , 93, 328-35	16
941	Endometrial pathologies associated with postmenopausal tamoxifen treatment. <b>2004</b> , 94, 256-66	218
940	Analysis of the time interval between diagnoses in women with double primary breast and ovarian or primary peritoneal cancers. <b>2004</b> , 94, 796-802	10
939	The fallacy of enrolling only high-risk subjects in cancer prevention trials: is there a "free lunch"? <b>2004</b> , 4, 24	4

938	Malignant breast disease and risk assessment. <b>2004</b> , 54, S40-S51	
937	Identifying and testing for hereditary susceptibility to common cancers. <b>2004</b> , 54, 309-26	32
936	Conservative management of breast cancer in BRCA1/2 mutation carriers. <b>2004</b> , 5, 37-42	22
935	Management of T1a breast cancer. <b>2004</b> , 5, 43-51	2
934	Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know?. <b>2004</b> , 5 Suppl 1, S18-23	2
933	Implications of first-line adjuvant treatment with aromatase inhibitors in recurrent metastatic breast cancer. <b>2004</b> , 5 Suppl 1, S24-30	
932	Tamoxifen and pregnancy. <b>2004</b> , 13, 446-51	77
931	Are all aromatase inhibitors the same? A review of the current evidence. <b>2004</b> , 13 Suppl 1, S10-8	25
930	Protection of tamoxifen against oxidation of mitochondrial thiols and NAD(P)H underlying the permeability transition induced by prooxidants. <b>2004</b> , 148, 149-61	20
929	Differences in the hepatic P450-dependent metabolism of estrogen and tamoxifen in response to treatment of rats with 3,3'-diindolylmethane and its parent compound indole-3-carbinol. <b>2004</b> , 28, 72-9	23
928	Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer. <b>2004</b> , 85, 89-97	38
927	Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. <b>2004</b> , 85, 151-9	378
926	Tamoxifen and cataracts: a null association. <b>2004</b> , 87, 189-96	16
925	Effects of drug treatment for malignancy on skeletal health of cancer survivors. <b>2004</b> , 2, 103-114	
924	Effects of tamoxifen on bone mineral density and metabolism in postmenopausal women with early-stage breast cancer. <b>2004</b> , 21, 117-21	26
923	Tamoxifen and megestrol acetate for postmenopausal breast cancer: diverging effects on liver proteins, androgens, and glucocorticoids. <b>2004</b> , 21, 309-18	13
922	Operating a comprehensive high-risk breast cancer management program in a community hospital setting. <b>2004</b> , 8, 434-40	1
921	Steroid receptors and cell cycle in normal mammary epithelium. <b>2004</b> , 9, 3-13	110



920	p27 deregulation in breast cancer: prognostic significance and implications for therapy. <b>2004</b> , 9, 67-80	72
919	Tamoxifen alters hepatic cytochrome P450 enzyme expression and circulating growth hormone levels in intact male rats. <b>2004</b> , 21, 1631-6	2
918	Determination of tamoxifen--DNA adducts in leukocytes from breast cancer patients treated with tamoxifen. <b>2004</b> , 17, 1577-83	17
917	Familial breast and ovarian cancers. <b>2004</b> , 9, 270-82	22
916	Prädiktion und endokrine Prävention des Mammakarzinoms. <b>2004</b> , 2, 145	
915	The role of transvaginal ultrasound in the management of abnormal uterine bleeding. <b>2004</b> , 1, 119-126	3
914	Applying the neoadjuvant paradigm to ductal carcinoma in situ. <b>2004</b> , 11, 28S-36S	14
913	Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results. <b>2004</b> , 11, 37S-43S	19
912	Cytotoxicity of tamoxifen in normal and tumoral cell lines and its ability to induce cellular transformation in vitro. <b>2004</b> , 28, 531-9	29
911	Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations. <b>2004</b> , 3, 265-81	28
910	Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) administrations. <b>2004</b> , 88, 9-16	15
909	Ductal lavage in the screening of high-risk women. <b>2004</b> , 6, 69-73	1
908	Progress in chemoprevention of breast cancer. <b>2004</b> , 49, 109-17	15
907	Chronic disease prevention: public health potential and research needs. <b>2004</b> , 23, 3409-20	3
906	Breast Cancer in Canadian Women. <b>2004</b> , 4 Suppl 1, S12	1
905	Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia. <b>2004</b> , 76, 240-4	50
904	Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. <b>2004</b> , 100, 238-44	116
903	Can the Gail model be useful in American Indian and Alaska Native populations?. <b>2004</b> , 100, 906-12	11

902	Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. <b>2004</b> , 100, 942-9	44
901	Acceptance of tamoxifen chemoprevention by physicians and women at risk. <b>2004</b> , 100, 1800-6	74
900	Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. <b>2004</b> , 100, 2562-72	140
899	Breast carcinoma screening and risk perception among women at increased risk for breast carcinoma: results from a national survey. <b>2004</b> , 100, 2338-46	21
898	The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. <b>2004</b> , 101, 439-49	140
897	The management of ductal carcinoma in situ in North America and Europe. Results of a survey. <b>2004</b> , 101, 1958-67	44
896	The prevention of invasive breast carcinoma. <b>2004</b> , 101, 2147-51	5
895	Atypia in the assessment of breast cancer risk: implications for management. <b>2004</b> , 30, 151-7	16
894	Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. <b>2004</b> , 112, 357-64	82
893	Antisense blocking of BRCA1 enhances sensitivity to plumbagin but not tamoxifen in BG-1 ovarian cancer cells. <b>2004</b> , 39, 15-25	36
892	The biological role of estrogen receptors alpha and beta in cancer. <b>2004</b> , 50, 3-22	233
891	Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. <b>2004</b> , 51, 55-67	269
890	Chemoprevention in prostate cancer. <b>2004</b> , 28, 218-30	2
889	Chemoprevention of breast cancer. <b>2004</b> , 28, 201-17	4
888	Synthesis of oligodeoxynucleotides containing a single diastereoisomer of alpha-(N2-2'-deoxyguanosinyl)-N-desmethyltamoxifen. <b>2004</b> , 14, 4051-4	2
887	Selective oestrogen receptor modulators in desmoid tumours. <b>2004</b> , 13, 1457-68	24
886	Genotoxic mechanism of tamoxifen in developing endometrial cancer. <b>2004</b> , 36, 199-218	51
885	Quantitative assessment of mammographic breast density: relationship with breast cancer risk. <b>2004</b> , 230, 29-41	373

884	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. <b>2004</b> , 310, 1062-75	506
883	Sex and gender issues and venous thromboembolism. <b>2004</b> , 25, 281-97	31
882	Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. <b>2004</b> , 15, 1262-72	192
881	Cancer in the elderly: is it preventable?. <b>2004</b> , 20, 293-316	9
880	The potential role of cyclooxygenase-2 inhibitors and 5alpha-reductase inhibitors in the prevention of urologic conditions. <b>2004</b> , 31, 213-8	2
879	Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs). <b>2004</b> , 18, 97-111	6
878	Aromatase inhibitors for chemoprevention. <b>2004</b> , 18, 113-30	35
877	Cancer chemoprevention: myth or reality?. <b>2004</b> , 1, 403-409	0
876	Targeted therapies for cancer â€”from tamoxifen to gefitinib (â€”ressaâ€”) <b>2004</b> , 1, 411-416	2
875	E3. Menopausal symptoms and uterine changes in postmenopausal breast cancer patients receiving tamoxifen or third generation aromatase inhibitors. <b>2004</b> , 2, 19-21	
874	E6. How do we choose candidates for breast cancer prevention?. <b>2004</b> , 2, 26-28	
873	E9. Side-effects of tamoxifen and solutions with aromatase inhibitors. <b>2004</b> , 2, 33-34	2
872	E10. Interpreting the results of the women. <b>2004</b> , 2, 35-40	
871	Endocrine treatment and prevention of breast and gynaecological cancers. <b>2004</b> , 2, 1-14	
870	The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. <b>2004</b> , 18, 47-66	101
869	Should tamoxifen be used in breast cancer prevention?. <b>2004</b> , 27, 979-89	8
868	The Role of Hormone Replacement Therapy and Alternative Treatments. <b>2004</b> , 3, 67-78	0
867	Rapid Cycle Real-Time PCR â€”Methods and Applications. <b>2004</b> ,	3

866	Strategies for managing breast cancer risk after the menopause. <b>2004</b> , 3, 289-307	3
865	Ductal carcinoma in situ of the breast. <b>2004</b> , 350, 1430-41	433
864	The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. <b>2004</b> , 6, 240-5	145
863	Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. <b>2004</b> , 6, 213-8	183
862	Ductal approaches to assessment and management of women at high risk for developing breast cancer. <b>2004</b> , 6, 75-81	12
861	Evaluation and management of breast pain. <b>2004</b> , 79, 353-72	117
860	Breast Cancer Risk Assessment: Identifying and Managing High Risk Patients. <b>2004</b> , 7, 153-158	
859	Cancer genetics in primary care. <b>2004</b> , 31, 649-83, xi	6
858	The effects of tamoxifen on the female genital tract. <b>2004</b> , 30, 291-301	56
857	Anastrozole is safer and may be more effective than tamoxifen in postmenopausal women with early-stage breast cancer. <b>2004</b> , 30, 303-7	
856	Genes that drive invasion and migration in Drosophila. <b>2004</b> , 14, 86-91	39
855	[Raloxifene and breast: from the SERMs concept to its place in clinical practice]. <b>2004</b> , 32, 75-84	3
854	Aromatase inhibitors that regulate estrogen target tissues selectively?. <b>2004</b> , 34, 372-5	3
853	Epidemiology of breast cancer among BRCA mutation carriers: an overview. <b>2004</b> , 205, 1-8	32
852	Tamoxifen induces the expression of maspin through estrogen receptor-alpha. <b>2004</b> , 209, 55-65	23
851	Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. <b>2004</b> , 210, 197-203	50
850	Medication use, tamoxifen (TAM), and TAM metabolite concentrations in women with breast cancer. <b>2004</b> , 211, 57-67	8
849	Impact of the selective estrogen receptor modulator, tamoxifen, on neuronal outgrowth and survival following toxic insults associated with aging and Alzheimer's disease. <b>2004</b> , 188, 268-78	46

848	Guidelines for the management of women at increased familial risk of breast cancer. <b>2004</b> , 40, 653-65	30
847	High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. <b>2004</b> , 30, 243-7	36
846	Analysis of tamoxifen-DNA adducts in endometrial explants by MS and 32P-postlabeling. <b>2004</b> , 320, 297-302	15
845	Breast cancer, stem/progenitor cells and the estrogen receptor. <b>2004</b> , 15, 193-7	258
844	Techniques: the application of accelerator mass spectrometry to pharmacology and toxicology. <b>2004</b> , 25, 442-7	23
843	Tamoxifen in gynaecology. <b>2004</b> , 4, 37-45	6
842	The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies. <b>2004</b> , 22, 362-8	12
841	Retained products of conception in hysteroscopy in a patient with breast cancer on tamoxifen. <b>2019</b> , 12,	0
840	Tumors of the Mammary Gland. <b>2019</b> , 604-625	4
839	Gonadal Hormones and Bone. <b>2020</b> , 262, 65-91	3
838	Estimating the magnitude of clinical benefit of systemic therapy in patients with DCIS or pre-invasive disease of the breast. <b>2019</b> , 48 Suppl 1, S39-S43	3
837	Endocrine Therapy for Hormone Receptor-Positive Breast Cancer. <b>2019</b> , 1-26	
836	Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ER $\Delta$ 537S and ER $\Delta$ 538G mutations. <b>2019</b> , 442, 373-382	18
835	Effects of Hormones. <b>2019</b> , 145-172	
834	Trends in lobular carcinoma in situ management: endocrine therapy use in California and New Jersey. <b>2019</b> , 30, 129-136	1
833	p38 MAPK signaling pathway activation by phenyl benzoxime in SNU-306 cells causes induction of apoptosis. <b>2019</b> , 126, 74-78	2
832	Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing. <b>2019</b> , 189, 956-965	10
831	Assessing the medical workforces perceived barriers to the prescription of risk-reducing medication for women at high-risk of breast cancer. <b>2019</b> , 25, 34-40	1

830	Perception of Breast Cancer Risk in Over 11,000 Patients During Routine Mammography Exam. <b>2020</b> , 35, 782-787	2
829	Assessment and management of B3 breast lesions with atypia: a focused review. <b>2020</b> , 23, 17-23	1
828	Why Breast Cancer Risk Models Fail: The Case of Lobular Carcinoma In Situ. <b>2020</b> , 27, 627-629	1
827	Choosing Breast Cancer Risk Models: Importance of Independent Validation. <i>Journal of the National Cancer Institute</i> , <b>2020</b> , 112, 433-435	9.7 5
826	Lifestyle and Cancer Prevention. <b>2020</b> , 337-374.e12	0
825	Management of Endometrial Cancer. <b>2020</b> ,	1
824	The pharmacology of selective estrogen receptor modulators: past and present. <b>2020</b> , 863-893	
823	Oestrogen receptors and breast cancer: are we prepared to move forward? A critical review. <b>2020</b> , 15, 627-649	
822	Patient and provider factors associated with the noninitiation of tamoxifen for young women at high-risk for the development of breast cancer. <b>2020</b> , 26, 464-468	1
821	Current and future approaches to screening for endometrial cancer. <b>2020</b> , 65, 79-97	14
820	Uterine Cancer. <b>2020</b> , 1508-1524.e4	2
819	Do Body Mass Index and Breast Density Impact Cancer Risk Among Women with Lobular Carcinoma In Situ?. <b>2020</b> , 27, 1844-1851	3
818	Screening and Early Detection. <b>2020</b> , 375-398.e7	1
817	Breast cancer prevention in high-risk women. <b>2020</b> , 65, 18-31	44
816	Radiologic Technologist and Radiologist Knowledge Gaps about Breast Density Revealed by an Online Continuing Education Course. <b>2020</b> , 2, 315-329	0
815	Genistin attenuates cellular growth and promotes apoptotic cell death breast cancer cells through modulation of ERalpha signaling pathway. <b>2020</b> , 263, 118594	5
814	Ratite oils for local transdermal therapy of 4-OH tamoxifen: development, characterization, and evaluation. <b>2021</b> , 31, 217-229	3
813	Recurrence Risk after Radical Colorectal Cancer Surgery-Less Than before, But How High Is It?. <b>2020</b> , 12,	8

812	Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial. <b>2020</b> , 54, 216-221	1
811	Lobular intraepithelial neoplasia: Outcomes and optimal management. <b>2020</b> , 26, 2383-2390	1
810	Metformin and Chemoprevention: Potential for Heart-Healthy Targeting of Biologically Aggressive Breast Cancer. <b>2020</b> , 8, 509714	7
809	Molecular mechanisms and clinical management of cancer bone metastasis. <b>2020</b> , 8, 30	33
808	Selective estrogen receptor modulators in the prevention of breast cancer in premenopausal women: a review.. <b>2020</b> , 9, 4444-4456	2
807	Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer. <b>2020</b> , 26, 1528-1534	10
806	A Comprehensive Review and Perspective on Anticancer Mechanisms of Withaferin A in Breast Cancer. <b>2020</b> , 13, 721-734	8
805	Evaluation of Cytotoxicity of Different Part Extracts of Ipomoea turpethum against Breast Cancer Cell Lines. <b>2020</b> , 39, 51-60	1
804	Presenting treatment options in breast cancer consultations: Advice and consent in Italian medical care. <b>2020</b> , 266, 113175	1
803	Delayed short-term tamoxifen treatment does not promote remyelination or neuron sparing after spinal cord injury. <b>2020</b> , 15, e0235232	1
802	Efficacy of Emu Oil Transfersomes for Local Transdermal Delivery of 4-OH Tamoxifen in the Treatment of Breast Cancer. <b>2020</b> , 12,	8
801	Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients. <b>2020</b> , 184, 665-674	1
800	Integrative genomic analysis implicates ERCC6 and its interaction with ERCC8 in susceptibility to breast cancer. <b>2020</b> , 10, 21276	3
799	Breast cancer in global health: beyond diversity and inequality. <b>2020</b> , 3, e32-e32	1
798	[Hot flushes and breast cancer with positive hormone receptors: Mechanisms and management]. <b>2020</b> , 107, 1171-1185	2
797	Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility. <b>2020</b> , 41,	21
796	Novel 1,2,4-Oxadiazole Derivatives in Drug Discovery. <b>2020</b> , 13,	40
795	Executive Summary of the Early-Onset Breast Cancer Evidence Review Conference. <b>2020</b> , 135, 1457-1478	7

794	Key steps for effective breast cancer prevention. <b>2020</b> , 20, 417-436	120
793	Is there still a role for SERMs in menopause management?. <b>2020</b> , 36, 567-568	
792	Biomarker Modulation Study of Celecoxib for Chemoprevention in Women at Increased Risk for Breast Cancer: A Phase II Pilot Study. <b>2020</b> , 13, 795-802	2
791	Estrogen regulates aquaporin-2 expression in the kidney. <b>2020</b> , 112, 243-264	3
790	Functional genomics based on germline genome-wide association studies of endocrine therapy for breast cancer. <b>2020</b> , 21, 615-625	0
789	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. <b>2020</b> , 17, 687-705	64
788	Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration. <b>2020</b> , 15, e0232870	6
787	Novel Tamoxifen Nanoformulations for Improving Breast Cancer Treatment: Old Wine in New Bottles. <b>2020</b> , 25,	23
786	Forty-year trends in menopausal hormone therapy use and breast cancer incidence among postmenopausal black and white women. <b>2020</b> , 126, 2956-2964	7
785	Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance). <b>2020</b> , 38, 1284-1292	9
784	Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen. <b>2020</b> , 12,	18
783	Emerging role of Fatty acid synthase in tumor initiation: implications for cancer prevention. <b>2020</b> , 7, 1709389	6
782	The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease. <b>2020</b> , 37, 331-348	3
781	Adherence to endocrine therapy and its relation to disease-free survival among breast cancer patients visiting an out-patient clinic at Khartoum Oncology Hospital, Sudan. <b>2020</b> , 26, 1731-1743	4
780	The Application of Gail Model to Predict the Risk of Developing Breast Cancer among Jordanian Women. <b>2020</b> , 2020, 9608910	1
779	Global mapping of randomised trials related articles published in high-impact-factor medical journals: a cross-sectional analysis. <b>2020</b> , 21, 34	6
778	Breast cancer risk prediction models and subsequent tumor characteristics. <b>2020</b> , 27, 662-669	1
777	Breast cancer risk reduction: Notable achievements and remaining challenges. <b>2020</b> , 26, 86-91	3



776	Use of Biomarker Modulation in Normal Mammary Epithelium as a Correlate for Efficacy of Chemopreventive Agents Against Chemically Induced Cancers. <b>2020</b> , 13, 283-290	
775	Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies. <b>2020</b> , 9, e013755	19
774	Disparities in Risk Reduction Therapy Recommendations for Young Women With Lobular Carcinoma In-Situ. <b>2020</b> , 20, e397-e402	
773	National Cancer Institute: Restructuring to Support the Clinical Trials of the Future. <b>2020</b> , 36, 151003	2
772	Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. <b>2020</b> , 181, 487-497	168
771	RNA-seq reveals novel cancer-selective and disease subtype-independent mechanistic targets of withaferin A in human breast cancer cells. <b>2021</b> , 60, 3-14	4
770	Background Parenchymal Uptake on Molecular Breast Imaging and Breast Cancer Risk: A Cohort Study. <b>2021</b> , 216, 1193-1204	5
769	Local Transdermal Delivery of Telapristone Acetate Through Breast Skin, Compared With Oral Treatment: A Randomized Double-Blind, Placebo-Controlled Phase II Trial. <b>2021</b> , 109, 728-738	6
768	Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status. <b>2021</b> , 303, 217-230	2
767	Endocrine Therapy for Breast Cancer. <b>2021</b> , 17, 177-181	
766	BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery. <b>2021</b> , 1875, 188459	2
765	Oncolytic Drugs. <b>2021</b> , 299-360	
764	Estrogen and estrogen analogs for prevention and treatment of osteoporosis. <b>2021</b> , 1711-1719	3
763	Effect of Personalized Breast Cancer Risk Tool on Chemoprevention and Breast Imaging: ENGAGED-2 Trial. <b>2021</b> , 5, pkaa114	2
762	Management of a Woman at Elevated Risk for Breast Cancer. <b>2021</b> , 107-136	
761	Effects of letrozole or tamoxifen coadministered with a standard stimulation protocol on fertility preservation among breast cancer patients. <b>2021</b> , 38, 743-750	1
760	Breast Cancer Patients at Increased Risk of Developing Type II Endometrial Cancer: Relative and Absolute Risk Estimation and Implications for Counseling. <b>2021</b> , 13, e12981	
759	Identification of factors that influence the decision to take chemoprevention in patients with a significant family history of breast cancer: results from a patient questionnaire survey. <b>2021</b> , 187, 207-213	

758	A Report of Tamoxifen and Parkinson's Disease in a US Population and a Review of the Literature. <b>2021</b> , 36, 1238-1242	0
757	50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened?. <b>2021</b> , 28, R11-R30	12
756	Present Options in the Prevention of Breast Cancer. <b>2021</b> , 117-127	
755	Postmenopausal Bleeding: Role of Imaging in the Diagnosis and Management. <b>2021</b> , 375-404	
754	Chemoresistance in female-specific cancers and the associated anti-resistance therapies. <b>2021</b> , 49-69	
753	Thickened Endometrium: When to Intervene? A Clinical Conundrum. <b>2021</b> , 71, 216-225	0
752	Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease. <b>2021</b> , 27, 3576-3583	2
751	Comprehensive analysis of regulation of DNA methyltransferase isoforms in human breast tumors. <b>2021</b> , 147, 937-971	10
750	Detecting endometrial cancer. <b>2021</b> , 23, 103-112	9
749	Prevention of mammary carcinogenesis in MMTV-neu mice by targeting RLIP. <b>2021</b> , 60, 213-223	0
748	Clinicopathological correlates, oncological impact, and validation of Oncotype DX® in a European Tertiary Referral Centre. <b>2021</b> , 27, 521-528	10
747	Tamoksifen Kullanan Hastalar'ın Jinekolojik Yâden Değ erlendirilmesi. <b>2021</b> , 30, 45-51	
746	Developing and validating an individualized breast cancer risk prediction model for women attending breast cancer screening. <b>2021</b> , 16, e0248930	2
745	The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies. <b>2021</b> , 188, 215-223	2
744	Estrogen receptor alpha in the brain mediates tamoxifen-induced changes in physiology in mice. <b>2021</b> , 10,	2
743	Obese Adipose Tissue as a Driver of Breast Cancer Growth and Development: Update and Emerging Evidence. <b>2021</b> , 11, 638918	5
742	The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial. <b>2021</b> , 14, 753-762	2
741	Osteoporosis Therapy: Mechanistic Antiresorptives. 1-24	

740	Preventing Breast Cancer Through Identification and Pharmacologic Management of High-Risk Patients. <b>2021</b> , 96, 1033-1040	1
739	Bone-modifying Agents (BMAs) in Breast Cancer. <b>2021</b> , 21, e618-e630	1
738	Estrogen Receptor on the move: Cistronic plasticity and its implications in breast cancer. <b>2021</b> , 78, 100939	2
737	Pathfinders in oncology from the time the causal relation between tobacco use and lung cancer was established to publication of the first Cancer Staging Manual by the American Joint Committee on Cancer. <b>2021</b> , 127, 2828-2854	
736	Best Practices in Breast Health and Breast Cancer Screening. <b>2021</b> , 3, 121-133	
735	Reflecting on 20 years of breast cancer modeling in CISNET: Recommendations for future cancer systems modeling efforts. <b>2021</b> , 17, e1009020	6
734	Risk of Endometrial Cancer and Frequencies of Invasive Endometrial Procedures in Young Breast Cancer Survivors Treated With Tamoxifen: A Nationwide Study. <b>2021</b> , 11, 636378	3
733	Endocrine prevention of breast cancer. <b>2021</b> , 530, 111284	1
732	Mechanistic Targets of Diallyl Trisulfide in Human Breast Cancer Cells Identified by RNA-seq Analysis. <b>2021</b> , 26, 128-136	3
731	Utilization of breast cancer risk prediction models by cancer genetic counselors in clinical practice predominantly in the United States. <b>2021</b> , 30, 1737-1747	1
730	Defensive Consequences of Hydroalcoholic Extract and Isolated Compounds of Ipomoea aquatica Forsskal against DMBA Method. <b>2021</b> , 3863-3868	
729	How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers?. <b>2021</b> , 28, 5657-5662	2
728	Updates on Lobular Neoplasms, Papillary, Adenomyoepithelial, and Fibroepithelial Lesions of the Breast. <b>2021</b> ,	1
727	Investigating the role of endogenous estrogens, hormone replacement therapy, and blockade of estrogen receptor-activity on breast metabolic signaling. <b>2021</b> , 190, 53-67	1
726	Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team. <b>2021</b> , 190, 19-38	5
725	Therapeutic Options in the Management of Aromatase Inhibitor-Associated Bone Loss. <b>2021</b> ,	1
724	Topical transdermal chemoprevention of breast cancer: where will nanomedical approaches deliver us?. <b>2021</b> , 16, 1713-1731	3
723	Regarding the Appropriate Target and Duration of Chemoprevention in Breast Cancer. <b>2021</b> , 39, 2965-2966	1

722	Hi-C profiling of cancer spheroids identifies 3D-growth-specific chromatin interactions in breast cancer endocrine resistance. <b>2021</b> , 13, 175	1
721	Development of 1,3-diynyl derivatives of noscapine as potent tubulin binding anticancer agents for the management of breast cancer. <b>2021</b> , 1-18	0
720	Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer. <b>2021</b> , 6,	2
719	Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer. <b>2021</b> , 190, 189-201	1
718	Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside. <b>2021</b> , 162,	0
717	Longitudinal Risk Management for Patients with Increased Risk for Breast Cancer. <b>2021</b> , 266, 421-429	0
716	Breast diseases. <b>2022</b> , 289-322.e3	
715	Breast conservation among older patients with early-stage breast cancer: Locoregional recurrence following adjuvant radiation or hormonal therapy. <b>2021</b> , 127, 1749-1757	2
714	Updated perspective and directions on hereditary diffuse gastric cancer. <b>2021</b> , 217-258	1
713	Genetic cancer risk assessment. <b>1999</b> , 86, 1663-1672	4
712	Mammary Gland Cancer.	2
711	Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. <b>2020</b> , 12, CD007245	3
710	The Use of Randomized Controlled Trials for Pharmacoepidemiologic Studies. 269-279	1
709	Screening. <b>2002</b> , 365-373	2
708	Challenges in Monitoring the Breast Cancer Prevention Trial. <b>2006</b> , 118-135	4
707	Clinical Pharmacology of Selective Estrogen Receptor Modulators (SERMs). <b>2006</b> , 49-69	5
706	The role of cooperative groups in cancer clinical trials. <b>2007</b> , 132, 111-29	6
705	Benign and Malignant Diseases of the Breast. <b>2008</b> , 2005-2035	1

704	Second Malignancies After Radiation Treatment and Chemotherapy for Primary Cancers. <b>2007</b> , 225-237	1
703	Expression of estrogen receptors alpha and beta in early steps of human breast carcinogenesis. <b>2008</b> , 617, 139-48	2
702	Response and resistance to the endocrine prevention of breast cancer. <b>2008</b> , 617, 201-11	10
701	Breast cancer prevention. <b>2008</b> , 141, 149-64	22
700	Adjuvant hormonal therapy for early-stage breast cancer. <b>2008</b> , 141, 63-78	1
699	Endogenous Hormone Levels and Risk of Breast, Endometrial and Ovarian Cancers:. <b>2008</b> , 148-165	112
698	Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. <b>2008</b> , 630, 206-19	42
697	Chemotherapy-associated thrombosis. <b>2009</b> , 148, 181-206	8
696	Risk Factors. <b>2010</b> , 3-22	4
695	Breast Cancer Chemoprevention. <b>2010</b> , 43-59	2
694	Management of Women with Inherited BRCA1 and BRCA2 Mutations. <b>2009</b> , 21-45	1
693	Benign Diseases of the Endometrium. <b>2011</b> , 305-358	16
692	Endometrial Carcinoma. <b>2011</b> , 394-452	10
691	Breast Cancer: Pathology, Cytology, and Core Needle Biopsy Methods for Diagnosis. <b>2013</b> , 19-37	5
690	Management of High-Risk Lesions. <b>2013</b> , 69-80	1
689	Chemoprevention in prostate cancer. <b>2001</b> , 106, 103-36	5
688	Chemoprevention of breast cancer. <b>2001</b> , 106, 137-54	3
687	Managing menopausal problems. <b>2000</b> , 103, 1-23	0

686	Methodological Issues in the Analysis of Quality of Life Data in Clinical Trials: Illustrations from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial. <b>2002</b> , 71-85	2
685	Third- and Fourth-Generation SERMs. <b>2002</b> , 167-187	2
684	Pathogenesis of Estrogen-Receptor-Positive and -Negative Breast Cancer. <b>2000</b> , 49-68	2
683	Cerebrovascular Complications of Cancer. <b>2003</b> , 137-157	2
682	Clinical Approaches to Discovering and Testing New Breast Cancer Prevention Drugs. <b>2005</b> , 213-237	5
681	Counteracting Estrogen as Breast Cancer Prevention. <b>2005</b> , 249-264	4
680	Functional Genomics for Identifying Surrogate Endpoint Biomarkers in Breast Cancer Chemoprevention. <b>2005</b> , 115-122	2
679	Resistance to Antiestrogens. <b>2006</b> , 413-433	1
678	Epidemiology of multiple primary cancers. <b>2009</b> , 471, 85-105	50
677	Clinical Importance of Prognostic Factors. <b>2008</b> , 27-41	1
676	Biomarkers in breast cancer. <b>2010</b> , 593, 137-56	6
675	New Insights on Estrogen Receptor Actions in Hormone-Responsive Breast Cancer Cells by Interaction Proteomics. <b>2013</b> , 149-174	1
674	Genomic Cancer Risk Assessment. <b>2020</b> , 187-207	1
673	Atypical Lobular Hyperplasia and Lobular Carcinoma In Situ. <b>2016</b> , 561-593	1
672	Breast Cancer Epidemiology. <b>2016</b> , 125-137	4
671	Osteoporosis for the Female Patient. <b>2017</b> , 195-208	1
670	Breast Cancer: Overview of Decision Making by the Medical Oncologist. <b>2018</b> , 103-112	1
669	Diagnostic Management of Papillomas, Radial Scars, and Flat Epithelial Atypia: Core Biopsy Alone Versus Core Biopsy Plus Excision. <b>2018</b> , 51-62	1

668	Rates, Risks, Measures of Association and Impact. <b>2005</b> , 89-156	4
667	Mammakarzinom. 1119-1183	1
666	A favorable view: progress in cancer prevention and screening. <b>2007</b> , 174, 3-17	21
665	Do we make optimal use of the potential of cancer prevention?. <b>2009</b> , 181, 3-17	5
664	The use of tamoxifen and raloxifene for the prevention of breast cancer. <b>2009</b> , 181, 113-9	24
663	Prevention of breast cancer by newer SERMs in the future. <b>2011</b> , 188, 141-5	2
662	Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. <b>2011</b> , 188, 147-62	47
661	Immuntherapeutika und Zytostatika. <b>2011</b> , 667-682	0
660	HRT opposed to low-dose tamoxifen (HOT study): rationale and design. <b>2003</b> , 163, 104-11; discussion 264-6	20
659	Chemoprevention of lung cancer: new directions. <b>2003</b> , 163, 172-81; discussion 264-6	1
658	Tamoxifen's impact as a preventive agent in clinical practice and an update on the STAR trial. <b>2003</b> , 163, 87-95; discussion 264-6	11
657	Benign and Malignant Diseases of the Breast. <b>2001</b> , 1699-1732	2
656	Merits and Demerits of Practice for Hereditary Breast and Ovarian Cancer Syndrome (Advices and Issues). <b>2016</b> , 33-45	1
655	Pathophysiology of the Pelvic Floor: Basic Physiology, Effects of Ageing, and Menopausal Changes. <b>2010</b> , 25-32	3
654	Future of Chemoprevention. <b>2017</b> , 169-173	1
653	Cancer Prevention, Screening, and Early Detection. <b>2008</b> , 361-395	1
652	Cancer of the Endometrium. <b>2008</b> , 1793-1825	4
651	Cancer of the Breast. <b>2008</b> , 1875-1943	8

650	Screening and Diagnosis of Ovarian CancerâHigh Risk. <b>2004</b> , 341-354	1
649	Breast pain and nodularity. <b>2009</b> , 107-138	5
648	Estrogen and Progesterone Receptors. <b>2001</b> , 97-136	1
647	Cancers of the Female Reproductive System. <b>2000</b> , 359-381	2
646	Adenocarcinoma of the Uterus. <b>2007</b> , 147-184	4
645	Metabolic Bone Disease. <b>2009</b> , 1579-1599	3
644	Primary Prevention of Breast Cancer. <b>2009</b> , 349-369	1
643	Clinical Management of the Patient at Increased or High Risk. <b>2009</b> , 1381-1392	1
642	Diseases of the Breast. <b>2012</b> , 824-869	3
641	Metabolic Bone Disease. <b>2013</b> , 1660-1679.e4	2
640	Cancer of the Breast. <b>2014</b> , 1630-1692.e9	1
639	Cancer Chemoprevention. <b>2008</b> , 711-720	1
638	Comment dvelopper et amliorer les actions de prvention dans le systme de santfranais ?. <b>2002</b> , 186, 447-540	4
637	Advances in endocrine therapy for the treatment and prevention of breast cancer. <b>2003</b> , 21, 211-22	1
636	Effects of oral administration of tamoxifen, toremifene, dehydroepiandrosterone, and vorozole on uterine histomorphology in the rat. <b>2000</b> , 223, 288-94	20
635	ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data. <b>2001</b> , 85 Suppl 2, 11-4	26
634	Anastrozole (Arimidex)--an aromatase inhibitor for the adjuvant setting?. <b>2001</b> , 85 Suppl 2, 6-10	4
633	Synergistic Cytotoxic and Apoptotic Effects of Local Probiotic Lactobacillus Brevis Isolated from Regional Dairy Products in Combination with Tamoxifen. <b>2021</b> , 73, 290-299	5



632	The human genome project: evolving status and emerging opportunities for disease prevention. <b>2000</b> , 45-60	3
631	Breast Cancer. <b>2006</b> , 995-1012	51
630	Endometrial Cancer. <b>2006</b> , 1027-1043	25
629	Tamoxifen-induced thrombocytopenia. <b>1999</b> , 22, 529-32	12
628	Chemoprevention of epithelial cancers. <b>1999</b> , 11, 408-13	4
627	Molecular and genetic targets in early detection. <b>1999</b> , 11, 419-25	14
626	Epidemiology, prevention, and early detection of breast cancer. <b>1999</b> , 11, 435-41	28
625	Systemic therapy. <b>1999</b> , 11, 468-74	4
624	The current social, political, and medical role of genetic testing in familial breast and ovarian carcinomas. <b>1999</b> , 11, 65-70	5
623	Selective estrogen receptor modulators in reproductive medicine and biology. <b>2000</b> , 55, S21-47	31
622	Venous thromboembolic disease. <b>2004</b> , 104, 118S-127S	4
621	Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. <b>2010</b> , 17, 642-53	43
620	Effects of bazedoxifene acetate with and without conjugated equine estrogens on the breast of postmenopausal monkeys. <b>2012</b> , 19, 1242-52	37
619	Breast cancer: risk assessment and prevention. <b>2010</b> , 103, 333-8	10
618	Cellular Mechanisms of Oestrogen in Breast Cancer Development. <b>2015</b> , 3,	2
617	Harnessing hormonal signaling for cardioprotection. <b>2005</b> , 2005, re6	11
616	To stop or not? Tamoxifen therapy for secondary prevention of breast cancer in a patient with ocular toxicity. <b>2016</b> , 2016,	5
615	Adjuvant therapy for breast cancer: who should get what?. <b>2001</b> , 174, 284-7	26

614	The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium. <b>2002</b> , 55, 514-9	36
613	Prevention strategies with aromatase inhibitors. <b>2004</b> , 10, 372S-9S	40
612	Bone protection by estrogens occurs through non-tissue-selective activation of the androgen receptor. <b>2006</b> , 116, 2500-9	27
611	Genetic rescue of nonclassical ER $\beta$ signaling normalizes energy balance in obese ER $\beta$ null mutant mice. <b>2011</b> , 121, 604-12	127
610	Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice. <b>2000</b> , 105, 1819-25	162
609	The role of cancer cooperative groups within the spectrum of cancer care. <b>2004</b> , 11, 55-63	3
608	Ductal Carcinoma In Situ of the Breast. <b>1999</b> , 6, 264-271	4
607	Thrombophilia: what's a practitioner to do?. <b>2001</b> , 322-38	10
606	Epigenetic biomarker screening by FLIM-FRET for combination therapy in ER+ breast cancer. <b>2019</b> , 11, 16	20
605	Risk factors and health promotion in families of patients with breast cancer. <b>2002</b> , 6, 83-7	4
604	Addressing the support needs of women at high risk for breast cancer: evidence-based care by advanced practice nurses. <b>2002</b> , 29, E77-84	28
603	Passive Cigarette Smoking and Breast Cancer. <b>2000</b> , 177-193	1
602	Pharmaceutical Applications of Accelerator Mass Spectrometry. <b>2009</b> , 391-418	1
601	Selective Estrogen Receptor Modulation. <b>2002</b> , 271-285	2
600	The Importance of the Estrogen Receptor in Breast Cancer. <b>2002</b> , 149-186	9
599	Aromatase Inhibitors and Their Application to the Treatment of Breast Cancer. <b>2002</b> , 251-269	7
598	Aromatase Inhibitors and Chemoprevention of Breast Cancer. <b>2002</b> , 309-318	1
597	Why Endocrine Therapy?. <b>2002</b> , 3-14	3

596	Abrogation of Estrogen-Mediated Cellular and Biochemical Effects by Indole-3-Carbinol. <b>2001</b> , 41, 180-187	4
595	Patient Reluctance Toward Tamoxifen Use for Breast Cancer Primary Prevention. <b>2001</b> , 8, 580	3
594	A Comparative Study On Viability Of MCF-7 Human Breast Cancer Cell Lines Using Piperine And Tamoxifen â An In Vitro Study With A Novel Mishmash. <b>2018</b> , 11, 1955-1959	1
593	SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ER-positive breast cancer through regulation of BRCA1. <b>2017</b> , 13, e1007031	12
592	Partial inhibition of estrogen-induced mammary carcinogenesis in rats by tamoxifen: balance between oxidant stress and estrogen responsiveness. <b>2011</b> , 6, e25125	25
591	Tamoxifen and flaxseed alter angiogenesis regulators in normal human breast tissue in vivo. <b>2011</b> , 6, e25720	29
590	Benzyl isothiocyanate causes FoxO1-mediated autophagic death in human breast cancer cells. <b>2012</b> , 7, e32597	48
589	Korean risk assessment model for breast cancer risk prediction. <b>2013</b> , 8, e76736	39
588	Evaluating the potential bioactivity of a novel compound ER1626. <b>2014</b> , 9, e86509	3
587	CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance. <b>2014</b> , 9, e91771	79
586	Crossover effects of estrogen receptor status on breast cancer-specific hazard rates by age and race. <b>2014</b> , 9, e110281	6
585	Cytoplasmic PELP1 and ERRgamma protect human mammary epithelial cells from Tam-induced cell death. <b>2015</b> , 10, e0121206	12
584	Anti-Tumor Action, Clinical Biochemistry Profile and Phytochemical Constituents of a Pharmacologically Active Fraction of <i>S. crispus</i> in NMU-Induced Rat Mammary Tumour Model. <b>2015</b> , 10, e0126426	19
583	Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention. <b>2017</b> , 12, e0168601	14
582	Risk of second breast cancers after lobular carcinoma in situ according to hormone receptor status. <b>2017</b> , 12, e0176417	6
581	Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells. <b>2018</b> , 13, e0194913	5
580	Chemoprevention for breast cancer: overcoming barriers to treatment. <b>2012</b> , 85-90	8
579	Competing risks in low-risk breast cancer. <b>2013</b> , 32-9	2

578	Reforming the community research program: from Community Clinical Oncology Program to the National Cancer Institute Community Oncology Research Program. <b>2014</b> , e116-9	1
577	Addressing barriers to uptake of breast cancer chemoprevention for patients and providers. <b>2015</b> , e50-8	15
576	Food and Cancer Prevention: Human Intervention Studies. <b>2000</b> , 395-403	4
575	Breast Cancer Therapy: A Mini Review. <b>2017</b> , 1,	8
574	An Overview of Cancer Prevention: Chemoprevention and Immunoprevention. <b>2020</b> , 25, 127-135	8
573	[The role of ductoscopy in the modern diagnostics and therapy of breast diseases]. <b>2011</b> , 152, 1284-93	0
572	Cancer treatment-related bone disease. <b>2009</b> , 19, 47-60	29
571	Hereditary Risk of Breast and Ovarian Carcinoma: The Role of the Oncologist. <b>1998</b> , 3, 403-412	8
570	Breast Cancer Highlights. <b>1999</b> , 4, 299-308	2
569	Synergistic Effects of Lauryl Gallate and Tamoxifen on Human Breast Cancer Cell. <b>2020</b> , 49, 1324-1329	1
568	Evaluating the benefits and adverse effects of an anthracycline-taxane-capecitabine combined regimen in patients with early breast cancer. <b>2017</b> , 8, 81636-81648	2
567	2'-Hydroxyflavanone: A novel strategy for targeting breast cancer. <b>2017</b> , 8, 75025-75037	27
566	Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib. <b>2013</b> , 4, 316-28	9
565	Interpretation of breast cancer screening guideline for Chinese women. <b>2019</b> , 16, 825-835	13
564	Milestone clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). <b>2017</b> , 6, 7	5
563	Osteoporosis. <b>2008</b> , 90, 1362-1374	32
562	The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis. <b>2007</b> , 2, 55-64	32
561	FACE: the barefaced facts of AI potency. <b>2010</b> , 2, 267-76	4

560	Achievements in Cancer Research and its Therapeutics in Hundred Years. <b>2019</b> , 19, 1545-1562	0
559	In-vitro Antiproliferative Activity of New Tetrahydroisoquinolines (THIQs) on Ishikawa Cells and their 3D Pharmacophore Models. <b>2014</b> , 11, 428-436	8
558	The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis. <b>2009</b> , 4, 88-102	20
557	Synthesis and In Vitro Evaluation of Tetrahydroquinoline Derivatives as Antiproliferative Compounds of Breast Cancer via Targeting the GPER. <b>2019</b> , 19, 760-771	7
556	New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight. <b>2019</b> , 19, 2156-2176	2
555	Preoperative evaluation for post-mastectomy reconstructive surgery. <b>2012</b> , 81-86	1
554	The Role of CYP2D6 Polymorphisms in Determining Response to Tamoxifen in Metastatic Breast Cancer Patients: Review and Egyptian Experience. <b>2020</b> , 21, 3619-3625	2
553	Synergy of novel coumarin derivatives and tamoxifen in blocking growth and inducing apoptosis of breast cancer cells. <b>2014</b> , 60, 35-44	2
552	PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. <b>2020</b> , 22,	72
551	The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. <b>2007</b> , 14, 89-96	30
550	Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. <b>2007</b> , 14 Suppl 1, S20-40	81
549	Cancer treatment-related bone loss: a review and synthesis of the literature. <b>2008</b> , 15, S30-40	33
548	Prognostic Factors of Local-Regional Recurrence in Patients with Operable Breast Cancer in Asia: A Meta-Analysis. <b>2019</b> , 7, 690-695	4
547	Breast cancer in the young: role of the geneticist. <b>2013</b> , 5 Suppl 1, S19-26	5
546	Hormonal therapies in young breast cancer patients: when, what and for how long?. <b>2013</b> , 5 Suppl 1, S36-46	16
545	Stock identification of neon flying squid ( <i>Ommastrephes bartramii</i> ) in the North Pacific Ocean on the basis of beak and statolith morphology. <b>2014</b> , 78, 239-248	9
544	Strategies for prostate cancer prevention: Review of the literature. <b>2008</b> , 24, 295-302	7
543	Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy. <b>2015</b> , 6, 59-65	5

542	Mitochondrial and caspase pathways are involved in the induction of apoptosis by nardosinen in MCF-7 breast cancer cell line. <b>2018</b> , 13, 12-21	13
541	Estrogen receptor testing and 10-year mortality from breast cancer: A model for determining testing strategy. <b>2012</b> , 3, 19	4
540	Problems of Breast Cancer Survivors Living in an Urban Area of Nepal. <b>2016</b> , 3, 289-296	5
539	extract reduces the invasiveness of MDA-MB-231 breast cancer and inhibits cytokines associated with metastasis. <b>2015</b> , 1, 94-100	12
538	Assessment of common risk factors and validation of the Gail model for breast cancer: A hospital-based study from Western India. <b>2020</b> , 32, 362-366	1
537	Reasons for Prophylactic Mastectomy in Women Carrying BRCA 1/2 Mutation: A Systematic Literature Review. <b>2013</b> , 02, 97-105	1
536	Understanding the molecular mechanisms of cancer prevention by dietary phytochemicals: From experimental models to clinical trials. <b>2016</b> , 7, 88-99	69
535	Korean Hereditary Breast Cancer. <b>2009</b> , 52, 952	1
534	Laboratory determination of hereditary susceptibility to breast and ovarian cancer. <b>1999</b> , 123, 1023-6	9
533	Hereditary cancer syndromes. <b>2001</b> , 125, 85-90	20
532	Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. <b>2002</b> , 126, 1304-18	94
531	Current Concepts in Diagnosis, Molecular Features, and Management of Lobular Carcinoma In Situ of the Breast With a Discussion of Morphologic Variants. <b>2017</b> , 141, 1668-1678	24
530	Virtual screening of novel compounds as potential ER-alpha inhibitors. <b>2019</b> , 15, 321-332	5
529	Suppressive effect of pioglitazone, a PPAR gamma ligand, on azoxymethane-induced colon aberrant crypt foci in KK-Ay mice. <b>2012</b> , 13, 4067-73	12
528	Identification of germline BRCA1 mutations among breast cancer families in Northeastern Iran. <b>2013</b> , 14, 4339-45	15
527	Upregulated Myc expression in N-methyl nitrosourea (MNU)- induced rat mammary tumours. <b>2013</b> , 14, 4883-9	4
526	Fulvestrant 250 mg versus anastrozole 1 mg in the treatment of advanced breast cancer: a meta-analysis of randomized controlled trials. <b>2014</b> , 15, 2095-100	5
525	Preventive and Risk Reduction Strategies for Women at High Risk of Developing Breast Cancer: a Review. <b>2016</b> , 17, 895-904	5

- 524 Incorporating quality of evidence into decision analytic modeling. **2007**, 146, 133-41 22
- 523 Breast Cancer: Lifestyle, the Human Gut Microbiota/Microbiome, and Survivorship. **2020**, 24, 10
- 522 Endometrial and Cervical Cancers. **2021**, 885-922
- 521 Locoregional and Locally Advanced Breast Cancer. **2021**, 429-466
- 520 ASO Author Reflections: Observation After a Core Biopsy Diagnosis of Classic-Type LCIS Is a Safe Standard of Practice. **2021**, 1
- 519 An Empirical Analysis of Precision Previvorship: Are Familial and High-Risk Cancer Preventive Programs Evidence Based?. **2021**,
- 518 Estrogen Receptor in Mammary Gland Physiology. **2000**, 1-16
- 517 A Personal Perspective About the Future of Breast Cancer Research and Treatment. **2000**, 7-21
- 516 Chemoprevention of Breast Cancer. **2000**, 183-207
- 515 Prevention Trials in Perimenopausal and Postmenopausal Women. **2000**, 405-420
- 514 Breast Cancer Epidemiology, Treatment, and Prevention. **2000**, 871-883 1
- 513 The Treatment of Estrogen Deficiency in Women at Risk for Breast Cancer and Survivors of the Disease. **2000**, 43-81
- 512 Risikoberatung, Prävention und Früherkennung. **2000**, 251-265
- 511 Sexualhormone. **2000**, 536-553
- 510 Tamoxifen and Other Antiestrogens in Prevention and Therapy of Breast Cancer. **2000**, 79-99
- 509 Impact of genetic information and genetic counseling on public health. **2000**, 361-384
- 508 MR IMAGING OF FEMALE PELVIC MALIGNANCIES. **2000**, 8, 887-914 7
- 507 Chemotherapy as an Adjunct to Surgery. **2001**, 1659-1676

- 506 Hormone Replacement Therapy for ~~at~~ <sup>At</sup> Risk ~~Patients~~ with Connective Tissue Diseases. **2001**,
- 505 Primary Prevention of Breast Cancer and Screening for Early Detection of Breast Cancer. **2001**, 20-54
- 504 Molekulare Diagnostik beim heredit~~ten~~ <sup>ären</sup> Mammakarzinom. **2001**, 131-148
- 503 Selective Estrogen Receptor Modulators (SERMs). **2001**, 603-620
- 502 A Unified General Mechanism for Hormonal Carcinogenesis Begins to Emerge. **2001**, 403-405
- 501 Thrombophilia: What's a Practitioner to Do?. **2001**, 2001, 322-338
- 500 Corpuscarcinom. **2001**, 113-133
- 499 Chemoprevention: progress and opportunity. **2001**, 492, 263-74
- 498 Sexualhormone. **2001**, 612-631
- 497 Sexualhormone. **2001**, 654-673
- 496 Heredit~~ter~~ <sup>ärer</sup> Brust- und Eierstockkrebs. **2001**, 257-281
- 495 Breast Cancer. **2001**, 109-129
- 494 Designer estrogen vs. hormone replacement therapy: the menopausal woman's dilemma. **2001**, 20, 66-72; quiz 72-4
- 493 Breast cancer in elderly patients. **2002**, 10, 135-137
- 492 SERMs in postmenopausal Women~~âs~~ <sup>'s</sup> health. **2002**, 279-295
- 491 Insights into the Molecular Mechanism of SERMs Through New Laboratory Models. **2002**, 147-165
- 490 Prim~~re~~ <sup>äre</sup> und sekund~~re~~ <sup>äre</sup> Pr~~ev~~ <sup>ä</sup>vention. **2002**, 109-124
- 489 Pr~~ev~~ <sup>ä</sup>vention von Karzinomen durch fr~~he~~ <sup>he</sup> Diagnostik, Ern~~hr~~ <sup>hr</sup>ung und Hormontherapie. **2002**, 43-59



488 Breast Cancer. **2002**, 345-365

1

487 ER. **2002**, 308-335

486 Hormone Replacement Therapy and Breast Cancer: Still More Questions Than Answers. **2002**, 213-220

485 Breast cancer susceptibility genes: Options for those carrying BRCA1 mutations. **2002**, 10, 119-122

1

484 Alternatives to Estrogen for Treatment of Menopause. **2002**, 313-343

483 Menopause Therapy. **2002**, 299-312

482 Menopause Hormone Replacement Therapy and Cancer: Epidemiology. **2002**, 329-338

481 Selektive Östrogenrezeptormodulatoren (SERMs) bei Osteoporose. **2002**, 90-95

480 Mammakarzinom. **2002**, 527-543

479 SERMs and Breast Cancer Prevention. **2002**, 267-278

478 Effects of SERMs on Bone in Clinical Studies. **2002**, 245-254

477 SERMs Effects on Cardiovascular Risk Factors and Disease. **2002**, 223-236

476 Familienes Mammakarzinom â Beratung und Betreuung betroffener Familien. **2002**, 43-59

475 Molekulare Therapie. **2002**, 389-441

474 Molekulare Grundlagen des sporadischen Mammakarzinoms. **2002**, 87-123

473 Gynecologic and Urogynecologic Aspects of Menopause. **2002**, 309-315

472 Use of Selective Antiestrogens for the Chemoprevention of Breast Cancer. **2002**, 303-308

471 Specificity of an association. **2002**, 13, 370-1; author reply 371-2

1

470 Meeting report from the national osteoporosis foundation 5th international symposium on clinical advances in osteoporosis.

469 Tamoxifen-DNA adducts. **2002**,

1

468 Hormone Replacement Therapy, the Menopause and Breast Cancer. **2002**, 373-403

467 Recent Developments in the Hormonal Treatment of Breast Cancer. **2002**, 343-371

466 Control of Proliferation in the Normal and Neoplastic Breast. **2002**, 73-91

465 Menopause and Hormone Replacement Therapy. **2002**, 417-474

464 Tamoxifen-Induced Nonalcoholic Steatohepatitis. **2003**, 96-104

463 Breast and Prostate Cancer: a Comparison of Two Common Endocrinologic Malignancies. **2003**, 159-166

462 Sexualhormone. **2003**, 704-725

461 The P160 Family of Steroid Hormone Receptor Coactivators. **2003**, 133-147

1

460 Breast Cancer. **2003**, 903-907

459 Early Breast Cancer. **2003**, 331-342

458 Molecular Therapeutics in Prostate Cancer. **2003**, 495-515

2

457 Genetische Beratung bei gynäkologischen Erkrankungen. **2003**, 823-830

456 Mammakarzinom. **2003**, 553-613

455 Breast cancer. **2003**, 21, 585-608

454 Principles of Cancer Chemoprevention. **2003**, 67-77

453 Hormonal Treatments of Endocrine-Dependent Tumors: Preclinical Aspects. **2003**, 161-168

452 Prevention of Ovarian Serous Epithelial Carcinoma. **2003**, 515-543

451 Endometrial Surveillance of Tamoxifen Patients. **2003**, 71-77

450 Tumor Angiogenesis as a Target for Early Intervention and Cancer Prevention. **2004**, 611-633

449 Nuclear Receptor Superfamily. **2004**, 195-208

1

448 Sexualhormone. **2004**, 776-798

447 Sexualhormone. **2004**, 835-856

1

446 Cancer Management in Older Women. **2004**, 1171-1185

445 Gender Differences in Hereditary Cancer Syndromes: Risks, Management, and Testing for Inherited Predisposition to Cancer. **2004**, 682-692

444 Prevention of Gynecologic Malignancies. **2004**, 883-919

443 Clinical Importance of Prognostic Factors. **2004**, 51-72

O

442 Endocrinology. **2004**, 283-303

441 Genetic Counseling for Hereditary Cancer Predisposition Testing. **2004**, 453-471

440 Breast Diseases in Older Women and Men. **2004**, 1154-1162

439 Breast Cancer Chemoprevention by Selective Estrogen Receptor Modulators. **2004**, 245-256

1

438 Venous Thromboembolism: Gender Effects and Gender-Specific Risk Factors for Women. **2004**, 332-346

437 Controversies in Endometrial Cancer Screening and Diagnosis. **2004**, 241-247

436 Aromatase Inhibitors as Chemopreventives of Breast Cancer. **2004**, 231-243

435 The Potential of EGFR-Targeted Agents in Cancer Prevention. **2004**, 317-324

1

434 Endometriumkarzinom. **2004**, 1073-1093

433 Genitourinary tract changes. **2004**, 104, 56S-61S

6

432 Ovarian, endometrial, and colorectal cancers. **2004**, 104, 77S-84S

1

431 Stroke. **2004**, 104, 97S-105S

2

430 Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. **2004**, 4, 279-281

429 [Pre-symptomatic diagnosis of severe hereditary diseases with late onset in Lebanon: a choice or a necessity?]. **2005**, 17, 617-26

428 Effects of Hormones. **2005**, 121-146

427 Women and cardiovascular heart disease. **2005**, 331-347

426 SoyâFood and SoyâDrug Interactions in Prevention and Treatment of Cancer. **2005**, 125-146

425 References. **2005**, 485-513

424 Genetics and breast screening. **2005**, 20-29

423 Fighting breast cancer: a call for a new paradigm. **2005**, 9, 73-6

422 Endocrine Therapy of Breast Cancer. **2006**, 221-247

421 Prevention of breast cancer. **2006**, 363-373

420 A Case-Control Study on the Risk Factors of Breast Cancer in Korean Women. **2006**, 9, 145

2

419 Mammakarzinom der Frau. **2006**, 4215-4331

418 Mammakarzinom. **2006**, 477-533

417 Hormone replacement therapy. **2006**, 139-149

- 416 Cancer Chemoprevention. **2006**, 1318-1340 1
- 415 Principles and Applications of Cancer Prevention and Control Interventions. **2006**, 1283-1291 2
- 414 Introduction. **2006**, 9-14
- 413 Oncology. **2007**, 439-457
- 412 Women in the Wilderness. **2007**, 2035-2071
- 411 Breast Diseases. **2007**, 327-357 1
- 410 Sonohysterography. **2007**, 197-211 1
- 409 Thrombotic Risk of Contraceptives and Other Hormonal Therapies. **2007**, 567-580
- 408 Noninvasive Breast Cancer. **2007**, 97-109
- 407 Breast Diseases. **2007**, 411-448
- 406 Gene profiling uncovers retinoid target genes. **2007**, 383, 101-21 2
- 405 True Local Recurrences or New Primary Tumors after Breast-Conserving Surgery and Radiation Therapy. **2007**, 57, 221-224
- 404 Statins, Diet, and Dietary Supplements for Prostate Cancer: A Potential Connection and Recommendation Based on Probability. **2007**, 3, 140-146
- 403 Primary Prevention of Breast Cancer, Screening for Early Detection of Breast Cancer, and Diagnostic Evaluation of Clinical and Mammographic Breast Abnormalities. **2008**, 27-55
- 402 A Personal Account of the Chemoprevention of Breast Cancer: Possible or Not Possible?. **2008**, 391-398
- 401 Triterpenoids, Vitamin D, and TGF- $\beta$ /Smad Signaling in Inflammation and Cancer. **2008**, 525-547
- 400 Sexualhormone. **2008**, 843-864
- 399 Sonohysterographi. **2008**, 239-256

398 Breast Disorders. **2008**, 213-249

397 Endocrine Therapy for Breast Cancer. **2008**, 411-434

396 Malignancy. **2008**, 832-848

395 Effects of Oral Administration of Tamoxifen, Toremifene, Dehydroepiandrosterone, and Vorozole on Uterine Histomorphology in the Rat. **2000**, 223, 288-294

394 Risk Management of Hereditary Breast Cancer. **2008**, 93-105

393 Endocrine Therapy with Selective Estrogen Receptor Modulators (SERMs) and Aromatase Inhibitors in the Prevention and Adjuvant Therapy Settings. **2009**, 147, 1-29 1

392 Strategies of hormonal prevention. **2009**, 147, 1-35

391 Risk assessment and management. **2009**, 327-337

390 Sexualhormone. **2009**, 835-856

389 Breast-Cancer Prevention with Antiestrogens. **2009**, 213-231

388 Cytopathology of the Breast. **2009**, 675-695

387 Family History: A Bridge Between Genomic Medicine and Disease Prevention. **2009**, 481-492 1

386 Recent Progress in Breast Cancer Research. **2009**, 385-408 1

385 Investigations after adjuvant therapy. **2009**, 151, 331-52

384 Identifying and Managing the High-Risk Patient. **2009**, 101-122

383 Clinical Utility of New Antiestrogens. **2009**, 195-212

382 Bilateral Breast Cancer. **2009**, 1329-1337

381 Biology and Management of Lobular Carcinoma in Situ of the Breast (Lobular Neoplasia). **2009**, 917-925

380 Endocrine Therapy for Breast Cancer. **2009**, 1263-1285

379 Cancer Prevention. **2009**, 351-392

378 Tumoren und Endokrinium. **2009**, 599-631

377 An Introduction to the Regulation of Sex Steroids for the Treatment of Cancer. **2009**, 1-13

376 Epidemiology of Breast Cancer. **2009**, 333-347

375 Steroid Receptors in Breast Cancer. **2009**, 485-497

374 BREAST CANCER. **2009**, 933-944

373 Teaching Visual: Breast Pathology. **2009**, 154-159

372 Prophylactic Mastectomy. **2009**, 200-209

371 Mammographic Density as a Potential Surrogate Marker for Breast Cancer. **2010**, 321-341

370 New Molecular Therapeutic Interventions: The Case of Breast Cancers. **2010**, 571-611

369 Intraductal Approaches: Mammary Ductoscopy and Ductal Lavage to Assist in the Diagnosis of Breast Cancer. **2010**, 197-204

368 Surgical Management of Inherited Susceptibility to Breast Cancer. **2010**, 61-78

367 Lifestyle Factors and Risk of Breast Cancer: A Review of Randomized Trial Findings. **2010**, 23-41

366 Chemoprevention of Breast Cancer. **2010**, 569-583

365 Breast Cancer in the Elderly. **2010**, 497-507

364 Malignant Breast Disease: Diagnosis and Assessment. **2010**, 17-38

363 Eye Symptoms and Toxicities of Systemic Chemotherapy. **2010**, 333-347

362 Identification and Management of Women at High Familial Risk for Breast Cancer. **2010**, 135-145

361 Chemoprevention of Head and Neck Cancer. **2010**, 81-93

1

360 Special situations, market fragmentation II: sex differences. **2010**, 387-402

359 Sexualhormone. **2010**, 867-888

358 Breast Cancer. **2010**, 263-311

1

357 The Theory of the Sick Lobe. **2010**, 1-17

1

356 Management of the Patient with a Genetic Predisposition for Breast Cancer. **2010**, 551-568

355 Lobular Carcinoma in Situ. **2010**, 181-199

354 Mammary Ductoscopy. **2010**, 253-259

353 Postmenopausal Hormone Replacement Therapy and Breast Cancer â€”Clinicopathologic Associations and Molecular Mechanisms. **2010**, 187-202

1

352 Basic Principles of Antineoplastic Therapies. **2010**, 707-715

351 A general perspective on breast disease and training system for breast cancer specialists in Europe. **2010**, 53, 565

350 Chemoprevention. **2011**, 209-226

349 Precursor Lesions and Noninvasive Cancers. **2011**, 27-39

348 Hereditary Breast Cancer Syndromes. **2011**, 51-104

347 The Role of Tomato Lycopene in Cancer Prevention. **2011**, 47-66

2

346 PET-CT in Breast Cancer. **2011**, 227-243

345 Cancer Chemoprevention. **2011**, 463-481



344 Pharmacogenomics of Tamoxifen. **2011**, 77-89

343 Cardiovascular Complications of Cancer Therapeutics. **2011**, 87-115

342 5 Breast Imaging. **2011**, 61-88

341 Performance Evaluation of Density Based Graph Cuts Segmentation Technique of Mammograms. **2011**, 104-116

1

340 Epidemiology of Breast Cancer. **2011**, 25-55

1

339 38 Current Issues in Gynecology: Screening for Ovarian Cancer in the Average Risk Population and Diagnostic Evaluation of Postmenopausal Bleeding. **2011**, 635-648

338 Endocrine therapy for advanced disease. **2011**, 13-34

337 Estrogen Receptor Signaling in Lung Cancer. **2012**, 191-210

336 Evolution of Selective Estrogen and Androgen Receptor Modulators: Status of Current Therapy and New Drug Development. 1

335 Noninvasive Breast Cancer. **2012**, 1311-1320

334 Role of Fish Oil from Gene Expression to Pharmacological Effect in Cancer Prevention. **2012**, 541-555

333 Epidemiology of Breast Cancer. **2012**, 44-56

332 Immuntherapeutika und Zytostatika. **2012**, 679-696

2

331 Breast Cancer. **2012**, 195-219

330 The Use of Randomized Controlled Trials for Pharmacoepidemiologic Studies. 640-654

329 Identifying Women at High Risk of Breast Cancer: Understanding the Risk Models. **2013**, 1-28

328 Understanding Triple-Negative Breast Cancer. **2013**, 97-116

327 Risk Reduction Strategies: Medical Oncology. **2013**, 97-101

- 326 Chemoprevention: Cinderella Waiting for the Ball. **2013**, 115-134 1
- 325 Overview of Cancer Prevention Strategies in Older Adults. 53-70
- 324 Carcinogenesis and Tamoxifen. **2013**, 101-114
- 323 Menopause. **2013**, 139-161
- 322 Metabolites of Tamoxifen as the Basis of Drug Development. **2013**, 47-67
- 321 Treating Health Risks or Putting Healthy Women at Risk: Controversies around Chemoprevention of Breast Cancer. **2013**, 206-227 O
- 320 Pharmacogenomics and Personalized Medicine for Cancer. **2013**, 215-235 2
- 319 Tamoxifen Goes Forward Alone. **2013**, 31-46
- 318 Breast Diseases. **2013**, 301-334
- 317 Mitochondrial Reactive Oxygen Species in Proapoptotic Effect of Promising Cancer Chemopreventive Phytochemicals. **2013**, 157-170
- 316 Endocrine prevention of breast cancer. **2013**, 39-49
- 315 Breast Cancer Prevention. 71-83
- 314 Immuntherapeutika und Zytostatika. **2013**, 667-685
- 313 Mammakarzinom. **2013**, 625-705
- 312 Familial Breast Cancer: Genetic Testing.
- 311 High Risk Lesions. **2014**, 249-267
- 310 Risk Assessment. **2014**, 3-30
- 309 Systemic Therapy. **2014**, 381-420

308 Endocrine Treatment for Breast Cancer. 190-214

307 Skin Cancer Prevention. **2014**, 321-376

306 Breast Cancer Prevention. **2014**, 445-489

305 Molecular Pathology and Diagnostics of Gynecologic Malignancies. **2014**, 365-395

304 The Bioepidemiology of Multiple Primary Cancers. **2014**, 227-239

303 Risk Assessment in Benign Breast Lesions. **2014**, 269-287

302 BioSurveillance and Longitudinal Lifelong Guidelines. **2014**, 153-169

301 Epithelial Proliferative Lesions. **2014**, 155-194

300 Designing the Chemoprevention Trials of Tomorrow: Applying Lessons Learned from Past Definitive Trials. **2014**, 265-284

299 Pathophysiologie und Behandlung der therapieinduzierten Osteoporose. **2014**, 139-165

1

298 Uterine Cancer. **2014**, 1575-1591.e4

297 Cancer Prevention, Screening, and Early Detection. **2014**, 322-359.e12

1

296 Treatment of ductal carcinoma in situ. **2014**, 179-198

295 Rates, Risks, Measures of Association and Impact. **2014**, 123-185

294 The genetics of breast cancer, risk-reducing surgery and prevention. **2014**, 127-145

293 Tumors of the Female Reproductive Organs. **2014**, 1-18

292 Chemoprevention and Heritable Cancer Risk. **1999**, 135-152

291 Hormone Replacement Including Osteoporosis. **1999**, 409-422

290 A Personal Perspective About the Future of Breast Cancer Research and Treatment. **1999**, 34-53

289 Hereditary Breast Cancer: an Overview. **1999**, 57-80

288 Genetics of Breast and Ovarian Cancer. **1999**, 55-64

287 Oncology. **1999**, 195-203

O

286 Strategien zur Prävention des Mammakarzinoms.

285 Adjuvant Therapy for Breast Cancer: Hormonal Therapy. **2015**, 353-362

284 The Role of the National Cancer Institute. **2015**, 145-154

283 Genetically Based Breast Cancer: Risk Assessment, Counseling, and Testing. **2015**, 137-159

282 CATEGORIZATION OF INSITU BREAST CARCINOMA BASED ON MORPHOLOGY AND IMMUNOHISTOCHEMISTRY. **2014**, 3, 11511-11519

281 Lobular Neoplasia: Atypical Lobular Hyperplasia and Lobular Carcinoma In Situ. **2015**, 161-174

280 Strategien zur Prävention des Mammakarzinoms. **2015**, 161-167

279 Drug-induced ocular side effects. **2015**, 47-343

278 Abnormal Screening Mammogram. **2015**, 37-44

277 Overview of Gynecologic Cancers. **2015**, 3-42

276 Breast Chapter. **2015**, 325-337

275 Nanotamoxifen Delivery System: Toxicity Assessment After Oral Administration and Biodistribution Study After Intravenous Delivery of Radiolabeled Nanotamoxifen. **2016**, 15, 7-11

274 Role of Genetic Profiling and Recurrence Scores in Treatment Planning for DCIS. **2015**, 109-115

273 Cancer Chemoprevention. **2015**, 809-824.e4

- 272 Endocrine therapy and its effect on sexual function. **2015**, e575-81 2
- 271 Lobular Carcinoma In Situ. **2016**, 123-129
- 270 Chronic Conditions and Cancer in Older Adults. **2016**, 421-454 2
- 269 The Role of Omega-3 Fatty Acids in Breast Cancer Prevention. **2016**, 51-81
- 268 Epidemiology, Risk Factors, and Prevention. **2016**, 57-87 1
- 267 Treatment of Metastatic Breast Cancer: Endocrine Therapy. **2016**, 489-522
- 266 Hormonal Anticancer Drugs. **2016**, 155-174
- 265 The Ideal 7-Step Breast Cancer Diet, Lifestyle, and Dietary Supplements Program for Prevention/Recurrence: Heart Healthy = Breast Healthy!. **2016**, 69-140
- 264 The Effects of Breast Cancer Treatments on Cognition. **2016**, 235-247
- 263 Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer. **2016**, 1-21
- 262 Overview. **2016**, 1284-1302.e3 1
- 261 Is There a Role for Raloxifene and Tamoxifen for the Prevention of Breast Cancer?. **2016**, 83-101
- 260 Special Situations, Market Fragmentation II: Sex Differences. **2016**, 361-375
- 259 Peutz-Jeghers Syndrome. **2016**, 117-164
- 258 Molecular Analysis of Breast Cancer in Cytology Samples. **2016**, 139-152
- 257 Breast Cancer in the Older Adult. **2016**, 519-528
- 256 Disturbances of Lipid Metabolism in a Cancer Cell and How This Knowledge Increases Its Role in Clinical Oncology. **2016**, 761-789
- 255 Prophylactic Risk-Reducing Surgery for Breast Cancer. **2016**, 21-32

- 254 Imaging of Tumor Response by Preoperative Systemic Treatment. **2016**, 295-308
- 253 Management of the Patient with a Genetic Predisposition for Breast Cancer. **2016**, 575-592
- 252 Analysis of the Ki-67 index in the vaginal epithelium of castrated rats treated with tamoxifen. **2016**, 71, 90-3 1
- 251 Tumors of the Female Reproductive Organs. **2017**, 1395-1410
- 250 Management of Perioperative Medications Including Steroids, Growth Factors, and Hormone Receptors. **2017**, 329-346
- 249 Avoiding Frankenstein's Monster and Partial Analysis Problems: Robustly Synthesising, Translating and Extrapolating Evidence. **2017**, 57-89
- 248 Five Decades of Hormone Therapy Research: The Long, the Short, and the Inconclusive. **2017**, 13-43 1
- 247 Menopause. **2017**, 161-193
- 246 Clinical Trials of Chemoprevention. **2017**, 163-167
- 245 EFFECTS OF TAMOXIFEN ON LIPID PROFILE, SERUM CALCIUM AND GONADOTROPIN LEVELS IN CARCINOMA BREAST PATIENTS. **2017**, 6, 2507-2511
- 244 Surgical Oncology Evaluation and Management of Breast Diseases. **2018**, 73-102
- 243 Effect of (GMODT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats. **2017**, 38, 61-72 1
- 242 The Role of Chemoprevention in the Prevention of Breast Cancer. **2018**, 129-145
- 241 Breast Cancer Risk Prediction in Women with Atypical Breast Lesions. **2018**, 103-113
- 240 Eye Symptoms and Toxicities of Systemic Chemotherapy. **2018**, 563-583 0
- 239 Endometrial İnekleme Yapı ılan Hastalar ın Sonografik Bulgular ını ın ve Histopatolojik Sonu ı ını ın De ı ırlendirilmesi. 81-87 0
- 238 Substantiated approaches to the diagnosis and treatment of tamoxifen-induced endometrial conditions in patients with breast cancer. **2018**, 67, 69-78 0
- 237 Prevention: Chemoprevention (Primary Prevention of Breast Cancer). **2019**, 207-216

- 236 Atypical Ductal Hyperplasia of the Breast: Management of a Clinical Case at the IBN SINA Hospital Centre with Literature Review. **2019**, 09, 1161-1167 1
- 235 Risk reduction strategies in BRCA patients: An Indian perspective. **2019**, 40, 319
- 234 Lobular Carcinoma In Situ. **2019**, 81-84
- 233 Introduction to Cancer Prevention. **2019**, 1-16
- 232 Breast Cancer Prevention. **2019**, 543-606
- 231 Treatment of Metastatic Breast Cancer: Endocrine Therapy. **2019**, 419-447
- 230 Epidemiology, Risk Factors, and Prevention. **2019**, 39-61
- 229 Skin Cancer Prevention. **2019**, 405-472
- 228 Lobular Carcinoma In Situ. **2019**, 109-113
- 227 Somatic Genetic Aberrations in Benign Breast Disease and the Risk of Subsequent Breast Cancer. 1
- 226 Meme Kanserli Kadınlarda Tamoksifen veya Tamoksifen+Leuprolid Asetat Tedavisi Alanlarda Endometrial Patoloji Sonuçları ve Karşılaştıkları Problemler. **2019**, 40, 1-15
- 225 Epidemiology, Risk Factors, and Prevention for Endometrial Cancer. **2020**, 61-67 1
- 224 Abnormal Screening Mammogram. **2020**, 43-49
- 223 Effects of mixed formulation of tamoxifen and blue honeysuckle on the pharmacokinetics profiles of tamoxifen after single oral administration. **2019**, 40, 1-15
- 222 Cell biological basis of tumor relapse and recurrence – A help from yeast quiescent biology and neuronal quiescent cell biology. 5, 27-34
- 221 Effect of the Single Oral Combination Treatment of Tamoxifen with Gamisoyo-san on the Pharmacokinetics Profiles of Tamoxifen. **2020**, 34, 201-208 2
- 220 Can Endocrine Therapy Reduce the Risk of Breast Cancer in South African Women?. **2020**, 2, 39
- 219 Accidental Discovery of Concomitant Lobular Carcinoma in situ and Ductal Carcinoma in situ of the Breast – A Case Report. **2020**, 81, 417-422

218 Exposure of mammary cells to lipid activates gene expression changes associated with ER-negative breast cancer via chromatin remodeling.

217 Prevention of Pulmonary and Venous Thromboembolism Post Coronary Artery Bypass Graft Surgery - Literature Review. **2020**, 35, 368-374

1

216 The Primary Prevention of Breast Cancer: Risk Assessment, Genetic Screening, Chemoprevention, and Modifiable Risk Factors. **2020**, 275-296

215 Endoplasmic Reticulum Stress and Autophagy in Cancer. **2020**, 355-402

214 Case Histories of Significant Medical Advances: Tamoxifen.

1

213 Tumors of the Female Reproductive Organs. **2020**, 1-15

212 Comparison of Outcomes for Classic-Type Lobular Carcinoma In Situ Managed with Surgical Excision After Core Biopsy Versus Observation. **2021**, 1

1

211 Clinical studies with anastrozole. **2008**, 101-125

210 Early Invasive Breast Cancer. **2003**, 204-217

209 Premalignant Breast Disease: Anatomic Lesions and Hormonal Associations. **2005**, 121-129

208 The High-Risk Patient and Magnetic Resonance Imaging. **2005**, 184-199

207 Breast Disease. **2005**, 335-354

206 Prevention and Early Detection of Endometrial and Ovarian Cancers. **2006**, 12-19

205 Second Malignancies After Radiation Treatment and Chemotherapy for Primary Cancers. **2006**, 1939-1951

204 Genetic Screening and Counseling for High-Risk Populations. **2006**, 341-357

203 Evidence-Based Management of Breast Cancer. **2006**, 960-991

1

202 Breast Imaging. **2006**, 28-56

201 Current Issues in Gynecology: Screening for Ovarian Cancer in the Average Risk Population and Diagnostic Evaluation of Postmenopausal Bleeding. **2006**, 553-569



200 Tumor-Host Interactions at the Metastatic Site: MKK4, Signal Transduction and the Stress Response. **2005**, 437-448

199 Tolfance de lâBormonothfapie adjuvante. **2006**, 401-415

198 Cervical and Endometrial Cancer Prevention. **2005**, 315-347

1

197 Complementary and Alternative Approaches to Cancer Prevention. **2005**, 105-129

196 Endokrinium und Tumorwachstum. **2005**, 527-557

1

195 Peptide Imaging. **2006**, 153-184

194 Sexualhormone. 888-911

193 Novel Targets for Lung Cancer Therapy. **2006**, 419-429

192 Chemoprevention of Lung Cancer. **2006**, 609-626

191 Genetische Beratung bei gynkologischen Erkrankungen. **2006**, 579-584

190 SERMs and the Breast. 239-270

189 Endometrial Effects of SERMs. 271-290

188 The Role of SERMs in the Management of Postmenopausal Women. 333-349

187 The Role of SERMs in the Treatment of Osteoporosis. 187-206

186 Clinical studies with anastrozole. **2006**, 95-118

185 Breast Disease. **2007**, 175-194

184 Breast Cancer: Side Effects of Tamoxifen and Anastrozole. **2008**, 433-457

183 Models of Absolute Risk. **2005**, 137-140

182 Ductal Lavage. **2005**, 239-247

181 Potential Use of Transgenic Mice in Chemoprevention Studies. **2005**, 47-55

180 Hereditary Issues In Ovarian Cancer. **2007**, 169-193

179 Endometrial CarcinomaâMolecular Genetic Aspects. **2007**, 91-100

178 Cerebrovascular Complications of Cancer. **2008**, 215-236

177 Targeted Therapy in Breast Cancer. **2008**, 43-59

176 Operative Berlegungen beim Familiïen Mammakarzinom. 93-106

o

175 Prevention of Breast Cancer. **2006**, 63-94

174 Ductal Carcinoma In Situ: a Modern Approach to Patient Management. **2006**, 125-135

173 Ductal Carcinoma In Situ: Systemic Treatment. **2006**, 137-156

172 Sexualhormone. **2007**, 893-917

171 Breast Cancer. **2007**, 293-310

170 Sexualhormone. **2008**, 845-867

169 Hypothalamic estrogen receptor alpha mediates key side effects of tamoxifen therapy in mice.

168 Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. **2001**, 164, 1681-90

26

167 Raloxifene and breast cancer. **2001**, 165, 888

1

166 Hormone replacement therapy: a time for pause. **2002**, 167, 357-9

7

165 Tamoxifen for breast cancer prevention: safety warning. **2002**, 167, 378-9

3

164	2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. <b>2002</b> , 167, S1-34	316
163	Weighing the risks and benefits of tamoxifen. <b>2003</b> , 168, 12-3; discussion 13	1
162	Should asymptomatic haemochromatosis be treated? Alternative strategies to appropriate diagnosis need testing. <b>2000</b> , 321, 955-6	
161	Participating in primary care research. <b>2002</b> , 52, 971-2	4
160	Breast cancer prevention. <b>2002</b> , 52, 972-3	
159	Women's views on chemoprevention of breast cancer: qualitative study. <b>2006</b> , 52, 624-5	37
158	Does raloxifene reduce postmenopausal women's risk of breast cancer?. <b>2000</b> , 46, 77-80	1
157	Educating women about breast cancer. An intervention for women with a family history of breast cancer. <b>2003</b> , 49, 56-63	13
156	Breast cancer in Canada. <b>1999</b> , 45, 1937-9, 1942-4	1
155	Breast cancer treatment and chemoprevention. <b>1999</b> , 45, 1917-24	
154	A vision for the future?. <b>2001</b> , 85 Suppl 2, 15-8	3
153	Economic disparities in treatment costs among ambulatory Medicaid cancer patients. <b>2004</b> , 96, 1565-74	9
152	A review of the use of exemestane in early breast cancer. <b>2009</b> , 5, 91-8	12
151	Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation. <b>2007</b> , 1, e92-8	16
150	Development of a Bayesian classifier for breast cancer risk stratification: a feasibility study. <b>2010</b> , 10, e25	7
149	Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial. <b>2010</b> , 1, 332-49	13
148	Arzoxifene: the evidence for its development in the management of breast cancer. <b>2008</b> , 2, 251-8	2
147	Effect of breast core needle biopsy technique on detection of lobular intraepithelial neoplasia. <b>2007</b> , 7, 121-4	1

146 Can breast cancer be prevented?. **2000**, 2, 10-3

145 Recent advances in the systemic therapy of breast cancer. **2000**, 2, 24-32

1

144 The ochsner cancer institute clinical trials program. **2006**, 6, 28-30

0

143 Construction of a database for the evaluation and the clinical management of patients with breast cancer treated with antiestrogens and/or aromatase inhibitors. **2011**, 8, 37-50

1

142 Prevention of breast cancer. **2005**, 12, 71-4

2

141 CYP2D6 testing in breast cancer: ready for prime time?. **2009**, 23, 1223-32

7

140 Soy consumption during menopause. **2012**, 4, 30-7

1

139 The Long and Short of Tamoxifen Therapy: A Review of the ATLAS Trial. **2014**, 5, 57-60

11

138 The role of immunohistochemical tests in multimodal treatment of the aggressive forms of breast cancer. **2014**, 7 Spec No. 2, 58-64

1

137 Hypomethylation of DNA-binding inhibitor 4 serves as a potential biomarker in distinguishing acquired tamoxifen-refractory breast cancer. **2015**, 8, 9500-5

6

136 Barriers and Facilitators to Patient-Provider Communication When Discussing Breast Cancer Risk to Aid in the Development of Decision Support Tools. **2015**, 2015, 1352-60

14

135 Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib. **2016**, 6, 981-95

3

134 Development and validation of a primary care-based family health history and decision support program (MeTree). **2013**, 74, 287-96

49

133 Introducing a Comprehensive Informatics Framework to Promote Breast Cancer Risk Assessment and Chemoprevention in the Primary Care Setting. **2017**, 2017, 58-67

3

132 Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data. **2016**, 12, 4-9

3

131 Precautions for Patients Taking Tamoxifen. **2018**, 9, 78-83

9

130 Evaluating the Impact of Uncertainty on Risk Prediction: Towards More Robust Prediction Models. **2018**, 2018, 1461-1470

2

129 Discriminatory Accuracy of the Gail Model for Breast Cancer Risk Assessment among Iranian Women. **2020**, 49, 2205-2213

- 128 Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer. **2021**, 11, 2005-2024 1
- 127 SERMs suppresses the growth of ER $\beta$ -positive cervical cancer xenografts through predominant inhibition of extra-nuclear ER $\beta$ -expression. **2021**, 11, 3335-3353
- 126 Current and Future Directions of Breast MRI. **2021**, 10, 3
- 125 Fear increases likelihood of seeking decisional support from others when making decisions involving ambiguity. 0
- 124 British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: Recommendations for practice.. **2021**, 270, 50-89 7
- 123 Cost-utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland. **2021**, 1 2
- 122 Association of Breast Surgeons of India (ABSI) Practical Consensus Statement, Recommendations, and Guidelines for the Treatment of Breast Cancer in India 2021âIndian Solutions for Indian Problems. 1
- 121 The Use of Randomized Controlled Trials for Pharmacoepidemiology. **2021**, 294-306
- 120 Preliminary Pharmacogenomic-Based Predictive Models of Tamoxifen Response in Hormone-dependent Chilean Breast Cancer Patients.. **2021**, 12, 661443 1
- 119 Selective Estrogen Receptor Modulators (SERMs). **2022**, 399-411
- 118 Breast Health. **2022**, 347-403
- 117 Prevention Trials: Challenges in Design, Analysis, and Interpretation of Prevention Trials. **2021**, 1-18
- 116 Evaluation of Optic Nerve Head Parameters and Electro-Physiology Among Breast Cancer Patients on Tamoxifen.. **2022**, 14, e21042
- 115 Comprehensive understanding of multiple actions of anticancer drug tamoxifen in isolated mitochondria.. **2021**, 1863, 148520 1
- 114 Pro und Contra (mit Tedbefragung): Pr $\ddot{u}$ ventive Therapie. **2000**, 32, 46-47
- 113 Discriminatory Accuracy of the Gail Model for Breast Cancer Risk Assessment among Iranian Women. **2020**, 49, 2205-2213 1
- 112 Preneoplastic Low-Risk Mammary Ductal Lesions (Atypical Ductal Hyperplasia and Ductal Carcinoma In Situ Spectrum): Current Status and Future Directions.. **2022**, 14, 0
- 111 Cancer Chemoprevention: A Strategic Approach Using Phytochemicals.. **2021**, 12, 809308 2

- 110 Potential Phytochemical Nanoemulsions in the Treatment of Oral Cancer and Oral Health. **2022**, 330-353
- 109 A new strategy: long-term adjuvant tamoxifen treatment and other discoveries at the University of Leeds. **2022**, 47-65
- 108 Underestimation Rate in the Percutaneous Diagnosis of Radial Scar/Complex Sclerosing Lesion of the Breast: Systematic Review.. **2022**, 44, 67-73
- 107 Management of Early Breast Cancer âSurgical Aspects. **2022**, 243-297
- 106 Management of Hereditary Breast Cancer: An Overview. **2022**, 353-397
- 105 Hormonal and Targeted Treatments in Breast Cancer. **2022**, 443-463 2
- 104 A Short History of Bernard Fisher's Contributions to Randomized Clinical Trials.. **2022**, 17407745211066498
- 103 âIf I wanted to buy your brain, what would that cost?ârebirth at M.D. Anderson Cancer Center. **2022**, 187-194
- 102 Endometrial hyperplasia as a risk factor of endometrial cancer.. **2022**, 1 5
- 101 Get out and go to Georgetown. **2022**, 163-169
- 100 Tumors of the Female Reproductive Organs. **2022**, 1491-1505
- 99 Risk of Cardiometabolic Risk Factors in Women With and Without a History of Breast Cancer: The Pathways Heart Study.. **2022**, JCO2101738 2
- 98 Discovery of novel therapeutic targets in cancer using patient-specific gene regulatory networks.
- 97 Design of the Anal Cancer/HSIL Outcomes Research study (ANCHOR study): A randomized study to prevent anal cancer among persons living with HIV.. **2022**, 113, 106679 1
- 96 Rapid Reductions in Breast Density following Tamoxifen Therapy as Evaluated by Whole-Breast Ultrasound Tomography.. **2022**, 11, 0
- 95 Lobular carcinoma in situ âA pragmatic approach to the controversies. **2022**, 27, 300589 0
- 94 The role of surgery in hereditary breast cancer prevention. **2003**, 5, 313-314
- 93 Clinical tools and counseling considerations for breast cancer risk assessment and evaluation for hereditary cancer risk.. **2022**,

- 92 Breast Cancer Risk Assessment and Management of the High-Risk Patient.. **2022**, 49, 87-116 o
- 91 Impact of Irradiation on the Pharmacokinetics and Biotransformation of Tamoxifen.. **2022**, 12, 833108
- 90 Estrogen Receptor Complex to Trigger or Delay Estrogen-Induced Apoptosis in Long-Term Estrogen Deprived Breast Cancer.. **2022**, 13, 869562
- 89 Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016.. **2022**, 193, 203 3
- 88 Gene Expression Changes by Diallyl Trisulfide Administration in Chemically-induced Mammary Tumors in Rats.. **2022**, 27, 22-30
- 87 Cytoplasmic Colocalization of RXR $\alpha$  and PPAR $\alpha$  as an Independent Negative Prognosticator for Breast Cancer Patients.. **2022**, 11, 1
- 86 Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen.. **2022**, 1 o
- 85 Lifetime risks for breast cancer are age-discriminatory when used for high-risk screening with MRI.. **2022**, 78, 102122 o
- 84 Breast cancer risk reduction: who, why, and what?. **2021**,
- 83 Validation of Breast Cancer Risk Models by Race/Ethnicity, Family History and Molecular Subtypes.. **2021**, 14, 1
- 82 High efficacy of tamoxifen-loaded L-lysine coated magnetic iron oxide nanoparticles in cell cycle arrest and anti-cancer activity for breast cancer therapy. **2021**, o
- 81 Strategies to Identify and Recruit Women at High Risk for Breast Cancer to a Randomized Controlled Trial of Web-based Decision Support Tools.. **2022**, OF1-OF8 1
- 80 Benign breast disease. 205-214
- 79 Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ.. **2022**,
- 78 Lipid exposure activates gene expression changes associated with estrogen receptor negative breast cancer.. **2022**, 8, 59 o
- 77 The morphologic spectrum of lobular carcinoma in situ (LCIS) observations on clinical significance, management implications and diagnostic pitfalls of classic, florid and pleomorphic LCIS.. **2022**, o
- 76 Breast Cancer. **2022**, 151-192
- 75 Evaluation of postmenopausal bleeding. 14-24

- 74 LncRNA TTN-AS1 confers tamoxifen resistance in breast cancer via sponging miR-107 to modulate PI3K/AKT signaling pathway.. **2022**, 14, 2267-2279
- 73 Branch retinal vein occlusion post severe acute respiratory syndrome coronavirus 2 vaccination. **2022**, 1
- 72 Tamoxifen: The Past, Present, and Future of a Previous Orphan Drug. **2022**, 4, 1-10
- 71 The Selective Estrogen Receptor Modulator, Raloxifene, Is Protective Against Renal IschemiaâReperfusion Injury. **3**, Publish Ahead of Print,
- 70 Mechanistic Effects of Estrogens on Breast Cancer. **2022**, 28, 224-240 0
- 69 Optimal breast cancer risk reduction policies tailored to personal risk level.
- 68 Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. **2022**, 20, 691-722 16
- 67 Evaluation of Breast Cancer Risk Assessment Techniques: A Cost-effectiveness Analysis. **2004**, 13, 2043-2052 4
- 66 General Principles of Medical Cancer Treatment.
- 65 Breast Cancer Selective Disruption of Actin Cytoskeleton by Diallyl Trisulfide. **2022**, 27, 101-111
- 64 Low-Dose Dietary Phytoestrogen Abrogates Tamoxifen-Associated Mammary Tumor Prevention. **2005**, 65, 879-886 32
- 63 Cancer Epidemiology, Prevention, and Survivorship. **2023**, 3-14
- 62 Endocrine Therapy Trials of Aromatase Inhibitors for Breast Cancer in the Adjuvant and Prevention Settings. **2005**, 11, 900s-905s 10
- 61 The molecular heterogeneity of the precancerous breast affects drug efficacy. **2022**, 12,
- 60 Estrogen, Estrogen Plus Progestin Therapy, and Risk of Breast Cancer. **2005**, 11, 909s-917s 10
- 59 Tamoxifen versus Aromatase Inhibitors for Breast Cancer Prevention. **2005**, 11, 925s-930s 12
- 58 Prevention Trials: Challenges in Design, Analysis, and Interpretation of Prevention Trials. **2022**, 1261-1277
- 57 Evaluation of the Pelvic Floor of Women with Breast Cancer Using Tamoxifen by Transperineal 3D Ultrasonography.



56	Characterization of a novel estrogen- and progesterone-responsive endometrial cancer cell line: HCI-EC-23.	
55	Targeting the mTOR Pathway for the Prevention of ER-negative Breast Cancer.	1
54	Racial disparities in breast cancer preclinical and clinical models. <b>2022</b> , 24,	0
53	Other rare uterine sarcomas: Adenosarcoma, endometrial stromal sarcoma, STUMP. <b>2023</b> , 161-182	
52	The Molecular Pharmacology of Estrogen Receptor Modulators: Implications for the Treatment of Breast Cancer. <b>2005</b> , 11, 871s-877s	20
51	TAS-108: A Novel Steroidal Antiestrogen. <b>2005</b> , 11, 906s-908s	2
50	Exemestane for Breast Cancer Prevention: A Feasible Strategy?. <b>2005</b> , 11, 918s-924s	0
49	Molecular Classification of Breast Carcinoma in a Tertiary Hospital of India: the Recent Trends.	0
48	Recalibrating risk prediction models by synthesizing data sources: adapting the lung cancer PLCO model for Taiwan.	0
47	Estradiol (E2) concentration shapes the chromatin binding landscape of the estrogen receptor.	0
46	Chemoprevention of Cancer. 1-25	0
45	Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies. <b>2022</b> , 14, 5206	1
44	Advances in Nanotechnology for Cancer Immunoprevention and Immunotherapy: A Review. <b>2022</b> , 10, 1727	0
43	Discovery of Highly Functionalized 5-hydroxy-2H-pyrrol-2-ones That Exhibit Antiestrogenic Effects in Breast and Endometrial Cancer Cells and Potentiate the Antitumoral Effect of Tamoxifen. <b>2022</b> , 14, 5174	0
42	Endometrial Cancer. 1-12	0
41	Lobular Neoplasia. <b>2022</b> , 102, 947-963	0
40	Breast diseases. <b>2023</b> , 311-344.e7	0
39	Adenocarcinoma of the uterine corpus and sarcomas of the uterus. <b>2023</b> , 125-174.e30	0

- 38 BREAST CANCER. **2000**, 35, 663-669 o
- 37 17- $\beta$ -Estradiol up-regulates energy metabolic pathways, cellular proliferation and tumor invasiveness in ER+ breast cancer spheroids. **2022**, 12, o
- 36 Characterization of HCl-EC-23 a novel estrogen- and progesterone-responsive endometrial cancer cell line. **2022**, 12, o
- 35 Surgical Management of the Patient with Invasive Carcinoma Discovered at Reduction Mammoplasty. **2003**, 69, 1003-1005 o
- 34 Atypical Lobular Hyperplasia and Lobular Carcinoma In Situ. **2022**, 615-654 o
- 33 Tamoxifen Delivery to Breast Cancer Cells (MCF-7) Via Hydroxyapatite Microspheres. o
- 32 Mitochondrial Dysfunction: Pathophysiology and Mitochondria-Targeted Drug Delivery Approaches. **2022**, 14, 2657 o
- 31 The Involvement of Long Non-Coding RNAs in Glutamine-Metabolic Reprogramming and Therapeutic Resistance in Cancer. **2022**, 23, 14808 o
- 30 Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer. **2022**, 5, e2243951 1
- 29 Current Perspectives on Lobular Neoplasia of the Breast. o
- 28 Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm?. **2022**, 11, 7239 2
- 27 Relationship between tamoxifen and cataracts: a nationwide cohort study of women in South Korea. o
- 26 Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer. o
- 25 Discovery and Chemical Development of Amcenestrant: An Oral Selective Estrogen Receptor Degradar (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer. 275-300 o
- 24 Determinants of the interval to brain metastasis from initial breast cancer diagnosis and its relation to survival: a single-center retrospective cohort. o
- 23 Effect of an Educational Intervention on Women's Health Care Provider Knowledge Gaps About Breast Cancer Risk Model Use and High-risk Screening Recommendations. 1
- 22 Prevention of Osteoporosis in Patients With Breast Cancer Treated With Aromatase Inhibitor Combined With Calcium/Vitamin D Supplements. **2022**, 10, 61-68 o
- 21 Epidemiologisches Wissen, persönliche Erfahrungen und Entscheidungsfindung – Überlegungen zum Konzept der ärztte-Patienten-Beziehung. **2023**, 125-138 o

- 20 Breast Cancer Disease Exploitation to Recure a Healthy Lifestyle. **2022**, 2617-2635 ○
- 19 Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy. **2023**, 133, 106425 ○
- 18 Variability Among Breast Cancer Risk Classification Models When Applied at the Level of the Individual Woman. ○
- 17 Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk. **2023**, 198, 335-347 ○
- 16 Cytotoxicity Study of Gold Nanoparticle Synthesis Using Aloe vera, Honey, and Gymnema sylvestre Leaf Extract. **2023**, 8, 6325-6336 ○
- 15 Vanillin-Based Indolin-2-one Derivative Bearing a Pyridyl Moiety as a Promising Anti-Breast Cancer Agent via Anti-Estrogenic Activity. **2023**, 8, 6968-6981 ○
- 14 Recent progress in gold and silver nanoparticle mediated drug delivery to breast cancers. **2023**, 291-328 ○
- 13 Counselling of path\_BRCA carriers who are considering risk-reducing oophorectomy. **2023**, 29, 42-52 ○
- 12 The Cardiovascular Risks Associated with Aromatase Inhibitors, Tamoxifen, and GnRH Agonists in Women with Breast Cancer. **2023**, 25, 145-154 ○
- 11 Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study. ○
- 10 Short-term changes in ultrasound tomography measures of breast density and treatment-associated endocrine symptoms after tamoxifen therapy. **2023**, 9, ○
- 9 Re-Evaluating the Association Between Hormonal Contraception and Breast Cancer Risk. Volume 15, 227-235 ○
- 8 Integrative multi-omic sequencing reveals the MMTV-Myc mouse model mimics human breast cancer heterogeneity. ○
- 7 A View on Drug Development for Cancer Prevention. OF1-OF26 ○
- 6 Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047. OF1-OF16 ○
- 5 Early endometrial carcinoma: Experience and outcomes. **2023**, 19, 0 ○
- 4 Ductal Carcinoma in Situ: A Detailed Review of Current Practices. **2023**, ○
- 3 Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women. ○

- 2 Maternal tamoxifen exposure leads to abnormal primordial follicle assembly. o
- 1 General aspects of cancer therapy. **2023**, 1-35 o